

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

09/824,178



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/11, C12Q 1/68	A2	(11) International Publication Number: WO 93/16178 (43) International Publication Date: 19 August 1993 (19.08.93)
(21) International Application Number: PCT/US93/01294 (22) International Filing Date: 12 February 1993 (12.02.93) (30) Priority data: 07/837,195 12 February 1992 (12.02.92) US (71) Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Washington, DC (US). (72) Inventors: VENTER, Craig, J. ; 1718 Nordic Hill Circle, Silver Spring, MD 20906 (US). ADAMS, Mark, D. ; 12812 Sage Terrace, Germantown, MD 20874 (US). MORENO, Ruben, F. ; 14415 Coral Gables Way, North Potomac, MD 20878 (US).		(74) Agents: ALTMAN, Daniel, E. et al.; Knobbe, Martens, Olson and Bear, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US). (81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: SEQUENCES CHARACTERISTIC OF HUMAN GENE TRANSCRIPTION PRODUCT (57) Abstract Partial and complete human cDNA and genomic sequences corresponding to particular expressed sequence tags (ESTs). The ESTs are cDNA sequences that are generally between 150 and 500 base pairs in length, are derived from human brain cDNA libraries, correspond to genes transcribed in human brain, and have base sequences identified herein as SEQ ID NOS: 1-2421.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SU	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

**SEQUENCES CHARACTERISTIC OF HUMAN GENE TRANSCRIPTION
PRODUCT**

5

Technical Field

The present invention relates to newly identified polynucleotide sequences corresponding to transcription products of human genes, and to complete gene sequences associated therewith.

10

Background

This invention relates to human genes. Identification and sequencing of human genes is a major goal of modern scientific research. The sequence of human genes is more than just a scientific curiosity. For example, by identifying genes and determining their sequences, scientists have been able to make large quantities of valuable human "gene products." These include human insulin, interferon, Factor VIII, tumor necrosis factor, human growth hormone, tissue plasminogen activator, and numerous other compounds. Additionally, knowledge of gene sequences can provide the key to treatment or cure of genetic diseases (such as muscular dystrophy and cystic fibrosis). The present invention represents a quantum leap forward in mankind's knowledge of human gene sequences.

20

25

There are several basic concepts of molecular biology which figure prominently in the invention. A brief explanation of those concepts follows. Additional background information and definitions for scientific terms can be found

30

-2-

in the literature. See, for example, "Glossary of Genetics, Classical and Molecular" by R. Rieger, A. Michaelis, and M.M. Green (Fifth Edition, Springer-Verlag, New York (1991)). The contents of this and other publications cited in the specification are incorporated by reference herein.

At an initial level, the present invention is based on identification and characterization of gene segments. Genes are the basic units of inheritance. Each gene is a string of connected bases called nucleotides. Most genes are formed of deoxyribonucleic acid, DNA. (Some viruses contain genes of ribonucleic acid, RNA.) The genetic information resides in the particular sequence in which the bases are arranged. A short sequence of nucleotides is often called a polynucleotide or an oligonucleotide.

Like genes, polypeptides are built from long strings of individual units. These units are amino acids. The nucleotide sequence of a gene tells the cell the sequence in which to arrange the amino acids to make the polypeptide encoded by that gene. In general, chains of up to about 200 amino acids are called polypeptides, while proteins are larger molecules made up of polypeptide subunits; both types of molecules are referred to generally herein as polypeptides. A triplet of nucleotides (codon) in DNA codes for each amino acid or signals the beginning or end of the message (anticodon). The term codon is also used for the corresponding (and complementary) sequences of three nucleotides in the mRNA into which the original DNA sequence is transcribed.

Generally, enzymes in the cell transcribe the permanent DNA of the gene into a temporary RNA copy, called messenger RNA or mRNA. The mRNA, in turn, can be translated into a polypeptide by the cell. This entire process is called gene expression, and the polypeptide is the gene product encoded by the gene.

Scientists have previously discovered how to reverse the transcription process and copy mRNA back into DNA using an

-3-

enzyme called reverse transcriptase. The resulting is called complementary DNA, or cDNA. This is schematically shown in the single Figure. When substantially all of the mRNA from one cell or tissue is converted to cDNA at once and cloned into multiple copies of a recombinant vector to allow replication and manipulation in the laboratory, the result is called a cDNA library.

The various types of genes include those which code for polypeptides, those which are transcribed into RNA but are not translated into polypeptides, and those whose functional significance does not demand that they be transcribed at all. Most genes are found on large molecules of DNA located in chromosomes. Double stranded cDNA carries all the information of a gene. Each base of the first strand is joined to a complementary base (hybridized) in the second strand. The linear DNA molecules in chromosomes have thousands of genes distributed along their length. Chromosomes include both coding regions (coding for polypeptides) and noncoding regions; the coding regions represent only about three percent of the total chromosome sequence.

An individual gene has regulatory regions that include a promoter which directs expression of the gene, a coding region which can code for a polypeptide, and a termination signal. The regulatory DNA sequence is usually a noncoding region that determines if, where, when, and at what level a particular gene is expressed.

The coding regions of many genes are discontinuous, with coding sequences (exons) alternating with noncoding regions (introns). The final mRNA copy of the gene does not include these introns (which can be much longer than the coding region itself), although it does contain certain untranslated regions that usually do not code for the polynucleotide gene product. Untranslated sequences at the beginning and end of the mRNA are known as 5'- and 3'-untranslated regions,

respectively. This nomenclature reflects the orientation of the nucleotide constituents of the mRNA.

5 A cDNA is a DNA copy of a messenger RNA, which contains all of the exons of a gene. The cDNA can be thought of as having three parts: an untranslated 5' leader, an uninterrupted polypeptide-coding sequence, and a 3' untranslated region. The untranslated leader and trailing sequences are important for initiation of translation, mRNA stability, and other functions. The untranslated leader and
10 trailing sequences are called 5'- and 3'-untranslated sequences, respectively. The 3' untranslated sequence is usually longer than the 5' untranslated leader, and can be longer than the polypeptide-coding sequence. The untranslated regions typically have many, randomly-
15 distributed stop codons, and do not display the nonrandom base arrangements found in coding sequences. The 5'-untranslated sequence is relatively short, generally between 20 and 200 bases. The 3'-untranslated sequence is often many times longer, up to several thousand bases.

20 The translated or coding sequence begins with a translational start codon (AUG or GUG) and ends with a translational stop codon (UAA, UGA, or UAG). Generally, translation begins at the first "start" codon on the mRNA and proceeds to the first "stop" codon. Coding sequences can be
25 distinguished by their nonrandom distribution of bases; numerous computer algorithms have been developed to distinguish coding from noncoding regions in this way.

Human DNA differs from person to person. No two persons (except perhaps identical twins) have identical DNA. While
30 the differences, called allelic variations or polymorphisms, are slight on a molecular level, they account for most of the physical and other observable differences between individuals. It has been estimated that approximately 14 million sequence polymorphism differences exist between
35 individuals.

-5-

The ability of one strand of DNA to attach or hybridize to a complementary strand has already been exploited for several purposes. For example, small pieces of DNA (15 to 25 base pairs long) can be made which will hybridize to longer strands of DNA which have a complementary sequence. These short "primers" can be selected such that they hybridize to a specific, unique location on the longer strand. Once the primers have hybridized to their target on the DNA, the polymerase chain reaction (PCR) can be employed to generate millions of copies of (or amplify) the particular segment of DNA between the locations to which two primers are bound. Briefly, this technique allows amplification of a DNA region situated between two convergent primers, using oligonucleotide primers that hybridize to opposite strands. Primer extension proceeds inward across the region between the two primers, and the product of DNA synthesis of one primer serves as a template for the other primer. Repeated cycles of DNA denaturation, annealing of primers, and extension result in an exponential increase in the number of copies of the region bounded by the primers.

Similarly, a labeled segment of single-stranded DNA can be hybridized to a longer DNA sequence, such as a chromosome, to mark a specific location on the longer sequence. Segments of DNA 50 bases long or longer that hybridize to a unique DNA location in the human genome are extremely unlikely to hybridize elsewhere in the human genome.

The Human Genome Project is an effort to sequence all human DNA (the human genome). The human genome is estimated to comprise 50,000 - 100,000 genes, up to 30,000 of which might be expressed in the brain (Sutcliffe, *Ann. Rev. Neurosci.* 11:157 (1988)). Once dedicated human chromosome sequencing begins in three to five years, it was expected that 12-15 years will be required to complete the sequence of the genome (Report of the Ad Hoc Program Advisory Committee on Complex Genomes, Reston, Va., Feb. 1988, D. Baltimore Ed. (NIH, Bethesda, Md, 1988)). At that rate, the majority of

human genes would remain unknown for at least the next decade. The present invention can greatly accelerate the pace at which human genes can be identified and mapped. Most gene researchers, in conjunction with publication of their results in this field, submit sequence data to the GenBank database. Prior to the present invention, GenBank listed the sequences of only a few thousand human genes and less than two hundred human brain mRNAs (GenBank Release 66.0, December, 1990).

The role of sequencing complementary DNA (cDNA), reverse transcribed from mRNA, as a part of the human genome project has been vigorously debated since the idea of determining the complete nucleotide sequence of humans first surfaced. The coding sequence of all human genes represents most of the information content of the genome, but only 3-5% of the total DNA. In contrast, cDNA (which is only made from the transcription product of active genes) is one-half to three-fourths (the remainder being 5'- and 3'-untranslated sequence) meaningful genetic information. Thus, some have argued that cDNA sequencing should take precedence over genomic sequencing (Brenner, CIBA Found. Symp. 149:6 (1990)). However, until now, such arguments have not been heeded.

Genomic sequencing proponents have argued the difficulty of finding every mRNA expressed in all tissues, cell types, and developmental states, and that much valuable information from intronic and intergenic regions, including control and regulatory sequences, will be missed by cDNA sequencing. (Report of the Committee on Mapping and Sequencing the Human Genome, National Research Council (National Academy Press, Washington, D.C. 1988)). Further, sequencing of transcribed regions of the genome using cDNA libraries has heretofore been considered impractical or unsatisfactory. Libraries of cDNA were believed to be dominated by repetitive elements, mitochondrial genes, ribosomal RNA genes, and other nuclear genes comprising common or housekeeping sequences. It was believed that cDNA libraries would provide few sequences

-7-

corresponding to structural and regulatory polypeptides or peptides. See, for example, Putney, et al., *Nature* 302:718-721 (1983). Putney, et al. sequenced over 150 clones from a rabbit muscle cDNA library and identified clones for 13 of the 19 known muscle polypeptides, including one new isotype but no unknown coding sequences.

Another perceived drawback of cDNA sequencing was that some mRNAs are abundant, and some are rare. The cellular quantities of mRNA from various genes can vary by several orders of magnitude. This led critics to believe that most information obtained from cDNA sequencing would be repetitious and useless.

The present invention demonstrates that, despite such skepticism, cDNA sequencing now provides a rapid method for obtaining enormous amounts of valuable genetic information and DNA products of great utility for the biotechnology and pharmaceutical industries. Not only can many distinct cDNAs be isolated and sequenced, even partial cDNAs can be used, with conventional, well-understood methods, to isolate entire genes, and to determine the chromosomal locations and biological functions of these genes. As is demonstrated here, fragments of only a few hundred bases are sufficient, in many cases, to identify the probable function of a new human gene if it is similar in structure to a gene from another animal, or from plants or bacteria. Similarly, even fragments of untranslated regions of a cDNA can be used to: i) isolate the coding sequence of the cDNA; ii) isolate the complete gene; iii) determine the position of the gene on a human chromosome, and hence the potential of the gene to cause a human genetic disease; and iv) determine the function of the gene by means of experiments in which the function of the native gene is disrupted by the addition of a short DNA fragment to the cell, e.g., using triple helix or antisense probes.

Because coding regions comprise such a small portion of the human genome, identification and mapping of transcribed

-8-

regions and coding regions of chromosomes is of significant interest. There is a corresponding need for reagents for identifying and marking coding regions and transcribed regions of chromosomes. Furthermore, such human sequences are valuable for chromosome mapping, human identification, identification of tissue type and origin, forensic identification, and locating disease-associated genes (i.e., genes that are associated with an inherited human disease, whether through mutation, deletion, or faulty gene expression) on the chromosome.

SUMMARY OF THE INVENTION

Contrary to the expectations of the scientific community, cDNA screening and sequencing techniques have now been used to discover a large number of heretofore unknown human genes. Disclosed herein are over 2,400 new human polynucleotide sequences. These sequences could represent up to 5% of all human genes. The novelty of these sequences has been established through comparison to both nucleotide sequence databases and amino acid sequence databases. Surprisingly, over 80% of the sequences generated were unrelated to any sequences previously described in the literature.

The sequences of the present invention were ascertained using a fast approach to cDNA characterization. This approach could facilitate the tagging of most expressed human genes within a few years at a fraction of the cost of complete genomic sequencing, provide new genetic markers, provide new DNA-based therapeutics and diagnostics, and provide other valuable nucleotide reagents.

The sequences disclosed herein, styled Expressed Sequence Tags ("ESTs"), are markers for human genes actually transcribed *in vivo*. Techniques are disclosed for using these ESTs to obtain the full coding region of the corresponding gene. The use of ESTs, complete coding sequences, or fragments thereof for marking chromosomes, for

-9-

mapping locations of expressed genes on chromosomes, for individual or forensic identification, for mapping locations of disease-associated genes, for identification of tissue type, and for preparation of antisense sequences, probes, and constructs is discussed in detail below. Unlike the random genomic DNA sequence tagged sites (STSs) (Olson et al., *Science* 245:1434 (1989)), ESTs point directly to expressed genes.

Various aspects of the present invention thus include the individual ESTs, corresponding partial and complete cDNA, genomic DNA, mRNA, antisense strands, triple helix probes, PCR primers, coding regions, and constructs. Also, where one skilled in the art is enabled by this specification to prepare expression vectors and polypeptide expression products, they are also within the scope of the present invention, along with antibodies, especially monoclonal antibodies, to such expression products.

BRIEF DESCRIPTION OF THE DRAWING

The single drawing Figure schematically illustrates the progression from chromosome to gene to mRNA to cDNA.

DETAILED DESCRIPTION OF THE INVENTION

The detailed description that follows provides not only the actual sequence of each new EST, but also explains how the ESTs were obtained, how to obtain the corresponding complete cDNA sequence and the corresponding genomic DNA sequence, how to make DNA constructs from the ESTs and corresponding sequences, how to use those sequences as reagents in molecular biology and other fields, how to produce gene products from the ESTs and corresponding sequences and antibodies to those gene products, and the functional categories of many ESTs and corresponding genes. Furthermore, numerous actual working examples and predictive

-10-

examples are provided to demonstrate and exemplify numerous aspects of the invention.

I. ESTs from cDNA Libraries

5 The sequences of the present invention were isolated from commercially available and custom made cDNA libraries using a rapid screening and sequencing technique. In general, the method comprises applying conventional automated DNA sequencing technology to screening clones, advantageously
10 randomly selected clones, from a cDNA library. Preferably, the library is initially "enriched" through removal of ribosomal sequences and other common sequences prior to clone selection. According to the present method, ESTs are generated from partial DNA sequencing of the selected clones.
15 The ESTs of the present invention were generated using low redundancy of sequencing, typically a single sequencing reaction. While single sequencing reactions may have an accuracy as low as 97%, this nevertheless provides sufficient fidelity for identification of the sequence and design of PCR
20 primers.

 Most human genes can be identified by EST sequencing from libraries of cDNA copies of messenger RNAs. However, some genes are expressed only at specific times during embryonic development, or only in small amounts in a few
25 specific cell types. Other genes have mRNAs that are degraded very quickly by the cell in which they are expressed. If any of these are the case, transcripts of the gene will not be represented in cDNA libraries so the gene will not be identifiable by EST sequencing. A new method
30 called "exon amplification", however, can be used to isolate and identify transcripts of such genes.

 Exon amplification works by artificially expressing part or all of a gene that is contained in a cloned fragment of genomic DNA such as a cosmid or yeast artificial chromosome
35 (YAC). The gene is cloned into a special vector, designed at MIT, that uses control elements from virus genes to express

-11-

the protein-coding exons of the human gene of interest. Exon trapping shows considerable promise as a general technique for identifying those genes in the human genome that cannot be found by cDNA cloning and EST sequencing. Exon amplification will also be useful for identifying the genes in regions of genomic DNA to which disease genes have been mapped. The exon amplification method can be used directly with the cosmid and YAC clones from human chromosomes that are being obtained by both NIH and DOE supported human genome centers. ESTs comprise DNA sequences corresponding to a portion of nuclear encoded messenger RNA. An EST is of sufficient length to permit: (1) amplification of the specific sequence from a cDNA library, e.g., by polymerase chain reaction (PCR); (2) use of a synthetic polynucleotide corresponding to a partial or complete sequence of the EST as a hybridization probe of a cDNA library, generally having 30 - 50 base pairs; or (3) unique designation of the pure cDNA clone from which the EST was derived (the EST clone) for use as a hybridization probe of a cDNA library. Preferably, EST-derived primer pairs and sequences amplify or detectably hybridize to a sequence from a genomic library.

It has been found that sufficient information is contained in the 150-400 base ESTs from one sequencing run to effect preliminary identification and exact chromosome mapping. Accordingly, the ESTs disclosed herein are generally at least 150 base pairs in length. The length of an EST is determined by the quality of sequencing data and the length of the cloned cDNA. Raw data from the automated sequencers is edited to remove low quality sequence at the end of the sequencing run. High quality sequences (usually a result of sequencing templates without excessive salt contamination) generally give about 400 bp of reliable sequence data; other sequences give fewer bases of reliable data. A 150 bp EST is long enough to be translated into a 50 amino acid peptide sequence. This length is sufficient to observe similarities when they exist in a database search. Furthermore, 150 bp is

-12-

long enough to design PCR primers from each end of the sequence to amplify the complete EST. Sequences shorter than 150 bp are difficult to purify and use following PCR amplification. Furthermore, a 150 bp polynucleotide is likely to give a very strong signal with low background in a screen of a genomic library.

Finally, it is highly unlikely that a sequence of the same 150 bp exists in any genes in the genome besides the one tagged by the EST. Some closely related gene family members have very similar nucleotide sequences, but no examples of pairs of human genes with long segments of identical sequence have been reported to date. For instance, there are three known β -tubulin genes in humans. Several ESTs were found that matched one or another of these tubulin genes, but several new members of this gene family were also found and could be clearly distinguished from the three known members. ESTs that match perfectly to several different genes can be detected by hybridizing to chromosomes: if many chromosomal loci are observed, the sequence (or a close variant) is present in more than one gene. This problem can be circumvented by using the 3'-untranslated part of the cDNA alone as a probe for the chromosomal location or for the full-length cDNA or gene. The 3'-untranslated region is more likely to be unique within gene families, since there is no evolutionary pressure to conserve a coding function of this region of the mRNA.

As demonstrated in the Examples that follow, ESTs can be used to map the expressed sequence to a particular chromosome. In addition, ESTs can be expanded to provide the full coding regions, as detailed below. In this manner, previously unknown genes can be identified.

While a variety of cDNA libraries can be used to obtain ESTs, human brain cDNA libraries are exemplified and represent a preferred embodiment. Suitable cDNA libraries can be freshly prepared or obtained commercially, e.g., as shown in Examples 1, 2, and 11. The cDNA libraries from the

-13-

desired tissue are preferably preprocessed by conventional techniques to reduce repeated sequencing of high and intermediate abundance clones and to maximize the chances of finding rare messages from specific cell populations. Preferably, preprocessing includes the use of defined composition prescreening probes, e.g., cDNA corresponding to mitochondria, abundant sequences, ribosomes, actins, myelin basic polypeptides, or any other known high abundance peptide; these prescreening probes used for preprocessing are generally derived from known ESTs. Other useful preprocessing techniques include subtraction, which preferentially reduces the population of certain sequences in the library (e.g., see A. Swaroop et al., *Nucl. Acids Res.* 19, 1954 (1991)), and normalization, which results in all sequences being represented in approximately equal proportions in the library (Patanjali et al, *Proc. Natl. Acad. Sci. USA* 88:1943 (1991)).

The cDNA libraries used in the present method will ideally use directional cloning methods so that either the 5' end of the cDNA (likely to contain coding sequence) or the 3' end (likely to be a non-coding sequence) can be selectively obtained."

Libraries of cDNA can also be generated from recombinant expression of genomic DNA. After they are amplified, ESTs can be obtained and sequenced, e.g., as illustrated in Example 11.

The sequences of the present invention include the specific sequences set forth in the Sequence Listing and designated SEQ ID NO: 1 - SEQ ID NO: 2412. In one aspect of this embodiment, the invention relates to those sequences of SEQ ID NOS: 1 - 2412 that comprise the cDNA coding sequences for polypeptides having less than 95% identity with known amino acid sequences (see Table 2) and more preferably less than 90% or 85% identity. In a second aspect, the invention relates to those sequences of SEQ ID NOS: 1 - 2412 that encode polypeptides having no similarity to known amino acid

-14-

sequences (see Examples that follow). Precisely because they do not contain coding regions and are therefore more unique in their sequence structures, those sequences which meet neither of the preceding criteria can be most useful and are generally preferred for mapping.

Consistent with the NIH mission and its responsibilities to disseminate knowledge and share the tangible fruits of its research, the present inventors have taken a number of steps to facilitate sequence data and clone availability. All EST sequences have been submitted to GenBank (representing an addition equivalent to 7% of the human nucleotides in Release 69 of GenBank, September 1991). The corresponding cDNA clones have been submitted to the American Type Culture Collection and information on clones and sequences has been submitted to the Genome Data Base (Pearson, P. Nucl. Acids Res. 19 (Suppl.): 2237-9 (1991)).

II. Complete Coding Sequences from ESTs

The ESTs of the present invention generally represent relatively small coding regions or untranslated regions of human genes. Although most of these sequences do not code for a complete gene product, the ESTs of the present invention are highly specific markers for the corresponding complete coding regions. The ESTs are of sufficient length that they will hybridize, under stringent conditions, only with DNA for that gene to which they correspond. Suitably stringent conditions comprise conditions, for example, where at least 95%, preferably at least 97% or 98% identity (base pairing), is required for hybridization. This property permits use of the EST to isolate the entire coding region and even the entire sequence. Therefore, only routine laboratory work is necessary to parlay the unique EST sequence into the corresponding unique complete gene sequence.

Thus, each of the ESTs of the present invention "corresponds" to a particular unique human gene. Knowledge

-15-

of the EST sequence permits routine isolation and sequencing of the complete coding sequence of the corresponding gene. The complete coding sequence is present in a full-length cDNA clone as well as in the gene carried on genomic clones. Therefore, each EST "corresponds" to a cDNA (from which the EST was derived), a complete genomic gene sequence, a polypeptide coding region (which can be obtained either from the cDNA or genomic DNA), and a polypeptide or amino acid sequence encoded by that region.

The first step in determining where an EST is located in the cDNA is to analyze the EST for the presence of coding sequence, e.g., as described in Example 14. The CRM program predicts the extent and orientation of the coding region of a sequence. Based on this information, one can infer the presence of start or stop codons within a sequence and whether the sequence is completely coding or completely non-coding. If start or stop codons are present, then the EST can cover both part of the 5'-untranslated or 3'-untranslated part of the mRNA (respectively) as well as part of the coding sequence. If no coding sequence is present, it is likely that the EST is derived from the 3'-untranslated sequence due to its longer length and the fact that most cDNA library construction methods are biased toward the 3' end of the mRNA.

One general procedure for obtaining complete sequences from ESTs is as follows:

1. Purify selected human DNA from an EST clone (the cDNA clone that was sequenced to give the EST), e.g., by endonuclease digestion using ECOR1, gel electrophoresis, and isolation of the aforementioned clone by removal from low-melting agarose gel.

2. Radiolabel the isolated insert DNA, e.g., with ³²P labels, preferably by nick translation or random primer labeling.

3. Use the labeled EST insert as a probe to screen a lambda phage cDNA library or a plasmid cDNA library.

-16-

4. Identify colonies containing clones related to the probe cDNA and purify them by known purification methods.

5. Nucleotide sequence the ends of the newly purified clones to identify full length sequences.

5 6. Perform complete sequencing of full length clones by Exonuclease III digestion or primer walking. Northern blots of the mRNA from various tissues using at least part of the EST clone as a probe can optionally be performed to check the size of the mRNA against that of the purported full
10 length cDNA.

 An EST is a specific tag for a messenger RNA molecule. The complete sequence of that messenger RNA, in the form of cDNA, can be determined using the EST as a probe to identify a cDNA clone corresponding to a full-length transcript,
15 followed by sequencing of that clone. The EST or the full-length cDNA clone can also be used as a probe to identify a genomic clone or clones that contain the complete gene including regulatory and promoter regions, exons, and introns.

20 ESTs are used as probes to identify the cDNA clones from which an EST was derived. ESTs, or portions thereof, can be nick-translated or end-labelled with P^{32} using polynucleotide kinase using labelling methods known to those with skill in the art. (*Basic Methods in Molecular Biology*, L.G. Davis, M.D.
25 Dibner, and J.F. Battey, ed., Elsevier Press, NY, 1986). The lambda library can be directly screened with the labelled ESTs of interest or the library can be converted en masse to pBluescript (Stratagene, La Jolla, California) to facilitate bacterial colony screening. Both methods are well known in
30 the art. Briefly, filters with bacterial colonies containing the library in pBluescript or bacterial lawns containing lambda plaques are denatured and the DNA is fixed to the filters. The filters are hybridized with the labelled probe using hybridization conditions described by Davis et al. The
35 ESTs, cloned into lambda or pBluescript, can be used as positive controls to assess background binding and to adjust

-17-

the hybridization and washing stringencies necessary for accurate clone identification. The resulting autoradiograms are compared to duplicate plates of colonies or plaques; each exposed spot corresponds to a positive colony or plaque. The colonies or plaques are selected, expanded and the DNA is isolated from the colonies for further analysis and sequencing.

The ESTs can additionally be used to screen Northern blots of mRNA obtained from various tissues or cell cultures, including the tissue of origin of the EST clone. Northern analysis will most often produce one to several positive bands. The bands can be selected for further study based on the predicted size of the mRNA.

Positive cDNA clones in phage lambda are analyzed to determine the amount of additional sequence they contain using PCR with one primer from the EST and the other primer from the vector. Clones with a larger vector-insert PCR product than the original EST clone are analyzed by restriction digestion and DNA sequencing to determine whether they contain an insert of the same size or similar as the mRNA size on a Northern blot.

Once one or more overlapping cDNA clones are identified, the complete sequence of the clones can be determined. The preferred method is to use exonuclease III digestion (McCombie, W.R., Kirkness, E., Fleming, J.T., Kerlavage, A.R., Iovannisci, D.M., and Martin-Gallardo, R., *Methods*: 3: 33-40, 1991). A series of deletion clones is generated, each of which is sequenced. The resulting overlapping sequences are assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a highly accurate final sequence.

A similar screening and clone selection approach can be applied to obtaining cosmid or lambda clones from a genomic DNA library that contains the complete gene from which the EST was derived (Kirkness, E.F., Kusiak, J.W., Menninger, J.,

Gocayne, J.D., Ward, D.C., and Venter, J.C. *Genomics* 10: 985-995 (1991). Although the process is much more laborious, these genomic clones can be sequenced in their entirety also. A shotgun approach is preferred to sequencing clones with inserts longer than 10 kb (genomic cosmid and lambda clones). In shotgun sequencing, the clone is randomly broken into many small pieces, each of which is partially sequenced. The sequence fragments are then aligned to produce the final contiguous sequence with high redundancy. An intermediate approach is to sequence just the promoter region and the intron-exon boundaries and to estimate the size of the introns by restriction endonuclease digestion (ibid.).

Using the sequence information provided herein, the polynucleotides of the present invention can be derived from natural sources or synthesized using known methods. The sequences falling within the scope of the present invention are not limited to the specific sequences described, but include human allelic and species variations thereof and portions thereof of at least 15-18 bases. (Sequences of at least 15-18 bases can be used, for example, as PCR primers or as DNA probes.) In addition, the invention includes the entire coding sequence associated with the specific polynucleotide sequence of bases described in the Sequence Listing, as well as portions of the entire coding sequence of at least 15-18 bases and allelic and species variations thereof. Furthermore, to accommodate codon variability, the invention includes sequences coding for the same amino acid sequences as do the specific sequences disclosed herein. Finally, although the error rate in the automated sequencing used in the present invention is small, there remains some chance of error. Therefore, claims to particular sequences should not be so narrowly construed as to require inclusion of erroneously identified bases or to exclude corrections.

Any specific sequence disclosed herein can be readily screened for errors by resequencing each EST in both directions (i.e., sequence both strands of cDNA).

-19-

The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form. As used herein, "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. Further, removal of clones corresponding to ribosomal RNA and "housekeeping" genes and clones without human cDNA inserts results in a library that is "enriched" in the desired clones.

The term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide present in a living animal is not isolated, but the same polynucleotide, separated from some or all of the coexisting materials in the natural system, is isolated.

It is also advantageous that the sequences be in purified form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition. Individual EST clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The cDNA clones are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an approximately 10^6 -fold purification of the native message. Purification of starting material or

-20-

natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.

5 In a cDNA library there are many species of mRNA represented. Each cDNA clone can be interesting in its own right, but must be isolated from the library before further experimentation can be completed. In order to sequence any specific cDNA, it must be removed and separated (i.e. isolated and purified) from all the other sequences. This
10 can be accomplished by many techniques known to those of skill in the art. These procedures normally involve identification of a bacterial colony containing the cDNA of interest and further amplification of that bacteria. Once a cDNA is separated from the mixed clone library, it can be
15 used as a template for further procedures such as nucleotide sequencing.

Although claims to large numbers of ESTs and corresponding sequences are presented herein, the invention is not limited to these particular groupings of sequences.
20 Thus, individual sequences are considered as applicants' discoveries or inventions, as are subgroupings of sequences. All of the functional subgroupings set forth in the tables define groupings for which separate claims are contemplated as being within the scope of this invention. Moreover, in
25 addition to claims to individual clones, it is intended that the present disclosure also support claims to numerical subgroupings. Thus, subgroupings of 50 ESTs (and corresponding sequences) are contemplated (e.g., SEQ ID NOS 1-50, 51-100, 101-150, etc.) as being within the scope of
30 this invention, as are subgroupings of 5, 10, 25, 100, 200, and 500 ESTs and corresponding sequences.

III. DNA Constructs

35 The present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as

-21-

a plasmid or viral vector, into which a sequence of the invention has been inserted, in a sense or antisense orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example.

Bacterial: pBs, phagescript, ϕ X174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene); pTrc99A, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia).

Eukaryotic: pWLneo, pSV2cat, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia).

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_R, and trc. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

In a further embodiment, the present invention relates to host cells containing the above-described construct. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a procaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., *Basic Methods in Molecular Biology*, (1986)).

The constructs in host cells can be used in a conventional manner to produce the gene product coded by the recombinant sequence. Alternatively, the encoded polypeptide

-22-

can be synthetically produced by conventional peptide synthesizers.

Certain ESTs have already been preliminarily categorized by analogy to related sequences in other organisms (see Table 2). Table 10 of Example 10 categorizes particular ESTs broadly as metabolic, regulatory, and structural sequences where known. Constructs comprising genes or coding sequences corresponding to each of these categories are, therefore, specifically and individually contemplated.

Table 11 more particularly separates 127 new ESTs into 13 categories using a different criteria. These are genes related to cell surface; developmental control; energy metabolism; kinase and phosphatase; oncogenes; other metabolism-related polypeptides; peptidases and peptidase inhibitors; receptors; structural and cytoskeletal; signal transduction; transporters; transcription, translation, and subcellular localization; and transcription factors. Table 11 further identifies the EST by the particular gene product for which it apparently codes. Each of these categories individually comprises a preferred category of EST, and preferred constructs and resulting polypeptide can be prepared from those ESTs or the corresponding complete gene sequence.

IV. ESTs and Corresponding Sequences as Reagents

Each of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. The sequences can be used as diagnostic probes for the presence of a specific mRNA in a particular cell type. In addition, these sequences can be used as diagnostic probes suitable for use in genetic linkage analysis (polymorphisms). Further, the sequences can be used as probes for locating gene regions associated with genetic disease, as explained in more detail below.

The EST and complete gene sequences of the present invention are also valuable for chromosome identification.

-23-

Each sequence is specifically targeted to and can hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The present invention constitutes a major expansion of available chromosome markers. One hundred ESTs have already been mapped to chromosomes. Using the techniques described in Example 5 or 6, the remaining ESTs and the corresponding complete sequences can similarly be mapped to chromosomes. The mapping of ESTs and cDNAs to chromosomes according to the present invention is an important first step in correlating those sequences with genes associated with disease.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the ESTs. Computer analysis of the ESTs is used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the EST will yield an amplified fragment.

PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular EST to a particular chromosome. Three or more clones can be assigned per day using a single thermal cycler. Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map an EST to its chromosome include in situ hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific cDNA libraries. Results of mapping ESTs to chromosomal segments are listed in Tables 3 and 4.

Fluorescence in situ hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 500 or 600 bases; however, clones larger than 2,000 bp have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. FISH requires use of the clone from which the EST was derived, and the longer the better. 2,000 bp is good, 4,000 is better, and more than 4,000 is probably not necessary to get good results a reasonable percentage of the time. For a review of this technique, see Verma et al., **Human Chromosomes: a Manual of Basic Techniques**. Pergamon Press, New York (1988).

Reagents for chromosome mapping can be used individually (to mark a single chromosome or a single site on that chromosome) or as panels of reagents (for marking multiple sites and/or multiple chromosomes). Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping (see Tables 8 and 9).

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. (Such data are found, for example, in V. McKusick, **Mendelian Inheritance in Man** (available on line through Johns Hopkins University Welch Medical Library).) The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

Next, it is necessary to determine the differences in the cDNA or genomic sequence between affected and unaffected individuals. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then

-25-

the mutation is likely to be the causative agent of the disease.

With current resolution of physical mapping and genetic mapping techniques, a cDNA precisely localized to a chromosomal region associated with the disease could be one of between 50 and 500 potential causative genes. (This assumes 1 megabase mapping resolution and one gene per 20 kb.)

Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that cDNA sequence. Ultimately, complete sequencing of genes from several individuals is required to confirm the presence of a mutation and to distinguish mutations from polymorphisms.

In addition to the foregoing, the sequences of the invention, as broadly described, can be used to control gene expression through triple helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide sequence to DNA or RNA. Polynucleotides suitable for use in these methods are usually 20 to 40 bases in length and are designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al, *Nucl. Acids Res.* 6: 3073 (1979); Cooney et al, *Science* 241: 456 (1988); and Dervan et al, *Science* 251: 1360 (1991)) or to the mRNA itself (antisense - Okano, *J. Neurochem.* 56: 560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988)). Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques have been demonstrated to be efficient in model systems. Information contained in the sequences of the present invention is necessary for the design of an antisense or triple helix oligonucleotide.

-26-

The present invention is also useful tool in gene therapy, which requires isolation of the disease-associated gene in question as a prerequisite to the insertion of a normal gene into an organism to correct a genetic defect. 5 high specificity of the cDNA probes according to this invention have promise of targeting such gene locations in a highly accurate manner.

The sequences of the present invention, as broadly defined, are also useful for identification of individuals 10 from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on 15 a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The sequences of the present invention are useful as additional 20 DNA markers for RFLP.

However, RFLP is a pattern based technique, which does not directly focus on the actual DNA sequence of the individual. The sequences of the present invention can be used to provide an alternative technique that determines the 25 actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA. One can, for example, take an EST of the invention and prepare two PCR primers from the 5' and 3' ends of the EST. 30 These are used to amplify an individual's DNA, corresponding to the EST. The amplified DNA is sequenced.

Panels of corresponding DNA sequences from individuals, made this way, can provide unique individual identifications, as each individual will have a unique set of such DNA 35 sequences, due to allelic differences. The sequences of the present invention can be used to particular advantage to

-27-

obtain such identification sequences from individuals and from tissue, as explained in Examples 12 - 14.

5 The EST sequences from Examples 1 and 2 and the complete sequences from Example 13 uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Each of the ESTs or complete coding sequences comprising a part of the present invention can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences of Table 9 for example, could comfortably provide positive individual identification with a panel of perhaps 100 to 1,000 primers which each yield a noncoding amplified sequence of 100 bp. If predicted coding sequences, such as those from Table 6, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

15 If a panel of reagents from ESTs or complete sequences of this invention is used to generate a unique ID database for an individual, those same reagents can later be used to identify tissue from that individual. Positive identification of that individual, living or dead can be made from extremely small tissue samples.

25 Another use for DNA-based identification techniques is in forensic biology. PCR technology can be used to amplify DNA sequences taken from very small biological samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, etc. In one prior art technique, gene sequences are amplified at specific loci known to contain a large number of allelic variations, for example the DQ α class II HLA gene (Erlich, H., PCR Technology, Freeman and Co.

(1992)). Once this specific area of the genome is amplified, it is digested with one or more restriction enzymes to yield an identifying set of bands on a Southern blot probed with DNA corresponding to the DQ α class II HLA gene.

5 The sequences of the present invention can be used to provide polynucleotide reagents specifically targeted to additional loci in the human genome, and can enhance the reliability of DNA-based forensic identifications. Those sequences targeted to noncoding regions (see, e.g., Tables 8
10 and 9) are particularly appropriate. As mentioned above, actual base sequence information can be used for identification as an accurate alternative to patterns formed by restriction enzyme generated fragments. Reagents for obtaining such sequence information are within the scope of
15 the present invention. Such reagents can comprise complete ESTs or corresponding coding regions, or fragments of either of at least 15 bp, preferably at least 18 bp.

 There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for
20 example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the ESTs or complete sequences of the present invention. Panels of such reagents can identify tissue by species and/or
25 by organ type. In a similar fashion, these reagents can be used to screen tissue culture for contamination.

V. Production of Polypeptide Corresponding to ESTs

 As previously explained, each EST corresponds not only
30 to a coding region, but also to a polypeptide. Once the coding sequence is known, or the gene is cloned which encodes the polypeptide, conventional techniques in molecular biology can be used to obtain the polypeptide.

 At the simplest level, the amino acid sequence encoded
35 by the polynucleotide sequence can be synthesized using commercially available peptide synthesizers. This is

-29-

particularly useful in producing small peptides and fragments of larger polypeptides. (Fragments are useful, for example, in generating antibodies against the native polypeptide.)

Alternatively, the DNA encoding the desired polypeptide
5 can be inserted into a host organism and expressed. The organism can be a bacterium, yeast, cell line, or multicellular plant or animal. The literature is replete with examples of suitable host organisms and expression techniques. For example, naked polynucleotide (DNA or mRNA)
10 can be injected directly into muscle tissue of mammals, where it is expressed. This methodology can be used to deliver the polypeptide to the animal, or to generate an immune response against a foreign polypeptide. Wolff, et al., *Science* 247:1465 (1990); Felgner, et al., *Nature* 349:351 (1991).
15 Alternatively, the coding sequence, together with appropriate regulatory regions (i.e., a construct), can be inserted into a vector, which is then used to transfect a cell. The cell (which may or may not be part of a larger organism) then expresses the polypeptide. (See Example 25.)

20 Antibodies generated against the polypeptide corresponding to a sequence of the present invention can be obtained by direct injection of the naked polypeptide into an animal (as above) or by administering the polypeptide to an animal, preferably a nonhuman. The antibody so obtained will
25 then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the polypeptide can be used to generate antibodies binding the whole native polypeptide. Such antibodies can then be used to isolate the polypeptide from tissue expressing that polypeptide.
30 Moreover, a panel of such antibodies, specific to a large number of polypeptides, can be used to identify and differentiate such tissue.

VI. Examples

35 Certain aspects of the present invention are described in greater detail in the non-limiting Examples that follow.

-30-

EXAMPLE 1

cDNA Sequences Determined by Random
Clone Selection: First set

5

METHODOLOGY:

With reference to the data presented in Table 1, lambda ZAP libraries were converted en masse to pBluescript plasmids, transfected into E. coli XL1-Blue cells, and plated on X-gal/IPTG/ampicillin plates. A total of 1058 clones were picked at random from three human brain cDNA libraries: fetal brain, two-year-old hippocampus, and two-year-old temporal cortex (Stratagene catalog #936206, 936205, 935, respectively. Stratagene, 11099 N. Torrey Pines Rd., La Jolla, CA 92037). An analysis of these clones is summarized in Table I (see below) In addition, clones selected from the hippocampus library were also analyzed after subtractive hybridization with the fibroblast library. These results are listed in the "Hippocampus Subtracted" column of Table 1.

Templates for DNA sequencing were PCR products or plasmids prepared by the alkaline lysis method. About half of the templates prepared by PCR failed to yield an amplified fragment suitable for sequencing. This was primarily due to use of PCR conditions that minimized the need for further purification of the product but also selected against amplification of long inserts (5 μ l fresh or frozen overnight culture of E. coli carrying the pBluescript plasmid, 7.5 μ M each dNTP, and 0.1 μ M each primer for 35 cycles: 94°C, 40 sec; 55°C, 40 sec; 72°C, 90 sec). A further percentage of the PCR-generated templates failed to sequence, largely due to primer-dimer or other amplification artifacts. Qiagen™ columns improved the percentage of plasmid templates, increasing the yields of usable sequence from about 60% with a standard alkaline lysis protocol to over 90%. Overall, 117 PCR-generated templates and 497 plasmid templates resulted in usable sequence. Dideoxy chain termination sequencing reactions were performed with fluorescent dye-labeled M13

-31-

universal or reverse primers. After a cycle sequencing protocol, carried out in a Perkin-Elmer thermal cycler, sequencing reactions were run on an Applied Biosystems, Inc. (Foster City, CA) 373A automated DNA sequencer. (Cycle sequencing was performed in a Perkin Elmer Thermal Cycler for 15 cycles of 95°C, 30 sec; 60°C, 1 sec; 70°C, 60 sec and 15 cycles of 95°C, 30 sec; 70°C, 60 sec with the Applied Biosystems, Inc. Taq Dye Primer Cycle Sequencing Core Kit protocol). Some sequencing reactions were performed on an ABI robotic workstation (Cathcart, *Nature* 347: 310 (1990) hereby incorporated by reference).

RESULTS:

Singe-run DNA sequence data were obtained from 609 randomly chosen cDNA clones. The number of clones sequenced from each library is summarized in Table 1. Double-stranded cDNA clones in the pBluescript vector were sequenced by a cycle sequencing protocol with dye-labeled primers and Applied Biosystems, Inc. 373A DNA Sequences. The average length of usable sequence was 397 bases with a standard deviation of 99 bases.

Subtractive hybridization has been used successfully to reduce the population of highly represented sequences in a cDNA library by selectively removing sequences shared by another library. (Schmid and Girou, *Neurochem.* 48: 307 (1987); Fagnoli et al, *Anal. Biochem.* 187: 364 (1990); Duguid and Dinauer, *Nucl. Acids. Res.* 18: 2789 (1990); Schweinfest, et al, *Genet. Anal. Techn. Appl.* 7: 64 (1990); Travis and Sutcliffe, *Proc. Natl. Acad. Sci. USA* 85: 1696 (1988); Kato, *Eur. J. Neurosci.* 2: 704 (1990)). Subtractive hybridization was therefore tested as a way of enhancing the number of brain-specific clones in the hippocampus library by hybridizing the hippocampus library with a WI38 human lung fibroblast cell line cDNA library and removing the common sequences (Schweinfest et al, *Genet. Anal. Techn. Appl.* 7: 64 (1990); Sive and St. John, *Nucl. Acids Res.* 16: 10937

-32-

(1988)). Clones from this subtraction are listed in the column "Hippocampus Subtracted" in Table 1.

The EST sequences from this Example 1 are identified as SEQ ID NOS 1-315.

TABLE 1. cDNA Library Composition Determined
By Random Clone Sequencing

-----cDNA Library-----

EST Category	Hippocampus		Hippocampus Subtracted		Fetal Brain		Temporal Cortex	
	Number	Percent	Number	Percent	Number	Percent	Number	Percent
Databases Match--Human	48	12.8	10	8.6	3	7.9	6	7.5
Mitochondrial Genes	39	10.4	14	12.2	6	15.8	0	0
Repeats: Alu, Line-1, etc.	10	2.7	7	6.0	0	0	11	13.8
Ribosomal RNA	32	8.6	7	6.0	4	10.5	0	0
Other Nuclear Genes	32	8.6	7	6.0	5	13.2	4	5.0
Database Match--Other	160	42.8	44	37.9	20	52.6	6	7.5
No Database Match	53	14.1	24	20.7	0	0	27	33.7
poly A Insert	1	0.3	3	2.6	0	0	26	32.5
No Insert								

-34-

EXAMPLE 2

Sequencing of Additional ESTs: Second set

Over 2600 additional cDNA clones have been isolated, partially sequenced and screened. The clones were isolated from four human brain cDNA libraries. The new sequences thus discovered, together with the 315 brain ESTs from Example 1, correspond to over 2400 new human genes. These data represent an approximate doubling of the number of human genes identified by DNA sequencing.

Specifically, four cDNA libraries were used as sources of clones for sequencing. Human hippocampus and fetal brain libraries, plasmid template preparation, sequencing reactions, and automated sequencing were performed as described (Adams, M.D., Kelley, J.M., Gocayne, J.D., Dubnick, M., Polymeropoulos, M.H., Xiao, H., Merrill, C.R., Wu, A., Olde, B., Moreno, R.F., Kerlavage, A.R., McCombie, W.R., & Venter, J.C. *Science*, 252: 1651-56 (1991)). A pooled probe consisting of inserts from 10 different EST clones with sequences that matched either mitochondrial genes or the 18S or 28S ribosomal RNAs was used to prescreen a gridded filter array of the hippocampus library; nonhybridizing clones are referred to as the "prescreened library". Another fetal brain library was constructed by and was a gift from Bento Soares (Columbia University). A directionally-cloned library was prepared using the method of Rubenstein, et al. (Rubenstein, J., Elizabeth, A., Brice, A., Ciaranello, R., Denney, D., Porteus, M. & Usdin, T. *Nucl. Acids Res.* 18: 4833-4842) using human adult brain mRNA purchased from Clontech (Palo Alto, CA; Catalogue # 6516-1). Of 482 clones analyzed by restriction enzyme digestion, 33% contained inserts at least 1500 base pairs in length. Stratagene hippocampus and fetal brain library totals include data from Adams et al *Science* 252: 1651.

Sequences of nuclear-encoded cDNAs that did not include interspersed repeats (Schmid, C. W. & Jelinek, W. R. *Science*

-35-

216: 1065-1070 (1982); Paulson, K. E., Deka, N., Schmid, C. W., Misra, R., Schlinder, C. W., Rush, M. G., Kadyk, L., & Leinwand, L. *Nature* 316: 359-361 (1985); Fanning, T. G. & Singer, M. F. *Biochem. Biophys. Acta* 910: 203-212 (1987))

5 were searched against all of GenBank and, in 6-frame translation, against a comprehensive, non-redundant peptide database using the network BLAST (Altschul, S. F., Gish, W., Miller, W., Myers, E.W., & Lipman, D. J. *Mol. Biol.* 215: 403-410 (1990)) server at the National Center for

10 Biotechnology Information. BLAST output was parsed, and an interactive alignment editor was used to select which matches, if any, from each search to record in a relational EST database, which was developed to track sequencing, identification, tissue localization, physical mapping, and

15 the public distribution of the clones, mapping and sequence data. For significant similarities, a putative gene name and Protein Identification Resource (PIR) gene family identification (Barker, W., George, D., Hunt, L., & Garavelli, J. *Nucl. Acids Res.* 19 (Suppl): 2231-2236 (1991))

20 for the EST were assigned. ESTs without significant matches using BLAST were searched in translation against PIR using FASTA. Ten additional marginal matches were found. A total of 2300 new EST sequences comprising 765,505 nucleotides from the current data set have been submitted to GenBank and

25 assigned accession numbers M77851-M79278 and M85308-M86179. All ESTs except those multiply representing actin, tubulin, and myelin basic protein clones were submitted. ATCC accession numbers of cDNA clones from which ESTs were derived are 77501-78999 and 81000-81756. The Genome Data Base

30 expressed D-segment numbers for these clones are D0S1E - D0S2422E. The ESTs from this Example are identified herein as SEQ ID NOs 316-2407.

EXAMPLE 3

EST Characterization: First Set

ESTs including SEQ ID NOS 1-315 were analyzed as follows. Initially, the EST sequences were examined for similarities in the GenBank nucleic acid database (GenBank Release 65.0), Protein Information Resource Release 26.0 (PIR), and ProSite (MacPattern from the EMBL data library, Fuchs R. *Comput. Appl. Biosci.* 7: 105 (1990) Release 5.0 were used). BLAST was used to search Genbank and the PIR (both maintained by the National Center for Biotechnology Information) ESTs without exact GenBank matches were translated in all six reading frames and each translation was compared with the protein sequence database PIR and the ProSite protein motif database. Comparisons with the ProSite motif database were done by means of the program MacPattern from the EMBL Data Library. GenBank and PIR searches were conducted with the "basic local alignment search tool" programs for nucleotide (BLASTN) and peptide (BLASTX) comparisons (Altschul et al, *J. Mol. Biol.* 215: 403 (1990)). PIR searches were run on the National Center for Biotechnology Information BLAST network service. The BLAST programs contain a very rapid database-searching algorithm that searches for local areas of similarity between two sequences and then extends the alignments on the basis of defined match and mismatch criteria. The algorithm does not consider the potential gaps to improve the alignment, thus sacrificing some sensitivity for a 6-80 fold increase in speed over other database-searching programs such as FASTA (Pegarson and Lipman, *Proc. Natl. Acad. Sci. USA*, 85: 2444 (1988)).

Sequence similarities identified by the BLAST programs were considered statistically significant with a Poisson P-value than 0.01. The Poisson P-value less than the probability of as high a score occurring by chance given the number of residues in the query sequence and the database.

-37-

After the BLASTN search, 30 unmatched ESTs were compared against GenBank by FASTA to determine if significant matches were missed due to the use of BLASTN for the database search. No additional statistically significant matches were found. Statistical significance does not necessarily mean functional similarity; some of the reported matches may indicate the presence of a conserved domain or motif or simply a common protein structure pattern. Those ESTs identified as fully corresponding to known human genes or proteins are not included in this disclosure. Statistically significant matches are reported in Table 2, together with the length and percent identity or similarity of each alignment.

On the basis of database searches, 609 EST sequences were classified into eight groups as shown in Table 1 (see Example 1 above). Four groups, with 197 or 32% of the sequences, consist of matches to human sequences: repetitive elements, mitochondrial genes, ribosomal RNA genes, and other nuclear genes. Forty-eight (8%) of the sequences matched non-human entries in GenBank or PIR while 230 (38%) had no significant matches. The remaining 134 (22%) sequences contained no insert or consisted entirely of polyA between the EcoRI cloning sites.

Thirty-six ESTs matched previously sequenced human nuclear genes with more than 97% identity. Four of these ESTs are from genes encoding enzymes involved in maintaining metabolic energy, including ADP/ATP translocase, aldolase C, hexokinase, and phosphoglycerate kinase. Human homologs of genes for the bovine mitochondrial ATP synthase $F_0\beta$ -subunit and porcine aconitase were also found (Table 2). Brain-specific cDNAs included synaptophysin, glial fibrillary acidic protein (GFAP), and neurofilament light chain. At least six ESTs are from genes encoding proteins involved in signal transduction: 2',3'-cyclic nucleotide 3'-phosphodiesterase (2 ESTs), calmodulin, c-erbA- α -2, $G_s\alpha$, and Na^+/K^+ ATPase α -subunit. Other ESTs were matches to genes for ubiquitous structural proteins -- actins, tubulins, and

-38-

fodrin (non-erythroid spectrin). ESTs also document the presence in the hippocampus cDNA library of the ret proto-oncogene, the ras-related gene rhoB, and one of the chromosome 22 breakpoint cluster region transcripts. Eight
5 ESTs are from genes known to be associated with genetic disorders (Online Mendelian Inheritance in Man). More than half of the human-matched ESTs from Example 1 have been mapped to chromosomes, indicating the bias of GenBank entries toward well-studied genes and proteins.

10 ESTs without significant GenBank matches were also compared to the ProSite database of recognized protein motifs. Not counting post-translational-modification signatures, fifty-four sequences contained motifs from the database. Some patterns, particularly the "leucine zipper",
15 are found in scores or hundreds of proteins that do not share the functional property implied by the presence of the motif.

Similarities to sequences from other organisms were also detected in the BLAST searches of GenBank and PIR (Table 2). Several ESTs displayed similarity to "housekeeping" genes,
20 including the ribosomal proteins S10 and L30 (rat) and the above glycolytic enzymes. EST00257 (SEQ ID NO:77) shows strong nucleotide sequence similarity to the squid (67%) and Drosophila (70.4%) kinesin heavy chain. Kinesin was first described as a microtubule-associated motor protein involved
25 in organelle transport in the squid giant axon (Vale et al, Cell 42: 39 (1985)). Six oncogene-related sequences were also among the cDNA clones sequenced. EST00299 (SEQ ID NO:180) and EST00283 (SEQ ID NO:271) show similarity to several ras-related genes and EST00248 (SEQ ID NO:102)
30 matched the 3' untranslated region of the bovine substrate of botulinum toxin ADP-ribosyltransferase. Similarities with an S. cerevisiae RNA polymerase subunit and Torpedo electromotor neuron-associated protein were also observed. Two ESTs may represent new members of known human gene families: EST00270
35 matched the three β -tubulin genes with 88-91% identity and

-39-

EST00271 (SEQ ID NO:248) matched α -actinin with 85% identity at the nucleotide level.

Among the most interesting of the primary sequence relationships was the similarity of ESTs to the *Drosophila* genes Notch and Enhancer of split. Nucleotide and peptide alignments of EST00256 (SEQ ID NO:188) and EST00259 (SEQ ID NO:227) with the *Drosophila* genes have been demonstrated. Both genes are part of a signal cascade encoded by the "neurogenic" genes that are involved in the differentiation of neuronal and epidermal cell lineages in the neuroectoderm of the developing *Drosophila* embryo (Campos-Ortega, *Trends in Neuro. Sci.* 11: 400 (1988)). It has been proposed that the Enhancer of split protein interacts with a membrane protein that is the product of the Notch gene to convert a developmental signal into an altered pattern of gene expression (id. *J. Mol. Biol.* 215: 403 (1990)). EST00256 (SEQ ID NO:188) matches near the 5' end of the Enhancer of split coding sequence, away from the mammalian G protein β subunit- and yeast *cdc4*-like elements (Hartley et al, *Cell* 55: 785 (1988); Klambt et al. *EMBO J.* 8: 203 (1989)). Part of the EST00259 (SEQ ID NO:227) match to Notch in the *cdc10/SW16* region that is similar to three cell-cycle control genes in yeast and is tightly conserved in the *Xenopus* Notch homolog, Xotch. In *Drosophila*, Enhancer of split is absolutely required for formation of epidermal tissue. Notch contains several epidermal growth factor-like repeats and appears to play a general role in cell-cell communication during development (Banerjee and Zipursky, *Neuron* 4:177 (1990)).

Seven genes were represented by more than one EST. Comparisons of all the ESTs against one another revealed two overlaps of unknown ESTs: EST00233 (SEQ ID NO:32) and EST00234 (SEQ ID NO:8) match in opposite orientations and EST00235 (SEQ ID NO:204) and EST00236 (SEQ ID NO:148) match in the same orientation beginning at the same nucleotide. Five human genes were represented by more than one EST: β -

actin (3), λ -actin (2), α -tubulin (2), α -2-macroglobulin (2), and 2'3'-cyclic-nucleotide-3'-phosphodiesterase (2). Those few instances where two or more ESTs represent different portions of a single cDNA can be readily ascertained when the sequence of the full cDNA insert is determined in accordance with Example 13.

Example 4

EST Sequences Characterization: Second Set

The ESTs of Example 2, including SEQ ID NOs 316-2407, were screened against known sequences listed in GenBank and other databases, as in Example 3. The results are reported in Table 2. The quality of the match is given as percent identity and length in base pairs for nucleotide matches and amino acid residues for peptide matches. In many cases ESTs match multiple domains on several related proteins; for example, EST00825 matches two transmembrane domains on both GABA and Norepinephrine transporters. Nucleotide databases are: GenBank (GB), and EMBL (E); peptide databases are: GenPept (GPU), Swiss-Prot (SP), and PIR.

The great majority (83%) of the partial cDNA sequences reported in Example 2 are unrelated to any sequences previously described in the literature. Based on database matches to known genes from humans as well as from such evolutionarily distant organisms as *E. coli*, yeast, *C. elegans*, *Drosophila*, barley, *Arabidopsis*, rice, and green algae, we have preliminarily identified the functional type of a number of the ESTs (Table 2). These include a novel gene similar to Notch/Tan-1 (Adams et al., *supra*), a new neurotransmitter transporter gene, and a new member of the multi-drug resistance gene family. Several genes involved in development or cell differentiation in *Drosophila* are represented by similar human ESTs, including seven in *absentia* (Carthew, R. & Rubin, G. Cell 63: 561-577 (1990)),

-41-

big-brain (bib) (Rao, Y., Jan, L., & Jan, Y. *Nature* 345: 163-167 (1990)), the discs tumor suppressor (Woods, D. & Bryant, P. *Cell* 66: 1-20 (1991)), and the homeotic gene orthodenticle (Finkelstein, R., Smouse, D. Capaci, T., Spradling, A. & Perrimon, N. *Genes. Dev.* 4: 1516-1527 (1990)). New members of gene families previously known in humans include a Ca^{+2} -transporting ATPase, an ADP ribosylation factor, and a new neural-cell adhesion molecule gene.

The 1971 ESTs without a putative identification were analyzed using the coding-region prediction program CRM via the GRAIL server (Uberbacher, E. & Mural, R. *Proc. Natl. Acad. Sci. USA* 88: 11261-5 (1991)). Fifteen percent of the unknown ESTs scored an excellent probability of containing protein-coding sequence. Fifty percent of the ESTs to known human genes contain protein-coding sequences, therefore, at most half of the unknown ESTs are likely to contain coding sequences. We have found no evidence that genomic DNA or cDNA to unspliced precursor RNA is a major contaminant of either the hippocampus or fetal brain library.

-42-

Table 2: ESTs Identified by Database Matches

SEQ ID	EST#	Putative Identification	Accession	DB	Len	%ID
208	EST00250	60K filarial antigen	A28209	PIR	108	56.9
2320	EST01784	60K filarial antigen	A28209	PIR	88	50.6
969	EST01982	ADP-ribosylation factor 1	B33283	PIR	84	41.2
1834	EST01620	AMP deaminase, brain	A37056	PIR	57	100.0
97	EST00289	Aconitase	A35544	PIR	105	90.6
251	EST00370	Actin, other	S10021	PIR	44	51.1
248	EST00271	Actinin, alpha	HUMACTAR	GB	271	85.3
891	EST01891	Actinin, alpha	HUMACTAR	GB	315	81.6
1500	EST02538	Actinin, alpha	HUMACTAR	GB	271	75.0
132	EST00110	Agrin	RATAGR	GB	269	82.2
1852	EST01825	Agrin	RATAGR	GB	103	84.6
1094	EST02113	Ala	HUMALA	GB	92	82.8
691	EST00675	Alcohol dehydrogenase	RICGOS2G_1	GPU	38	59.0
2408	EST00244	Amyloid A4	HUMAFPA4	GB	135	91.9
1965	EST01684	Amyloid A4	A29030	PIR	52	54.7
2068	EST01694	Amyloid A4	QRHUA4	PIR	83	69.0
2092	EST01700	Anion exchanger homolog AE3	A33638	PIR	95	97.9
1880	EST01634	Axonal glycoprotein TAG-1	A34695	PIR	69	87.1
1492	EST02530	B cell-specific Mo-MLV integration site 1 (bmi-1)	MUSBMI1A	GB	111	87.5
1277	EST02306	Bib protein	S09699	PIR	57	53.4
13	EST00255	Cadherins	CADN\$HUMAN	SP	41	45.2
1348	EST02378	cAMP-dependent protein kinase inhibitor	MUSPKI	GB	234	91.5
1931	EST01041	cAMP-regulated phosphoprotein	B35308	PIR	21	86.4
1413	EST02447	cAMP-specific phosphodiesterase	HUMPDEAA	GB	363	69.0
396	EST01443	CDPdiacylglycerol-serine O-phosphatidyltransferase	JH0368	PIR	33	41.2
1956	EST01663	Ca2+-transporting ATPase 2	B28085	PIR	125	88.9
1126	EST02146	Calbindin D28	RATCALBD28	GB	81	87.8
1039	EST02055	Calcium channel	S05054	PIR	33	67.6
1910	EST01645	Calmodulin	RATRCM1	GB	120	90.1
485	EST01466	Calmodulin-dependent protein kinase, type II, beta	A28464	PIR	93	98.9
913	EST01913	Clathrin coat assembly protein AP50 homolog	YSCYAP54_1	GPU	62	63.5
2004	EST01676	Cofilin	PIGCOFIL	GB	132	89.5
2400	EST01824	Cysteine-rich intestinal protein	GYRTI	PIR	56	66.7
1588	EST02633	D2223 repetitive DNA	HUMREP	GB	160	76.4
2192	EST01257	Diacylglycerol kinase, lymphocyte	S09156	PIR	44	42.2
1441	EST02477	Diamine acetyltransferase	ATDA\$HUMAN	SP	74	45.3
650	EST00642	Dilute (myosin heavy chain)	MUSDILUTE_1	GPU	27	100.0
2302	EST01779	Disca-large tumor suppressor	DRODLGA_1	GPU	53	83.0
188	EST00256	Enhancer of split	A30047	PIR	86	58.6
2289	EST01325	Fatty acid synthase	RATFAS	GB	98	79.8
310	EST00377	Fo ATPase beta subunit, mitochondrial	BOVMTASB	GB	293	85.4
1332	EST02362	GA binding protein, beta subunit	MUSGAC_1	GPU	86	90.8
1667	EST00825	Gamma-aminobutyric acid transporter	A35918	PIR	26	59.3
2217	EST01738	Gelation factor ABP-280	A37088	PIR	74	80.0
1412	EST02446	Glutamate-aspartate carrier protein	JV0092	PIR	57	37.9
1020	EST02034	Glutaminase	GLS\$RAT	SP	34	74.3
1885	EST01639	Histocompatibility antigen modifier 1	A37779	PIR	63	75.0
1495	EST02533	Hypothetical 43.5K protein	JU0319	PIR	43	52.3
2326	EST01791	Inositol-1,4,5-trisphosphate 3-kinase	JN0129	PIR	65	68.2
SEQ ID	EST#	Putative Identification	Accession	DB	Len	%ID

SUBSTITUTE SHEET

-43-

724	EST01529	Interferon-induced 54K protein	IN14#HUMAN	SP	76	70.1
1035	EST02051	J1 protein	MUSJ1PRO	GB	362	85.7
1229	EST02258	KUP protein	HUMKUPMR_1	GPU	54	36.4
993	EST02007	Kinase 5 protein	CHKCEK5_1	GPU	68	94.2
77	EST00257	Kinesin	A35075	PIR	57	86.2
78	EST00258	Kinesin	A35075	PIR	62	47.6
2245	EST01748	Kinesin	A35075	PIR	98	52.5
2282	EST01764	Lamin B receptor	A38427	PIR	76	71.4
2173	EST01724	Lon protease	JQ0901	PIR	103	41.3
1427	EST02463	Long-chain-fatty-acid-CoA ligase	A36275	PIR	36	62.2
313	EST00276	Lysosomal membrane glycoprotein 1 (LAMP-1)	A31959	PIR	53	48.3
161	EST00247	MARCKS (myristoylated alanine-rich protein kinase	BOVMARCKS	GB	139	83.6
1386	EST02418	MARCKS homolog	MMF52	EU	237	92.4
769	EST00734	MARCKS homolog	S08341	PIR	61	40.3
43	EST00371	Maternal G10 protein	S05955	PIR	38	92.3
1468	EST02505	Matrin 3	RATMATRIN3	GB	137	93.5
639	EST00632	Membrane transport superfamily (GTP-dependent)	A24400	PIR	63	39.1
1894	EST01643	Membrane transport superfamily (GTP-dependent)	A24400	PIR	71	50.0
824	EST01865	Microtubule-associated protein 1B	RATNEU	GB	293	86.4
223	EST00368	Microtubule-associated protein 1B	A33845	PIR	30	54.8
2032	EST01683	Microtubule-associated protein 1B	A33845	PIR	49	62.0
2017	EST01678	Milk fat globule membrane protein	A36479	PIR	48	61.2
1704	EST01580	Myeloid differentiation primary response gene MyD1	MUSMYD118_1	GPU	76	88.3
2226	EST01744	NAD(P)+ transhydrogenase (B-specific)	DEBOXM	PIR	88	93.1
1567	EST02610	Neural cell adhesion molecule L1	S05479	PIR	82	43.4
506	EST01471	Neuraxin	S06017	PIR	120	84.3
1566	EST02609	Neutrophil oxidase factor	A34855	PIR	43	47.7
952	EST01981	Notch/Xotch	HUMTAN1_1	GPU	85	57.0
227	EST00259	Notch/Xotch	A35844	PIR	74	85.3
1395	EST02429	Nuclear factor 1-like protein (NF1)	HAMNF1A	GB	111	92.0
1681	EST01573	Nucleoside diphosphate kinase	A33386	PIR	71	52.8
346	EST01828	Otd homeotic protein	A35912	PIR	35	52.8
2254	EST01751	Phosphatidylinositol-4,5-bisphosphate phosphodiester	A28807	PIR	40	90.2
1869	EST00992	Polymyxin B resistance	A32714	PIR	20	76.2
93	EST00287	Processing enhancing protein	S03968	PIR	96	58.8
2353	EST01806	Prohibitin	RATPROHIB_1	GPU	120	97.5
2297	EST01775	Prohormone cleavage enzyme	MUSMPC1A_1	GPU	91	93.5
9	EST00376	Prolyl endopeptidase	PIGPREP	GB	223	83.9
1069	EST02087	Protein kinase C, zeta	HUMPKCL	GB	382	58.7
1933	EST01650	Protein phosphatase 2A beta subunit	HUMPROP2AB	GB	288	76.8
202	EST00298	Protein-tyrosine phosphatase LRP	LRP#MOUSE	SP	62	44.4
1654	EST01572	Protochlorophyllide reductase	S04783	PIR	34	57.1
38	EST00374	RNA polymerase II 6th subunit (RPO26)	A36352	PIR	72	75.3
1478	EST02515	Rab5	F34323	PIR	91	82.6
2368	EST01389	Radial spoke protein 3	S05962	PIR	58	52.5
37	EST00038	ras p21-like small GTP-binding protein (smg GDS)	BOVSMGGDS	GB	131	89.4
180	EST00299	ras-related proteins	S10493	PIR	51	46.1
1700	EST01579	Retrovirus-related gag polyprotein	FOHUE2	PIR	95	77.1
1511	EST02550	Retrovirus-related pol polyprotein	GNLJGL	PIR	50	54.9
102	EST00248	rho H12/ ARH12	BOVBGBRH	GB	195	79.6
1715	EST01583	Ribosomal protein L18a	R5RT18	PIR	68	95.7
SEQ ID	EST#	Putative Identification	Accession	DB	Len	%ID

-44-

1856	EST01627	Ribosomal protein L1a	A24579	PIR	75	63.1
1974	EST01667	Ribosomal protein L3	JQ0771	PIR	74	80.0
301	EST00300	Ribosomal protein L30	R6RT30	PIR	57	96.5
22	EST00301	Ribosomal protein S10	R3RT10	PIR	66	97.0
2402	EST01826	Ribosomal protein S10	R3YM10	PIR	36	51.4
463	EST01459	Ribosomal protein YL10	S11581	PIR	40	68.3
1408	EST02442	Seven in absentia	A36195	PIR	46	80.8
299	EST00249	smg p25A GDP dissociation inhibitor	A35652	PIR	97	77.5
951	EST01960	Spectrin, beta	HUMSPTB	GB	268	67.7
2089	EST01699	Sperm membrane protein	A35981	PIR	52	58.5
2073	EST01697	Succinate dehydrogenase flavoprotein	BOVSDHFP1_1	GPU	44	100.0
2138	EST01715	Succinate dehydrogenase flavoprotein	BOVSDHFP1_1	GPU	49	92.0
430	EST00472	Synaptotagmin (p65)	SY654HUMAN	SP	27	53.6
1371	EST02402	Talin	MUSTALINR_1	GPU	79	81.2
1771	EST01601	Thiosulfate sulfurtransferase (rhodanese)	ROBO	PIR	65	81.8
300	EST00232	Transforming protein (dbl)	TVHUDB	PIR	25	65.4
189	EST00282	trkB	A35104	PIR	33	67.6
653	EST01512	Tubulin, alpha	HUMTUBAG	GB	223	75.0
594	EST01490	Tubulin, beta	HUMT885	GB	298	93.6
757	EST01542	Tubulin, beta	HUMT88M	GB	217	90.4
1245	EST02274	Tubulin, beta	A26581	PIR	105	88.7
1147	EST02169	Tyrosine kinase	HUMECK	GB	384	74.3
1701	EST00863	Unc-104	JN0114	NR	36	45.0
2121	EST01711	Valine-tRNA ligase	A29871	PIR	56	57.9
187	EST00152	Wilm's tumor-related protein	HUMQM	GB	228	99.6
1728	EST01588	XPR2 alkaline extracellular protease	B26955	PIR	88	48.1
249	EST00275	Zinc Finger Proteins	S06551	PIR	25	57.7
413	EST01446	Zinc Finger Proteins	S00754	PIR	45	60.9
469	EST01460	Zinc Finger Proteins	C32891	PIR	34	54.3
833	EST01560	Zinc Finger Proteins	S00754	PIR	105	67.0
1230	EST02259	Zinc finger proteins	S00754	PIR	71	62.5
1496	EST02534	Zinc finger proteins	A34612	PIR	50	45.1
2324	EST01352	Zinc Finger Proteins	S10397	PIR	29	56.7

SUBSTITUTE SHEET

-45-

There is little redundancy in EST sequencing according to the present invention. Of the nuclear-encoded messenger RNAs, the most common ESTs were to the β -actin (0.6% of the EST clones) and myelin basic protein genes (MBP, 0.5% of the clones). MBP, a highly expressed structural component of nerve tissue (Kamholtz, J., de Ferra, F., Puckett, C., & Lazzarini, R. *Proc. Natl. Acad. Sci., USA* 83: 4962-4966 (1986)), displays four alternate splicing forms, of which at least two are present among the ESTs reported here. Other common ESTs were Gs-alpha gamma-actin and both α - and α -tubulin.

By matching ESTs to known database sequences, a phenotypic characterization of the tissue begins to emerge. Protein superfamilies matched by ESTs were grouped into three broad functional categories to assess the biological spectrum represented by these randomly selected cDNA clones. Structural and metabolic classes comprised about 30% of the ESTs with database matches. Twenty-five percent were involved in regulatory pathways and the remainder were not classifiable. Eleven of the eighteen enzymes of glycolysis and the citric acid cycle are represented by at least one subunit or isozyme. In addition, several genes not previously known to be expressed in the brain were matched, including spermine/spermidine acetyltransferase (Casero, R., Celano, P., Ervin, S., Applegren, N., Wiest, L. & Pegg, A. *J. Biol. Chem.* 266: 810-814 (1991)) and osteopontin (Young, M., Kerr, J., Termine, J., Wewer, U., Wang, M., McBride, W. & Fisher, L. *Genomics* 7:491-502 (1990)).

30

EXAMPLE 5**Mapping of ESTs to Human Chromosomes**

Randomly selected ESTs corresponding to SEQ ID NOs. were assigned to chromosomes via PCR (see Table 3). Oligonucleotide primer pairs were designed from EST

-46-

sequences to minimize the chance of amplifying through an intron. The oligonucleotides were 18-23 bp in length and designed for PCR amplification using the computer program INTRON (National Institutes of Mental Health, Bethesda, MD). The program is based on the assumptions that: 1) introns are genomic sequences that interrupt the coding and noncoding sequences of genes (Smith, J. Mol. Evol. 27:45-55 (1988)); 2) there are consensus sequences for splice junctions (Shapiro, et al., Nucl. Acids Res. 15:7155-7174 (1987)); and 3) that 90% of the human genes studied have 3' untranslated regions of mRNA not interrupted by introns in the genomic DNA (Hawkins, Nucl. Acids Res. 16:9893-9908 (1988)).

The program evaluates the likelihood that a given GG or CC dinucleotide represents a former exon-intron boundary. Specifically, every input strand is processed by the INTRON program twice, first evaluating the sense mRNA strand, and then processing the complementary or anti-sense strand. The program evaluates each sequence by finding all GG or CC pairs (possible former splice sites), searching for STOP codons in all three reading frames, and analyzing the GG or CC pairs surrounded by stop codons. All regions of the EST that are unlikely to contain splice junctions based on CC content, GG content, and stop codon frequency are then marked by the program in uppercase.

The creation of PCR primers from known sequences is well known to those with skill in the art. For a review of PCR technology see Erlich, H.A., PCR Technology; Principles and Applications for DNA Amplification. 1992. W.H. Freeman and Co., New York. ESTs were examined for the presence of stop codons in each reading frame and for consensus splice junctions. The presence of stop codons and absence of splice junction sequences are more characteristic of 3' untranslated sequences than of introns. The untranslated sequences are unique to a given gene; thus, primers from

-47-

these regions are less likely to prime other members of a gene family or pseudogenes.

The primers were used in polymerase chain reactions (PCR) to amplify templates from total human genomic DNA. PCR conditions were as follows: 60 ng of genomic DNA was used as a template for PCR with 80 ng of each oligonucleotide primer, 0.6 unit of Tag polymerase, and 1 uCi of a ³²P-labeled deoxycytidine triphosphate. The PCR was performed in a microplate thermocycler (Techne) under the following conditions: 30 cycles of 94°C, 1.4 min; 55°C, 2 min; and 72°C, 2 min; with a final extension at 72°C for 10 min. The amplified products were analyzed on a 6% polyacrylamide sequencing gel and visualized by autoradiography. If the size of the resulting product was equivalent to the EST from which the primers are derived, then the PCR reaction was repeated with DNA templates from two panels of human-rodent somatic cell hybrids; BIOS PCRable DNA (BIOS Corporation) and NIGMS Human-Rodent Somatic Cell Hybrid Mapping Panel Number 1 (NIGMS, Camden, NJ).

PCR was used to screen a series of somatic cell hybrid cell lines containing defined sets of human chromosomes for the presence of a given EST. DNA was isolated from the somatic hybrids and used as starting templates for PCR reactions using the primer pairs from EST sequences selected above. Only those somatic cell hybrids with chromosomes containing the human gene corresponding to the EST will yield an amplified fragment. ESTs were assigned to a chromosome by analysis of the segregation pattern of PCR products from hybrid DNA templates. For a review of techniques and analysis of results from somatic cell gene mapping experiments. (See Ledbetter et al., *Genomics* 6:475-481 (1990).) The single human chromosome present in all cell hybrids that give rise to an amplified fragment represents the chromosome containing that EST.

The assignment of 100 ESTs and corresponding genes to chromosomes by PCR is shown in Table 3.

-49-

Table 3: Assignment of ESTs to Chromosomes by PCR

SEQ ID	EST#	Chr	PRIMER #1	PRIMER #2
5	EST00012	1	TCCAGGCAATCCCAGAATAG	CTAATTGAGCTCACTGGCCC
57	EST00058	1	CTGTTTGCAAGTTTCAAAGC	GCCATTTCTAACAACCAGAG
64	EST00066	1	GCCATTGTGCTGAATAGAGT	GTTAGTGTTCCTTAGCAAG
83	EST00079	1	CAGCTAATTGACCTGGGCTA	CAACATGCTCTGAGCTTTAG
83	EST00079	1	GGCAGAGCATAATGAGTATA	CATATGCATATGGTCCCTAT
91	EST00086	1	AGTTTAGATGGAGGGCTGTC	TCTGCCCTAATGCGCAGGCT
105	EST00365	1	CTTAATCACCTCCCTTTTGT	CCTTAGTTGGAGATAAGGTC
109	EST00095	1	AGTCTAATCCTGTACACTTG	CGGGCTTTCTCTGAATTGGT
116	EST00100	1	TTAGAAGTGCCCATGGGAGG	TTTTAAGGCTCTGGAGTGTT
141	EST00118	1	CTCAGAGAACTTAGGTGAA	CTACAGAATCATTTCACCAG
220	EST00372	1	AAGTTGCACATTGCCCAAGG	ATAGTACTGCAAGGTTATTTC
237	EST00187	1	TTACAAATTTCTTTGACGC	CTGAAGGAGCACAGTTTCTC
242	EST00192	1	GGATCAGATAATCAAACAGG	GCTTAGGATATGAATGCATA
259	EST00202	1	GCATCACAGTTTAACTGAGG	CTACATATTTGTGCCTCCTT
269	EST00293	1	CTGTTGCTGTGTCAGTAGCTT	CTTTTGACCCAGTGAAACTT
299	EST00249	1	GATCATGCAGACGTAGATAT	CCAACCTCTGCCAGATCATT
1651	EST00810	1	TAGTCGCTGTAAGTTGATTC	GCTTTGCTGGATGCTTCATT
16	EST00021	2	CAGGCAAGTTTCTTCCAGGA	TCAGACCCATGGTCAGCTT
1898	EST01013	2	GGCTGAGAACGGTTAGCATA	CCCTCAGCTTAGGGGAATG
8	EST00234	2	TAGAAGGCCAACTATGTCCC	GGTTGAGGATTGGCTTTTAC
36	EST00037	2	AGCCAGAAGGCTGCTTAAAG	GCAGTGAACCCAGTACTCCTA
123	EST00106	2	GTCTAATTTGTAACCTTCAG	GATAGATTGTATAAGAAGCC
192	EST00155	2	GATTTATGTCTGGGAACATA	GCAGCATGTGAAAGAATGAT
200	EST00162	2	TTTAATGGGTGGTGGGAGCT	CGATGCACATCCTTCTCCAT
284	EST00216	2	CCTAAGAATTCGTTTGGCTC	GTCTGGCACATAATAGATTG
102	EST00248	3	ATACTACATCTAGTCTGG	TTACAGTTCTGTGGTTTTT
167	EST00138	3	AAACAGCTGCGGAGTACA	AAAGGATCTCCACTCCAGA
12	EST00274	3	CCTAGCAAACCTCATAACAC	CATAAGTGAATGGACACAGG
60	EST00062	3	ACACATTAAACGGTGTGTCAG	GGAATCAGCCCTTGAGGACT
77	EST00257	3	AAGCTCACAAACGAGATCTG	CTGGAACAGCTTACAAAGGT
107	EST00093	3	ATTGAACTCTGTCAACAGTG	TGTAAACAAAGGCCAAACT
108	EST00094	3	AL2 - GCAGGATGTCAGTCTTTGAG	AGCACACATTATCTACCACGGC
1706	EST00857	3	AL2 - GCAGGATGTCAGTCTTTGAG	CCAGCACACATTATCTACCACG
37	EST00038	4	AACTTCGCGAGTCATGAGAAC	TGTATCGGGCAGTTCTCAG
6	EST00013	4	CACATGTTCTCCCTCTTTCA	GCATTTTGAGCTCTTCCGT
37	EST00038	4	AL2 - GGAAGTACAGGATTGGC	TTAGAGATGGGATGATGCCG
31	EST00033	5	TGGGTACCCCTAAGGTGTTTG	GACTAATCTAAGGTCTAGG
28	EST00030	5	AGATAAGTTAGGAAGCTGGT	ACTACTGTAGTATCATCC
59	EST00061	5	AAAGTTTCTTAGCACCCCCC	CAGACTTTGACAAAAGAATC
74	EST00073	5	ATCAGACACGTGGCAGGGTT	AAGTCCCTGAGGGTGCAGAA
121	EST00104	5	TGAAGGCAGCTGCTAAATCT	GGATGTATTGATCTGACTCA
149	EST00123	5	ATACTGTCAACGGAGGGTGA	GTCTGCAGGTTTCTCCTTGA
235	EST00185	5	TTACTGTCCCATCAGATATC	TACACTCTTAAAGAGGTATG
1643	EST00803	5	GAGCGTTTAAAAGAGATTCT	TACAGACAGCCATGTTCCAA
1677	EST00835	5	AL2 - TCTCCAACACAGTCATGC	CGGATGCCATCATATACC
23	EST00026	5	CCTGCAGTGCACTTAACAT	CTGCTCACCTGAAATTGATAC
121	EST00104	5	AL2 - CAGATCAATACATCTCTGGG	CTGTGCAGTGGTGAGTAAAGG

SUBSTITUTE SHEET

-50-

SEQ ID	EST#	Chr	PRIMER #1	PRIMER #2
1	EST00007	6	TAGTTGATGGTCTGGGTTAT	GAAATCCCAGGGAGACAATG
19	EST00023	6	CAACTTACATTAGGGGTTTG	GACCTCATTAGAAGAGCCCA
155	EST00129	6	GGAAGCTGCCATATAAGCTC	TCAGTGTCTGACAATCTACC
224	EST00356	6	GCTGTATGTTAACCCTTTGT	TGGAACCTCAAACACTGCT
288	EST00219	6	ACTTTCATGTTGAGAAGTAT	ATCTAGCTGAAACATTGCTG
1638	EST00798	6	CTTCATCTGTTAACTGTTGA	TGAAAATGAGTCACAGGCAG
1675	EST00833	6	AL2 - ACCCAGTTCTCAAAGACC	GGTTTACCATTTCAGAGGC
22	EST00301	6	CTCCGTGATTACCTTCATCT	TTGTAGGTATCTCTGTACGCT
207	EST00167	7	GGTGTACTTTGTGAATGCT	AGCAATGTGATTTTGTAGG
137	EST00272	7	AGTGGTCACTATCTACATGG	GATTCAGAATTACTAAGCCG
1659	EST00817	7	TGTATAGGCTCTACATAAAG	CTTAATCATGGATTCTTCGT
1680	EST00838	7	AL2 - GTTCTTTCCACGGTATGC	TTGTTGGTACTGAGGAAGTGCG
292	EST00223	8	TGCAGCAGTGACCATGAGAA	ATCATCTTTCCACGCGGCTT
134	EST00375	9	TCTGGGCTTCTGTGTTCAA	CTGGCTGCTCAGCAACTCAT
1906	EST01021	9	GGATGTTTTCTATGTGACGA	TTCCAGTGCCCCCTTTTGTCC
1645	EST00804	10	CTCCTTTGGGACAAACAACT	CCAACCCAAACATATTCTA
20	EST00024	10	AGCTGTTCTCTGAGAGATGCA	CCTTGTGAAGAAAGACTTTC
157	EST00131	10	TACGCAACAGGTCACTTGG	CTAAGCAATCTGCATGCTCAG
172	EST00142	10	TACTAGCATTTCTTACTCTC	TATGCTGATTGTTTGCACCTC
250	EST00197	10	GGTGATTAGAGAGTCTGTTG	GAACCTCTGTAGTGTTCTAAA
133	EST00111	11	GGAAATTAGGCTTAGCTCAC	GTGCGAATACTTAGAGTCC
178	EST00294	11	TTTTGAAGGAAGTGATTTCC	TAGGGCCACCTCCAGTTCAT
10	EST00016	11	GTCCTTGGATTCTACGTAGA	CGATAATGACATTTCTTCTGG
126	EST00109	11	AL2 - CTAACCACAACCACACATTG	CCTCAGCACAAGAGAAGATGG
7	EST00014	12	AACCTGCAACATAAATACTAG	GAGCAATGATTTCTAACAGT
254	EST00200	13	TTGTGTACTGTCTGATAGAC	TAAGCCATGGGCATCTATAA
2409	EST00273	13	GCAAGATGATGGAACATCCC	TTCTTCTGAGGGCTCTACA
170	EST00295	14	GGTGCTTAAGGCCACTTTTG	CTTAGAGGATCATAGGCTCG
255	EST00201	14	CCAGGAGAGTAAGAAGATCA	GCAGAGTTGAATATGAACCT
290	EST00221	14	GTGCCAAGATGGCTCATGTA	GTATAGCTTTAAGCCAGTTC
293	EST00224	14	AATGCATTATGCCTGGTCTT	GGAAAAGTCTAGAACTTAGT
1664	EST00822	14	GGGTCAGAATTAAGAGGTCT	GTTTATCTCTAACTCCTTTC
315	EST00008	14	AAGCTGGCTGGGAAATGTTT	GTCTAGCTAGTAACTTACAC
1689	EST00845	14	AL2 - AGGAGGAAGCTGAAATCC	GGAAAGTCCATAAGAGACTCACC
95	EST00088	15	GTGACAGACCATGTCTATTG	AAGTGAGCGATTGCACCTTC
205	EST00165	15	AGGATGACCTGAGTGAGCTG	CCATGGCAGCAAGGAACTCT
33	EST00034	16	TGTGTGAAAGGGAGTCTTGT	CCATTTTGACTGTTCCATAG
247	EST00279	16	TGGCTAGGGCAGGCCTTAAA	GAGAAGAATATCAAATGGGG
18	EST00373	16	CCATCTGTGTCCCAATTAAGC	AGGGAAGAAGTCTAGAGCGA
68	EST00068	17	CAAAGACGGGAGACGAATGA	AGTGGAAACGCGTGGCCTATG
1652	EST00811	17	GAGCTGCATGTTGATAAGTA	TTGACTTAAGCTGACCTTAA
1702	EST00854	17	AL2 - TTGCTGTGGAATCCATGAGAG	GGCAAGTGATCTGTTCTTGG
84	EST00080	19	AGAGATGTCACTCCATTATC	CTATTCCACCTTACTCAAGG
223	EST00368	19	CATCATGTCTGGAGACGCATT	TGGATGACCTGAGTCTGCAG
21	EST00025	20	AGTTCCTGGAGGCTAGGAGTT	ATGTAAGGACCCCTAGATGG
210	EST00168	20	TGTCAACTTCCCTTTGGCCT	GAAGCTTGCTCATTACAGGAA
136	EST00113	20	AL2 - TCGGAGAAGTTGCAGTTTCTG	GTTAAAAGCTGTTAGACGGGGC
120	EST00103	22	CACTGACTGACTCCTCTTTA	GGAACCGTAACTCTCCATAG
313	EST00276	X	ATTGACCTTCAATGTAATAA	TTGGATTGGGCAAAATAG

SUBSTITUTE SHEET

-51-

<u>SEQ ID</u>	<u>EST#</u>	<u>Chr</u>	<u>PRIMER #1</u>	<u>PRIMER #2</u>
162	EST00133	X	ATGTGAGCATCTATACCTGC	AATGAAGGCATGAGAATAGG
1669	EST00827	X	CGGACAAC TAGGATAAATGC	TACGCGTTTGAATGGCTTGA
1917	EST01029	X	GAATAGCATTATTAGCCAGT	GGACCTATTGGAGATCTACT
1708	EST00858	X	AL2-AAGGCGAGGATTATGTGC	TTCTACTGGGTACACTTCGACC

Abbreviation: AL2: Amino-Link-2 Fluorescent Tag, Chr.: Chromosome.

SUBSTITUTE SHEET

The foregoing techniques have been used to further localize 9 ESTs and their associated genes to precise locations onto chromosome 6 or chromosome X, as reflected in Table 4A (in Example 7 below), using sublocalization techniques that employ somatic cell hybrids. ESTs were used as hybridization probes and mapped to other chromosomes using techniques disclosed in Example 7. Somatic cell hybrids were prepared that contained defined subsets of chromosomes 6 and X. Methods for preparing and selecting somatic cell hybrids are known in the art. For a review of an exemplary procedure to generate somatic cell hybrids containing the short arm of human chromosome 6, see Zoghbi, et al., *Genomics* 9(4):713-720 (1991). For a general review of somatic cell hybridization see Ledbetter et al. (*supra*). The hybrids were processed to obtain DNA and analyzed by PCR and by fluorescence in situ hybridization. SEQ ID NOs 19, 22, 1, 224, 288 mapped to chromosome 6, while SEQ ID NOs 162, 1917, 1699 and 1899 mapped to chromosome X using somatic cell hybrids.

EXAMPLE 6

Mapping of All ESTs to Human Chromosomes

The procedure of Example 5 is repeated for all of the ESTs from Examples 1 and 2 not previously mapped to human chromosomes. Data are generated corresponding to the data in Table 3 for all of the unmapped ESTs. As previously mentioned, virtually all of the ESTs will map to a unique chromosomal location. The inability of any ESTs to localize to a unique location will be readily ascertainable during the mapping process.

Physical mapping of the type reported in Table 4 on all the EST clones reported here would provide human chromosome markers spaced on average every 1.2 megabases and would roughly double the number of expressed sequences that have been localized to chromosomes (McKusick, V. FASEB

-53-

J. 5: 12-20 (1991)). Mapped ESTs are also a new resource to identify candidates for the estimated 5000 single-locus disease-associated genes (Id.).

EXAMPLE 7

5 **Alternative Technique for Mapping to Chromosomes**
 Mapping of ESTs to chromosomes using fluorescence in situ
 hybridization

10 This technique was used to map an EST to a particular location on a given chromosome. Cell cultures, tissue, or whole blood were used to obtain chromosomes.

 0.5 ml. of whole blood was added to RPMI 1640 and incubated 96 hours in a 5%CO₂/37°C incubator. 0.05 ug/ml colcemide was added to the culture one hour before harvest. Cells were collected and washed in PBS. The suspension was
15 incubated with a hypotonic solution of KCl added dropwise to reach a final volume of 5 ml. The cells were spun down and fixed by resuspending the cells in methanol and glacial acetic acid (3:1). The cell suspension was dropped onto glass slides and dried.

20 The slides were treated with RNase A and washed then dehydrated in a series of increasing concentrations of ethanol.

 The EST to be localized was nick-translated using fluorescently labeled nucleotide (Korenberg, Jr., et al.,
25 Cell 53(3):391-400 (1988)). Following nick translation, unincorporated label was removed by spin dialysis through Sepharose. The probe was further extracted with phenol-chloroform to remove additional protein. The chromosomes were denatured in formamide using techniques known in the art and the denatured probe was added to the slides. Following
30 hybridization, the cells were washed. The slides were studied under a fluorescent microscope. In addition, the chromosomes can be stained for G-banding or Q-banding using techniques known in the art.

-54-

The resulting metaphase chromosomes had fluorescent tags localized to those regions of the chromosome that were homologous to the EST. Thus, a particular EST was localized to a particular region on a given chromosome. In this manner, SEQ ID NOs 396, 485, 506, 1880 and 1894 were mapped using fluorescent in situ hybridization to locations on chromosomes 17, 7, 10 and 1 respectively (See Table 4B below). For a review of the technique see Verma et al., *Human Chromosomes: A Manual of Basic Techniques*. Pergamon Press, NY (1988), which is hereby incorporated by reference.

Table 4: Precise Chromosomal Localization of ESTs

	SEQ ID	EST#	Map Location
	-----	-----	-----
15	A.	19	EST00023 6p
		22	EST00301 6p
		1894	EST01643 6p21
		1	EST00007 6q
		224	EST00356 6q
		288	EST00219 6q
20		162	EST00133 Xp11.21 - Xp21.2
		1917	EST01029 Xp11.21 - Xp21.2
		1669	EST00827 Xq26 - Xq27.1
		1899	EST01014 Xq28
25	B.	1880	EST01634 1q32
		485	EST01466 7p13
		506	EST01471 10q11.2
		396	EST01443 17q25

EXAMPLE 8**Automated DNA Sequencing Accuracy**

ESTs that match human sequences in GenBank are excellent tools for the analysis of the accuracy of double-strand automated DNA sequencing. Ninety EST/GenBank matches were examined for the number of nucleotide mismatches and gaps required to achieve optimal alignment by the Genetics Computer Group (GCG) program BESTFIT (Devereux et al, *Nucleic Acids Research* 12: 387 (1984)).

-55-

The number of mismatches, insertions and deletions was counted for each hundred bases of the sequence (Table 5). As expected, the sequence quality was best closest to the primer and decreased rapidly after about 400 bases. The number of deletions and insertions relative to the GenBank reference sequence increased five- to ten-fold beyond 400 bases, while the number of mismatches doubled. The average accuracy rate for individual double-stranded sequencing runs was 97.7% to 400 bases.

TABLE 5. Accuracy Of Single-Run Double-Stranded Automated Sequencing

<u>Bases from Primer</u>	<u>Mismatches/ Ambiguities</u> ⁺	<u>Gaps Insertions</u> ⁺	<u>Percent Deletions</u> ⁺	<u>Aligned Accurate</u>	<u>Bases</u>
101 - 200	1.45	0.18	0.19	98.2	8,800
201 - 300	1.72	0.25	0.11	97.9	8,130
301 - 400	2.07	0.98	0.37	96.6	5,404
>400	3.53	2.63	1.06	92.8	3,197

ESTs statistically identical to known human sequences and those matching mitochondrial and ribosomal genes were aligned with sequenced from GenBank using the GCG program BESTFIT. The first 85 nucleotides was polylinker sequence which was not aligned with the pBluescript SK reference sequence. Tabulation of errors began 15 bases into the BESTFIT alignment and thus is reported beginning with bases 101-200. ⁺Error rates are reported as number of mismatches, insertions, or deletions per hundred aligned bases. "Mismatches" includes ambiguous base calls.

EXAMPLE 9

Probability of ESTs Containing Coding Sequences

The ESTs of the present invention were statistically evaluated using the coding-region prediction program CRM via the GRAIL server (Uberbacher, E. & Mural, R. Proc. Natl. Acad. Sci. USA, 88: 11261-5 (1991)). The CRM program uses a neural network to combine results from several different coding regions by looking at different 6 bp sequences found in coding exons and in introns. The program additionally conducts reading frame searches and assesses randomness at the third position of codons. This protocol categorizes sequences as having an excellent, good, marginal, or poor probability of containing coding regions. The results are reported in Tables 6-9. There were 219 ESTs categorized as "excellent" (Table 6); 120 categorized as "good" (Table 7); 113 categorized as "marginal" (Table 8); and 1743 categorized as "poor" (Table 9). These results indicate that most ESTs of the present invention comprise noncoding regions.

Table 6: ESTs with Excellent Probability of Containing Coding Sequence

SEQ ID#	EST#				
7	EST00014	973	EST01987	1807	EST00941
15	EST00020	979	EST01993	1809	EST00943
48	EST000291	980	EST01994	1820	EST00951
62	EST00064	986	EST02000	1829	EST00958
66	EST00067	1000	EST02014	1849	EST00975
75	EST00074	1004	EST02018	1860	EST00983
98	EST00260	1007	EST02021	1866	EST00989
106	EST00092	1018	EST02032	1871	EST00994
108	EST00094	1021	EST02035	1888	EST01005
114	EST00098	1034	EST02050	1890	EST01007
115	EST00099	1047	EST02063	1892	EST01009
124	EST00107	1090	EST02109	1903	EST01018
128	EST00252	1096	EST02115	1904	EST01019
156	EST00130	1115	EST02135	1914	EST01026
164	EST00135	1118	EST02138	1930	EST01040
166	EST00137	1129	EST02149	1944	EST01050
174	EST00296	1133	EST02153	1949	EST01054
179	EST00145	1141	EST02163	1962	EST01062
183	EST00148	1163	EST02187	1973	EST01071
201	EST00163	1183	EST02208	1977	EST01075
205	EST00165	1243	EST02272	1982	EST01080
215	EST00172	1264	EST02293	1991	EST01088
230	EST00181	1265	EST02294	1993	EST01090
253	EST00199	1266	EST02295	2000	EST01097
263	EST00203	1287	EST02317	2001	EST01098
268	EST00369	1308	EST02338	2012	EST01106
270	EST00207	1324	EST02354	2013	EST01107
271	EST00283	1344	EST02374	2024	EST01117
273	EST00208	1356	EST02386	2043	EST01131
276	EST00211	1365	EST02396	2051	EST01138
281	EST00214	1383	EST02415	2056	EST01142
285	EST00286	1399	EST02433	2058	EST01144
333	EST00394	1401	EST02435	2059	EST01145
336	EST00397	1405	EST02439	2064	EST01149
339	EST00400	1417	EST02452	2090	EST01167
362	EST00418	1451	EST02487	2094	EST01171
389	EST00440	1457	EST02493	2116	EST01192
441	EST00481	1463	EST02500	2117	EST01193
454	EST00493	1473	EST02510	2128	EST01202
476	EST00509	1479	EST02516	2131	EST01205
493	EST00522	1516	EST02555	2134	EST01208
504	EST00529	1528	EST02569	2144	EST01216
516	EST00538	1531	EST02572	2145	EST01217
518	EST00540	1544	EST02586	2150	EST01222
551	EST01482	1551	EST02593	2155	EST01227
552	EST00565	1558	EST02601	2161	EST01231
559	EST00570	1561	EST02604	2163	EST01238
582	EST00592	1581	EST02625	2174	EST01242
602	EST00606	1586	EST02631	2176	EST01244
606	EST00609	1591	EST02636	2189	EST01255
608	EST00611	1616	EST02661	2214	EST01272
621	EST00620	1624	EST02670	2225	EST01278
635	EST00629	1630	EST02676	2227	EST01279
642	EST00634	1637	EST00796	2233	EST01284
644	EST00636	1639	EST00799	2235	EST01286
687	EST00671	1649	EST00808	2236	EST01287
700	EST00683	1651	EST00810	2255	EST01302
743	EST00714	1677	EST00835	2259	EST01304
753	EST00721	1682	EST00839	2263	EST01307
760	EST00726	1694	EST00849		
764	EST00729	1706	EST00857		
808	EST00761	1708	EST00858		
823	EST01864	1710	EST00860		
834	EST00771	1716	EST00865		
886	EST01886				
919	EST01921				
930	EST01933				
936	EST01939				
948	EST01957				
965	EST01978				

-59-

Table 7: ESTs with Good Probability of Containing Coding Sequence

<u>SEQ ID#</u>	<u>EST#</u>				
		1041	EST02057	2362	EST01383
		1083	EST02102	2378	EST01397
20	EST00024	1099	EST02118	2399	EST01423
72	EST00071	1105	EST02124	2407	EST02714
82	EST00078	1113	EST02133		
88	EST00084	1139	EST02161		
137	EST00272	1146	EST02168		
177	EST00328	1196	EST02221		
193	EST00156	1210	EST02238		
200	EST00162	1233	EST02262		
218	EST00175	1285	EST02314		
228	EST00179	1331	EST02361		
247	EST00279	1388	EST02421		
264	EST00204	1418	EST02453		
267	EST00297	1439	EST02475		
296	EST00228	1502	EST02540		
371	EST00426	1537	EST02578		
385	EST00436	1563	EST02606		
392	EST00442	1599	EST02644		
414	EST00460	1602	EST02647		
433	EST00474	1693	EST00848		
453	EST00492	1695	EST00850		
471	EST00505	1729	EST00877		
496	EST00525	1730	EST00878		
524	EST00544	1738	EST00883		
526	EST00546	1739	EST00885		
529	EST00549	1743	EST00888		
549	EST00563	1768	EST00908		
557	EST00569	1780	EST00916		
578	EST00588	1804	EST00938		
596	EST00602	1805	EST00939		
607	EST00610	1811	EST00945		
619	EST00619	1819	EST00950		
657	EST00646	1826	EST00956		
660	EST00649	1830	EST00959		
689	EST00673	1845	EST00971		
695	EST00679	1848	EST00974		
699	EST00682	1853	EST00977		
729	EST00703	1967	EST01066		
742	EST00713	1992	EST01089		
747	EST00717	1994	EST01091		
755	EST00723	<u>SEQ ID#</u>	<u>EST#</u>		
759	EST00725				
776	EST00738	1997	EST01094		
778	EST00740	2046	EST01134		
782	EST01551	2101	EST01177		
829	EST00768	2102	EST01178		
835	EST00772	2105	EST01181		
836	EST00773	2106	EST01182		
862	EST01872	2141	EST01213		
881	EST01881	2184	EST01251		
<u>SEQ ID#</u>	<u>EST#</u>	2196	EST01260		
		2203	EST01264		
884	EST01884	2232	EST01283		
924	EST01926	2308	EST01339		
929	EST01932	2345	EST01368		
938	EST01941	2346	EST01369		
971	EST01985	2351	EST01373		
995	EST02009	2354	EST01375		
996	EST02010	2355	EST01376		
1031	EST02046	2359	EST01380		

Table 8: ESTs with Marginal Probability of Containing Coding Sequence

<u>SEQ ID#</u>	<u>EST#</u>		
11	EST00018	1222	EST02251
12	EST00274	1224	EST02253
24	EST00027	1228	EST02257
45	EST00364	1267	EST02296
79	EST00076	1301	EST02331
90	EST00302	1397	EST02431
110	EST00096	1448	EST02484
144	EST00120	1480	EST02517
145	EST00121	1493	EST02531
192	EST00155	1499	EST02537
222	EST00177	1503	EST02541
234	EST00184	1527	EST02568
277	EST00212	1536	EST02577
319	EST00381	1548	EST02590
368	EST00423	1562	EST02605
370	EST00425	1572	EST02615
387	EST00438	1575	EST02618
402	EST00451	1595	EST02640
415	EST00461	1608	EST02653
418	EST00464	1610	EST02655
426	EST00470	1621	EST02667
503	EST00528	1627	EST02674
517	EST00539	1629	EST02677
522	EST00543	1631	EST02678
532	EST00551	1683	EST00840
540	EST00557	1692	EST00847
570	EST00580	1751	EST00895
573	EST00583	1756	EST00900
576	EST00586	1764	EST02690
613	EST00615	1770	EST00910
617	EST00617	1793	EST00929
626	EST00622	1847	EST00973
681	EST00665	1877	EST00998
726	EST00700	1897	EST01012
727	EST00701	1900	EST01015
738	EST00711	1939	EST01655
745	EST00715	1940	EST01046
752	EST00720	1954	EST01058
791	EST00746	<u>SEQ ID#</u>	<u>EST#</u>
795	EST00749	1990	EST01087
803	EST00756	2008	EST01103
845	EST00777	2031	EST01123
852	EST00782	2041	EST01130
854	EST00784	2044	EST01132
907	EST01907	2060	EST01146
912	EST01912	2100	EST01176
935	EST01938	2136	EST01210
<u>SEQ ID#</u>	<u>EST#</u>	2153	EST01225
968	EST01981	2204	EST01265
985	EST01999	2212	EST01270
988	EST02002	2248	EST01297
1043	EST02059	2250	EST01299
1081	EST02100	2266	EST01310
1089	EST02108	2309	EST01340
1116	EST02136	2347	EST01370
1134	EST02154	2388	EST01406
1205	EST02233	2398	EST01422
		2405	EST01427

Table 9: ESTs with Poor Coding Probability

SEQ ID#	EST#	103	EST00317	204	EST00235	309	EST00174	404	EST00453
		104	EST00354	206	EST00166	315	EST00008	405	EST00454
1	EST00007	105	EST00365	207	EST00167	316	EST00378	406	EST00455
2	EST00009	107	EST00093	209	EST00331	317	EST00379	407	EST00456
3	EST00010	109	EST00095	210	EST00168	318	EST00380	408	EST00457
4	EST00011	111	EST00281	211	EST00332	320	EST00382	409	EST01444
5	EST00012	112	EST00318	212	EST00169	321	EST00383	410	EST00458
6	EST00013	113	EST00097	213	EST00170	322	EST00384	411	EST00459
8	EST00234	116	EST00100	214	EST00171	323	EST00385	412	EST01445
10	EST00016	117	EST00319	216	EST00173	325	EST00386	416	EST00462
14	EST00019	118	EST00101	219	EST00176	326	EST00387	417	EST00463
16	EST00021	119	EST00102	220	EST00372	327	EST00388	419	EST00465
17	EST00022	120	EST00103	221	EST00359	328	EST00389	420	EST00466
18	EST00373	121	EST00104	224	EST00356	329	EST00390	421	EST00467
19	EST00023	122	EST00105	225	EST00178	330	EST00391	422	EST01447
21	EST00025	123	EST00106	226	EST00333	331	EST00392	423	EST00468
23	EST00026	125	EST00108	229	EST00180	332	EST00393	424	EST01448
25	EST00028	126	EST00109	231	EST00334	334	EST00395	425	EST00469
27	EST00029	127	EST00320	232	EST00182	335	EST00396	427	EST01449
28	EST00030	129	EST00321	233	EST00183	337	EST00398	428	EST01451
29	EST00031	130	EST00355	235	EST00185	340	EST00402	429	EST00471
30	EST00032	131	EST00322	236	EST00186	341	EST00403	431	EST00473
31	EST00033	133	EST00111	237	EST00187	342	EST00404	432	EST01452
32	EST00233	134	EST00375	238	EST00188	344	EST00405	434	EST00475
33	EST00034	135	EST00112	239	EST00189	345	EST00406	435	EST00476
34	EST00035	136	EST00113	240	EST00335	347	EST01829	436	EST00477
35	EST00036	138	EST00114	241	EST00191	348	EST01830	437	EST00478
36	EST00037	139	EST00116	242	EST00192	349	EST01831	438	EST00479
39	EST00039	140	EST00117	243	EST00193	350	EST00407	439	EST00480
40	EST00040	141	EST00118	244	EST00194	351	EST00408	440	EST01454
41	EST00041	142	EST00323	245	EST00347	352	EST00409	442	EST01456
42	EST00042	143	EST00119	246	EST00196	353	EST00410	443	EST00482
46	EST00044	146	EST00122	250	EST00197	354	EST01433	444	EST00483
47	EST00046	147	EST00292	252	EST00198	355	EST00411	446	EST00485
49	EST00047	148	EST00236	254	EST00200	356	EST00412	447	EST00486
50	EST00048	149	EST00123	255	EST00201	357	EST00413	448	EST00487
51	EST00049	150	EST00124	256	EST00345	358	EST00414	449	EST00488
52	EST00052	151	EST00125	257	EST00337	359	EST00415	450	EST00489
53	EST00054	152	EST00126	259	EST00202	360	EST00416	451	EST00490
54	EST00055	153	EST00127	260	EST00357	361	EST00417	452	EST00491
55	EST00056	154	EST00128	261	EST00338	363	EST00419	455	EST00494
56	EST00057	155	EST00129	262	EST00339	364	EST00420	457	EST00495
57	EST00058	157	EST00131	265	EST00205	365	EST01434	458	EST00496
58	EST00059	158	EST00132	266	EST00206	366	EST00421	459	EST00497
59	EST00061	159	EST00325	272	EST00340	367	EST00422	460	EST01457
60	EST00062	160	EST00326	274	EST00268	369	EST00424	461	EST01836
63	EST00065	162	EST00133	275	EST00209	372	EST00427	462	EST00498
64	EST00066	163	EST00134	278	EST00342	373	EST01832	464	EST00499
67	EST00351	165	EST00136	279	EST00213	374	EST00428	465	EST00500
68	EST00068	167	EST00138	280	EST00343	375	EST00429	466	EST00501
69	EST00360	168	EST00140	283	EST00215	376	EST01436	467	EST00502
71	EST00070	169	EST00141	284	EST00216	377	EST00430	468	EST00503
73	EST00072	170	EST00295	286	EST00217	378	EST00431	470	EST00504
74	EST00073	171	EST00327	287	EST00218	379	EST00432		
76	EST00075	172	EST00142	288	EST00219	380	EST01439		
80	EST00077	173	EST00143	289	EST00220	381	EST00433	473	EST00506
81	EST00315	175	EST00144	290	EST00221	382	EST00434	474	EST00507
83	EST00079	178	EST00294	291	EST00222			477	EST01463
84	EST00080	182	EST00329	292	EST00223			478	EST00510
85	EST00081	184	EST00149	293	EST00224	383	EST00435	479	EST00511
86	EST00082	185	EST00150	294	EST00225	384	EST01440	480	EST01464
87	EST00083	186	EST00151			386	EST00437	481	EST00512
89	EST00085	190	EST00153			388	EST00439	482	EST01465
91	EST00086	191	EST00154	295	EST00226	390	EST01442	483	EST00513
92	EST00087	194	EST00157	297	EST00230	391	EST00441	484	EST00514
94	EST00353			298	EST00231	393	EST00443	487	EST00516
95	EST00088			302	EST00303	395	EST00445	488	EST00517
96	EST00089	195	EST00158	303	EST00348	397	EST00446	489	EST00518
99	EST00316	196	EST00159	304	EST00307	398	EST00447	490	EST00519
		197	EST00160	305	EST00308	399	EST00448	491	EST00520
		198	EST00161	306	EST00309	400	EST00449	492	EST00521
		199	EST00277	307	EST00312	401	EST00450	495	EST00524
100	EST00090	203	EST00164	308	EST00314	403	EST00452	497	EST00526
101	EST00091								

498	EST01467	600	EST01492	697	EST00680	799	EST00752	894	EST01894
499	EST01468	601	EST01493	698	EST00681	800	EST00753	895	EST01895
500	EST00527	603	EST01494	701	EST01522	801	EST00754	896	EST01896
501	EST02715	604	EST00607	702	EST00684	804	EST00757	897	EST01897
502	EST01469	605	EST00608	703	EST00685	805	EST00758	898	EST01898
507	EST00530	609	EST01496	704	EST00686	806	EST00759	899	EST01899
508	EST00531	610	EST00612	705	EST00687	807	EST00760	900	EST01900
509	EST01472	611	EST00613	706	EST00688	809	EST00762	901	EST01901
510	EST00532	612	EST00614	708	EST00689	810	EST00763	902	EST01902
511	EST00533	615	EST00616	709	EST00690	811	EST00764	903	EST01903
512	EST00534	616	EST01497	710	EST00691	813	EST00765	904	EST01904
513	EST00535	618	EST01498	711	EST00692	814	EST00766	905	EST01905
514	EST00536	620	EST01499	712	EST00693	815	EST01855	906	EST01906
515	EST00537	622	EST01843	713	EST00694	816	EST01856	908	EST01908
519	EST00541	623	EST00621	714	EST00695	817	EST01857	909	EST01909
520	EST00542	624	EST01500	715	EST01523	818	EST01858	910	EST01910
521	EST01474	625	EST01844	716	EST01524	819	EST01859	911	EST01911
523	EST01838	627	EST00623	717	EST01525	820	EST01860	914	EST01914
525	EST00545	628	EST01503	718	EST00696	822	EST01863	915	EST01915
527	EST00547	629	EST00624	719	EST01526	825	EST01866	916	EST01917
528	EST00548	630	EST01505	720	EST00697	826	EST01867	917	EST01919
530	EST01477	631	EST00625	721	EST01527	827	EST01558	918	EST01920
531	EST00550	632	EST00626	722	EST01528	828	EST00767	920	EST01922
533	EST00552	633	EST00627	723	EST00698	830	EST01559	921	EST01923
534	EST01478	634	EST00628	725	EST00699	831	EST00769	922	EST01924
535	EST00553	636	EST01507	728	EST00702	832	EST00770	923	EST01925
536	EST01479	637	EST00630	730	EST00704	837	EST01561	925	EST01927
537	EST00554	638	EST00631	731	EST00705	838	EST00774	926	EST01929
538	EST00555	640	EST01509	732	EST00706	839	EST01562	927	EST01930
539	EST00556	641	EST00633	733	EST00707	840	EST00775	928	EST01931
541	EST00558	643	EST00635	734	EST00708	841	EST00776	931	EST01934
542	EST01480	645	EST00637	735	EST00709	842	EST01563	932	EST01935
543	EST00559	646	EST00638	736	EST01532	843	EST01564	933	EST01936
544	EST00560	647	EST00639	737	EST00710	844	EST01565	934	EST01937
545	EST01481	648	EST00640	739	EST01534	846	EST00778	937	EST01940
547	EST00561	649	EST00641	740	EST01535	847	EST00779	939	EST01943
548	EST00562	651	EST00643	741	EST00712	848	EST01566	SEQ ID#	EST#
550	EST00564	652	EST01510	744	EST01537	849	EST01567	940	EST01944
553	EST00566	654	EST00644	746	EST00716	850	EST00780	941	EST01945
555	EST01483	655	EST00645	748	EST01850	851	EST00781	942	EST01947
556	EST00568	656	EST01513	749	EST00719	SEQ ID#	EST#	943	EST01948
558	EST01484	658	EST00647	750	EST01539	853	EST00783	944	EST01949
560	EST01485	659	EST00648	751	EST01540	855	EST00785	945	EST01950
561	EST00571	661	EST00650	754	EST00722	856	EST01568	946	EST01953
562	EST00572	662	EST00651	SEQ ID#	EST#	857	EST01868	947	EST01954
563	EST00573	663	EST00652	756	EST01541	858	EST01869	949	EST01958
564	EST00574	664	EST00653	758	EST00724	859	EST01870	950	EST01959
565	EST00575	665	EST00654	761	EST01544	860	EST00786	953	EST01962
566	EST00576	SEQ ID#	EST#	762	EST00727	861	EST01871	954	EST01963
567	EST00577	666	EST01514	763	EST00728	863	EST01873	956	EST01968
568	EST00578	667	EST00655	765	EST00730	864	EST00787	957	EST01969
569	EST00579	668	EST00656	766	EST00731	865	EST01569	958	EST01970
SEQ ID#	EST#	669	EST00657	767	EST00732	866	EST01874	959	EST01972
571	EST00581	670	EST00658	768	EST00733	867	EST01875	960	EST01973
572	EST00582	671	EST00659	770	EST00735	868	EST01876	961	EST01974
574	EST00584	672	EST00660	771	EST01546	869	EST00788	962	EST01975
575	EST00585	673	EST01515	772	EST00736	870	EST00789	963	EST01976
577	EST00587	674	EST01516	774	EST01548	871	EST00790	964	EST01977
580	EST00590	675	EST00661	775	EST00737	872	EST00791	966	EST01979
581	EST00591	676	EST00662	777	EST00739	873	EST00792	967	EST01980
583	EST00593	677	EST00663	779	EST00741	874	EST00793	970	EST01983
584	EST00594	678	EST01517	780	EST01549	875	EST00794	972	EST01986
585	EST00595	679	EST01518	781	EST01550	876	EST00795	974	EST01988
586	EST00596	680	EST00664	783	EST01552	877	EST01877	975	EST01989
587	EST01488	682	EST00666	785	EST01553	878	EST01878	976	EST01990
588	EST00597	683	EST00667	786	EST00742	879	EST01879	977	EST01991
589	EST00598	684	EST00668	787	EST00743	880	EST01880	978	EST01992
590	EST00599	685	EST00669	788	EST00744	882	EST01882	981	EST01995
591	EST01489	686	EST00670	789	EST00745	883	EST01883	982	EST01996
592	EST00600	688	EST00672	790	EST01554	885	EST01885	983	EST01997
593	EST00601	690	EST00674	792	EST00747	887	EST01887	984	EST01998
595	EST01840	692	EST00676	793	EST00748	889	EST01889	987	EST02001
597	EST00603	693	EST00677	794	EST01555	890	EST01890	989	EST02003
598	EST00604	694	EST00678	796	EST00750	892	EST01892	990	EST02004
599	EST00605	696	EST01521	797	EST00751	893	EST01893	991	EST02005

-63-

992	EST02006	1086	EST02105	1184	EST02209	1274	EST02303	1363	EST02394
994	EST02008	1087	EST02106	1185	EST02210	1275	EST02304	1364	EST02395
997	EST02011	1088	EST02107	1186	EST02211	1276	EST02305	1366	EST02397
999	EST02013	1091	EST02110	1187	EST02212	1278	EST02307	1367	EST02398
1001	EST02015	1093	EST02112	1188	EST02213	1279	EST02308	1368	EST02399
1002	EST02016	1095	EST02114	1189	EST02214	1280	EST02309	1370	EST02401
1003	EST02017	1097	EST02116	1190	EST02215	1281	EST02310	1372	EST02403
1005	EST02019	1098	EST02117	1191	EST02216	1282	EST02311	1373	EST02404
1006	EST02020	1100	EST02119	1192	EST02217	1283	EST02312	1375	EST02406
1008	EST02022	1101	EST02120	1193	EST02218	1284	EST02313	1376	EST02407
1009	EST02023	1102	EST02121	1194	EST02219	1286	EST02316	1377	EST02408
1010	EST02024	1104	EST02123	1195	EST02220	1288	EST02318	1378	EST02409
1011	EST02025	1106	EST02125	1197	EST02222	1289	EST02319	1379	EST02410
1012	EST02026	1107	EST02126	1198	EST02223	1290	EST02320	1380	EST02411
1013	EST02027	1108	EST02127	1199	EST02224	1291	EST02321	1381	EST02413
1014	EST02028	1109	EST02128	1200	EST02226	1292	EST02322	1382	EST02414
1015	EST02029	1110	EST02129	1201	EST02228	1293	EST02323		
1016	EST02030	1111	EST02131	1202	EST02229	1294	EST02324		
1017	EST02031	1112	EST02132	1203	EST02230	1295	EST02325		
1019	EST02033	1114	EST02134	1204	EST02232	1296	EST02326		
1022	EST02036	1117	EST02137	1206	EST02234	SEQ ID#	EST#		
1023	EST02037	1119	EST02139	1207	EST02235				
1024	EST02038	1120	EST02140	1208	EST02236	1298	EST02328		
1025	EST02040	1121	EST02141	1209	EST02237	1299	EST02329		
1026	EST02041	1122	EST02142	SEQ ID#	EST#	1300	EST02330		
1027	EST02042	1123	EST02143			1302	EST02332		
1028	EST02043	1124	EST02144	1211	EST02239	1303	EST02333		
1029	EST02044	1125	EST02145	1212	EST02240	1304	EST02334		
1030	EST02045	SEQ ID#	EST#	1213	EST02241	1305	EST02335		
1032	EST02048			1214	EST02242	1306	EST02336		
1033	EST02049	1127	EST02147	1215	EST02244	1307	EST02337		
1036	EST02052	1128	EST02148	1216	EST02245	1309	EST02339		
SEQ ID#	EST#	1130	EST02150	1217	EST02246	1310	EST02340		
		1131	EST02151	1218	EST02247	1311	EST02341		
1037	EST02053	1132	EST02152	1219	EST02248	1313	EST02343		
1038	EST02054	1135	EST02155	1220	EST02249	1314	EST02344		
1040	EST02056	1136	EST02156	1221	EST02250	1315	EST02345		
1042	EST02058	1137	EST02157	1223	EST02252	1316	EST02346		
1044	EST02060	1138	EST02159	1225	EST02254	1317	EST02347		
1045	EST02061	1140	EST02162	1226	EST02255	1318	EST02348		
1046	EST02062	1142	EST02164	1227	EST02256	1319	EST02349		
1048	EST02064	1143	EST02165	1232	EST02261	1320	EST02350		
1049	EST02065	1144	EST02166	1234	EST02263	1321	EST02351		
1050	EST02066	1145	EST02167	1235	EST02264	1322	EST02352		
1051	EST02067	1148	EST02170	1236	EST02265	1323	EST02353		
1052	EST02068	1149	EST02171	1237	EST02266	1325	EST02355		
1053	EST02069	1150	EST02172	1238	EST02267	1326	EST02356		
1054	EST02070	1152	EST02174	1239	EST02268	1327	EST02357		
1055	EST02071	1153	EST02175	1240	EST02269	1328	EST02358		
1056	EST02072	1154	EST02176	1241	EST02270	1329	EST02359		
1057	EST02073	1155	EST02177	1242	EST02271	1330	EST02360		
1058	EST02074	1156	EST02178	1244	EST02273	1333	EST02363		
1059	EST02075	1157	EST02180	1246	EST02275	1334	EST02364		
1060	EST02076	1158	EST02181	1247	EST02276	1335	EST02365		
1061	EST02078	1159	EST02182	1248	EST02277	1336	EST02366		
1062	EST02079	1160	EST02183	1249	EST02278	1337	EST02367		
1063	EST02081	1161	EST02184	1250	EST02279	1338	EST02368		
1064	EST02082	1162	EST02185	1251	EST02280	1339	EST02369		
1065	EST02083	1164	EST02188	1252	EST02281	1342	EST02372		
1066	EST02084	1165	EST02189	1253	EST02282	1343	EST02373		
1067	EST02085	1166	EST02190	1254	EST02283	1345	EST02375		
1068	EST02086	1167	EST02191	1255	EST02284	1346	EST02376		
1070	EST02088	1168	EST02193	1256	EST02285	1347	EST02377		
1071	EST02089	1169	EST02194	1257	EST02286	1349	EST02379		
1072	EST02090	1170	EST02195	1258	EST02287	1350	EST02380		
1073	EST02091	1171	EST02196	1259	EST02288	1351	EST02381		
1074	EST02092	1172	EST02197	1260	EST02289	1352	EST02382		
1075	EST02093	1173	EST02198	1261	EST02290	1353	EST02383		
1076	EST02094	1174	EST02199	1262	EST02291	1354	EST02384		
1077	EST02096	1175	EST02200	1263	EST02292	1355	EST02385		
1078	EST02097	1176	EST02201	1268	EST02297	1357	EST02387		
1079	EST02098	1177	EST02202	1269	EST02298	1358	EST02388		
1080	EST02099	1178	EST02203	1270	EST02299	1359	EST02390		
1082	EST02101	1179	EST02204	1271	EST02300	1360	EST02391		
1084	EST02103	1180	EST02205	1272	EST02301	1361	EST02392		
1085	EST02104	1182	EST02207	1273	EST02302	1362	EST02393		

1907	EST01022	2016	EST01110	2118	EST01194	2223	EST01742	2332	EST01794
1908	EST01023	2018	EST01111	2119	EST01195	2224	EST01277	2333	EST01357
1909	EST01024	2019	EST01112	2122	EST01197	2228	EST01280	2335	EST01359
1911	EST02694	2020	EST01113	2123	EST01713	2229	EST01281	2336	EST01360
1912	EST01025	2021	EST01114	2124	EST01198	2231	EST01746	2337	EST01361
1913	EST01646	2022	EST01115	2125	EST01199	2237	EST01288	2340	EST01802
1915	EST01027	2023	EST01116	2126	EST01200	2238	EST01289	2341	EST01364
1916	EST01028	2025	EST01118	2127	EST01201	2239	EST01290	2343	EST01366
1917	EST01029	2026	EST01119	2129	EST01203	2240	EST01291	2344	EST01367
1918	EST02695	2027	EST01120	2130	EST01204	2241	EST01747	2349	EST01372
1919	EST01030	2028	EST01121	2132	EST01206	2242	EST01292	2350	EST02708
1920	EST01031	2029	EST01682	2133	EST01207	2243	EST01293	2352	EST01374
1921	EST01647	2030	EST01122	2135	EST01209	2244	EST01294	2356	EST01377
1922	EST01032	2033	EST01684	2137	EST01211	2246	EST01295	2357	EST01378
1923	EST01033	2034	EST01124	2139	EST01716	2247	EST01296	2360	EST01381
1924	EST01034	2035	EST01125	2140	EST01212	2249	EST01298	2361	EST01382
1925	EST01035	2036	EST01126	2142	EST01214	2251	EST01300	2363	EST01384
1926	EST01036	2037	EST01686	2143	EST01215	2252	EST01750	2364	EST01385
1927	EST01037	2038	EST01127	2147	EST01219	2253	EST01301	2365	EST01386
1929	EST01039	2039	EST01128	2148	EST01220	2256	EST02718	2366	EST01387
1932	EST01042	2040	EST01129	2151	EST01223	2257	EST01303	2369	EST01811
1934	EST01043	2042	EST01688	2152	EST01224	2258	EST01754	2370	EST01390
1935	EST01044	2045	EST01133	2154	EST01226	2260	EST01305	2371	EST01391
1936	EST01045	2047	EST01135	2156	EST01718	2261	EST01755	2372	EST01392
1937	EST01652	2048	EST01136	2157	EST01719	2262	EST01306	2375	EST01815
1938	EST01654	2049	EST01689	2158	EST01228	2264	EST01308	2376	EST01395
1941	EST01047	2050	EST01137	2159	EST01229	2265	EST01309	2377	EST01396
1942	EST01048	2052	EST01139	2160	EST01230	2268	EST01311	2379	EST01398
1943	EST01049	2053	EST01140	2162	EST01232	2269	EST01312	2380	EST01399
1945	EST01051	2054	EST01141	2163	EST01233	2270	EST01313	2381	EST01400
1946	EST02696	2055	EST01690	2164	EST01234	2271	EST01314	2382	EST01401
1947	EST01052	2057	EST01143	2165	EST01720	2272	EST01762	2383	EST01402
1948	EST01053	2061	EST01147	2166	EST01236	2273	EST01315	2384	EST01403
1950	EST01055	2062	EST02701	2167	EST01237	2275	EST01316	2385	EST01816
1951	EST01056	2063	EST01148	2169	EST01722	2276	EST01317	2386	EST01404
1952	EST01057	2065	EST01691	2170	EST01239	2277	EST01318	2387	EST01405
1955	EST01662	2066	EST01692	2171	EST01240	2278	EST01319		
1957	EST01059	2067	EST01693	2172	EST01241	2279	EST01320		
1958	EST01060	2069	EST01150	2175	EST01243	2280	EST01763		
1959	EST01061	2070	EST01151	2177	EST01245	2284	EST01323		
1963	EST01063	2072	EST01152	2178	EST01726	SEQ ID#	EST#		
1964	EST01064	2074	EST01698	2179	EST01246				
1966	EST01065	2075	EST01153	2180	EST01247	2285	EST01768		
1968	EST01067	2076	EST02702	2181	EST01248	2287	EST01770		
1969	EST01068	2077	EST01154	SEQ ID#	EST#	2288	EST01324		
1970	EST01666	2078	EST01155			2290	EST01772		
1971	EST01069	2079	EST01156	2182	EST01249	2291	EST01773		
1972	EST01070	2080	EST01157	2183	EST01250	2292	EST01326		
1975	EST01073	SEQ ID#	EST#	2185	EST01252	2293	EST01327		
1976	EST01074			2186	EST01253	2294	EST01328		
1978	EST01076	2081	EST01158	2187	EST01727	2295	EST01329		
1979	EST01077	2082	EST01159	2188	EST01254	2296	EST01330		
SEQ ID#	EST#	2083	EST01160	2190	EST01728	2298	EST01331		
		2084	EST01161	2191	EST01256	2299	EST01332		
1980	EST01078	2085	EST01162	2193	EST01258	2301	EST01334		
1981	EST01079	2086	EST01163	2194	EST01729	2304	EST01780		
1983	EST01081	2087	EST01164	2195	EST01259	2305	EST01336		
1984	EST01082	2088	EST01166	2197	EST01261	2306	EST01337		
1985	EST01083	2091	EST01168	2198	EST01730	2310	EST01341		
1986	EST01084	2093	EST01170	2199	EST01262	2311	EST01342		
1988	EST01085	2095	EST01701	2200	EST01731	2312	EST01343		
1989	EST01086	2096	EST01172	2201	EST01263	2313	EST01344		
1995	EST01092	2097	EST01173	2202	EST01732	2315	EST01346		
1996	EST01093	2098	EST01174	2205	EST01735	2316	EST01782		
1998	EST01095	2099	EST01175	2206	EST01736	2317	EST01347		
1999	EST01096	2103	EST01179	2208	EST01267	2318	EST01348		
2002	EST01099	2104	EST01180	2209	EST02717	2319	EST01349		
2003	EST01675	2107	EST01183	2210	EST01268	2321	EST01350		
2005	EST01100	2108	EST01184	2211	EST01269	2322	EST01351		
2006	EST01101	2109	EST01185	2213	EST01271	2323	EST01789		
2007	EST01102	2110	EST01186	2215	EST01273	2325	EST01353		
2009	EST01677	2111	EST01187	2218	EST01274	2327	EST01354		
2010	EST01104	2112	EST01188	2219	EST01275	2328	EST01355		
2011	EST01105	2113	EST01189	2220	EST01740	2329	EST01792		
2014	EST01108	2114	EST01190	2221	EST01741	2330	EST01793		
2015	EST01109	2115	EST01191	2222	EST01276	2331	EST01356		

-66-

<u>SEQ ID#</u>	<u>EST#</u>
2389	EST01407
2391	EST01415
2392	EST01416
2395	EST01419
2397	EST01421
2401	EST01424
2403	EST01425
2404	EST01426
2406	EST02713
2409	EST00273

SUBSTITUTE SHEET

-67-

EXAMPLE 10

Functional Groupings of ESTs and Corresponding Genes

By matching new human ESTs to known sequences from other species, the apparent function of the gene corresponding to the EST can be ascertained. The data generated in Example 3 and 4 have been used to categorize 127 of the ESTs of the present invention, and their corresponding genes, into predicted functional groups. (These 127 are ESTs with database matches to sequences from other species for which a function was known.) Two different grouping schemes have been used.

The first scheme separates the sequences into three broad categories: metabolic; regulatory; and structural. These groupings are set out in Table 10.

The second grouping scheme separates the sequences into 13 specific categories: cell surface proteins; developmental control; energy metabolism; kinases and phosphatases; oncogenes; other metabolism-related polypeptides; peptidases and peptidase inhibitors; receptors; structural and cytoskeletal; signal transduction; transporters; transcription, translation, and subcellular localization; and transcription factors. These groupings are set out in Table 11.

Table 10: Three-Class Functional Groupings of ESTs

SEQ ID	EST#	Group	Putative Identification
1834	EST01620	M	AMP deaminase, brain
97	EST00289	M	Aconitase
691	EST00675	M	Alcohol dehydrogenase
2092	EST01700	M	Anion exchanger homolog AE3
396	EST01443	M	CDPdiacylglycerol-serine O-phosphatidyltransferase
1956	EST01663	M	Ca ²⁺ -transporting ATPase 2
1039	EST02055	M	Calcium channel
2192	EST01257	M	Diacylglycerol kinase, lymphocyte
1441	EST02477	M	Diamine acetyltransferase
2289	EST01325	M	Fatty acid synthase
310	EST00377	M	Fo ATPase beta subunit, mitochondrial
1667	EST00825	M	Gamma-aminobutyric acid transporter
1412	EST02446	M	Glutamate-aspartate carrier protein
1020	EST02034	M	Glutaminase
2326	EST01791	M	Inositol-1,4,5-trisphosphate 3-kinase
2173	EST01724	M	Lon protease
1427	EST02463	M	Long-chain-fatty-acid-CoA ligase
2226	EST01744	M	NAD(P) ⁺ transhydrogenase (B-specific)
1566	EST02609	M	Neutrophil oxidase factor
1681	EST01573	M	Nucleoside diphosphate kinase
2254	EST01751	M	Phosphatidylinositol-4,5-bisphosphate phosphodiesterase
93	EST00287	M	Processing enhancing protein
2297	EST01775	M	Prohormone cleavage enzyme
9	EST00376	M	Prolyl endopeptidase
1654	EST01572	M	Protochlorophyllide reductase
38	EST00374	M	RNA polymerase II 6th subunit (RPO26)
1715	EST01583	M	Ribosomal protein L18a
1856	EST01627	M	Ribosomal protein L1a
1974	EST01667	M	Ribosomal protein L3
301	EST00300	M	Ribosomal protein L30
22	EST00301	M	Ribosomal protein S10
2402	EST01826	M	Ribosomal protein S10
463	EST01459	M	Ribosomal protein YL10
2073	EST01697	M	Succinate dehydrogenase flavoprotein
2138	EST01715	M	Succinate dehydrogenase flavoprotein
1771	EST01601	M	Thiosulfate sulfurtransferase (rhodanese)
2121	EST01711	M	Valine-tRNA ligase
1726	EST01588	M	XPR2 alkaline extracellular protease
913	EST01913	M	Clathrin coat assembly protein AP50 homolog
1035	EST02051	M	J1 protein
969	EST01982	R	ADP-ribosylation factor 1
1126	EST02146	R	Calbindin D28
1910	EST01645	R	Calmodulin
485	EST01466	R	Calmodulin-dependent protein kinase, type II, beta
2302	EST01779	R	Discs-large tumor suppressor
188	EST00256	R	Enhancer of split
1229	EST02258	R	KUP protein
993	EST02007	R	Kinase 5 protein
2282	EST01764	R	Lamin B receptor
SEQ ID	EST#	Group	Putative Identification
161	EST00247	R	MARCKS (myristoylated alanine-rich protein kinase)
769	EST00734	R	MARCKS homolog
1386	EST02418	R	MARCKS homolog
227	EST00259	R	Notch/Xotch
952	EST01961	R	Notch/Xotch
1395	EST02429	R	Nuclear factor 1-like protein (NF1)
2353	EST01806	R	Prohibitin
1069	EST02087	R	Protein kinase C, zeta
1933	EST01650	R	Protein phosphatase 2A beta subunit

-69-

202	EST00298	R	Protein-tyrosine phosphatase LRP
1478	EST02515	R	Rab5
1408	EST02442	R	Seven in absentia
300	EST00232	R	Transforming protein (dbl)
1147	EST02169	R	Tyrosine kinase
1348	EST02378	R	cAMP-dependent protein kinase inhibitor
1931	EST01041	R	cAMP-regulated phosphoprotein
1413	EST02447	R	cAMP-specific phosphodiesterase
37	EST00038	R	ras p21-like small GTP-binding protein (smg GDS)
102	EST00248	R	rho H12/ ARH12
299	EST00249	R	smg p25A GDP dissociation inhibitor
189	EST00282	R	trkB
1332	EST02362	R	GA binding protein, beta subunit
1277	EST02306	R	Bib protein
43	EST00371	R	Maternal G10 protein
1704	EST01580	R	Myeloid differentiation primary response gene My
346	EST01828	R	Otd homeotic protein
187	EST00152	R	Wilm's tumor-related protein
249	EST00275	R	Zinc Finger Proteins
413	EST01446	R	Zinc Finger Proteins
469	EST01460	R	Zinc Finger Proteins
833	EST01560	R	Zinc Finger Proteins
1230	EST02259	R	Zinc finger proteins
1496	EST02534	R	Zinc finger proteins
2324	EST01352	R	Zinc Finger Proteins
208	EST00250	S	60K filarial antigen
2320	EST01784	S	60K filarial antigen
251	EST00370	S	Actin, other
2146	EST01218	S	Actin, other
248	EST00271	S	Actinin, alpha
891	EST01891	S	Actinin, alpha
1500	EST02538	S	Actinin, alpha
132	EST00110	S	Agrin
1852	EST01625	S	Agrin
1965	EST01664	S	Amyloid A4
2068	EST01694	S	Amyloid A4
2408	EST00244	S	Amyloid A4
1880	EST01634	S	Axonal glycoprotein TAG-1
2004	EST01676	S	Cofilin
650	EST00642	S	Dilute (myosin heavy chain)
2217	EST01738	S	Gelation factor ABP-280
1885	EST01639	S	Histocompatibility antigen modifier 1
77	EST00257	S	Kinesin
SEQ ID	EST#	Group	Putative Identification
78	EST00258	S	Kinesin
2245	EST01748	S	Kinesin
313	EST00276	S	Lysosomal membrane glycoprotein 1 (LAMP-1)
223	EST00368	S	Microtubule-associated protein 1B
824	EST01865	S	Microtubule-associated protein 1B
2032	EST01683	S	Microtubule-associated protein 1B
2017	EST01678	S	Milk fat globule membrane protein
1567	EST02610	S	Neural cell adhesion molecule L1
506	EST01471	S	Neuraxin
2368	EST01389	S	Radial spoke protein 3
951	EST01960	S	Spectrin, beta
2089	EST01699	S	Sperm membrane protein
653	EST01512	S	Tubulin, alpha
311	EST00270	S	Tubulin, beta
594	EST01490	S	Tubulin, beta
757	EST01542	S	Tubulin, beta
1245	EST02274	S	Tubulin, beta
1589	EST02634	S	Tubulin, beta
1468	EST02505	S	Matrin 3

-70-

1371	EST02402	S	Talin
1701	EST00853	S	Unc-104

Group Key: M: Metabolic, R: Regulatory, S: Structural

Table 11: Thirteen-Class Functional Groupings of ESTs

<u>SEO ID</u>	<u>EST#</u>	<u>Group</u>	<u>Putative Identification</u>
208	EST00250	CS	60K filarial antigen
2320	EST01784	CS	60K filarial antigen
1965	EST01664	CS	Amyloid A4
2068	EST01694	CS	Amyloid A4
2408	EST00244	CS	Amyloid A4
1880	EST01634	CS	Axonal glycoprotein TAG-1
1885	EST01639	CS	Histocompatibility antigen modifier 1
313	EST00276	CS	Lysosomal membrane glycoprotein 1 (LAMP-1)
2017	EST01678	CS	Milk fat globule membrane protein
1567	EST02610	CS	Neural cell adhesion molecule L1
2368	EST01389	CS	Radial spoke protein 3
2089	EST01699	CS	Sperm membrane protein
1277	EST02306	DC	Bib protein
188	EST00256	DC	Enhancer of split
43	EST00371	DC	Maternal G10 protein
1704	EST01580	DC	Myeloid differentiation primary response gene MyD1
227	EST00259	DC	Notch/Xotch
952	EST01961	DC	Notch/Xotch
346	EST01828	DC	Orthodentical homeotic protein
1408	EST02442	DC	Seven in absentia
97	EST00289	EM	Aconitase
310	EST00377	EM	Fo ATPase beta subunit, mitochondrial
485	EST01466	KP	Calmodulin-dependent protein kinase, type II, beta
993	EST02007	KP	Kinase 5 protein
1069	EST02087	KP	Protein kinase C, zeta
1933	EST01650	KP	Protein phosphatase 2A beta subunit
202	EST00298	KP	Protein-tyrosine phosphatase LRP
1348	EST02378	KP	cAMP-dependent protein kinase inhibitor
2302	EST01779	OG	Discs-large tumor suppressor
2353	EST01806	OG	Prohibitin
1478	EST02515	OG	Rab5
300	EST00232	OG	Transforming protein (dbl)
37	EST00038	OG	ras p21-like small GTP-binding protein (smg GDS)
102	EST00248	OG	rho H12/ ARH12
1834	EST01620	OM	AMP deaminase, brain
691	EST00675	OM	Alcohol dehydrogenase
396	EST01443	OM	CDPdiacylglycerol-serine O-phosphatidyltransferase
2192	EST01257	OM	Diacylglycerol kinase, lymphocyte
1441	EST02477	OM	Diamine acetyltransferase
2289	EST01325	OM	Fatty acid synthase
1020	EST02034	OM	Glutaminase
2326	EST01791	OM	Inositol-1,4,5-trisphosphate 3-kinase
1427	EST02463	OM	Long-chain-fatty-acid-CoA ligase
2226	EST01744	OM	NAD(P)+ transhydrogenase (B-specific)
1566	EST02609	OM	Neutrophil oxidase factor
1681	EST01573	OM	Nucleoside diphosphate kinase

<u>SEQ ID</u>	<u>EST#</u>	<u>Group</u>	<u>Putative Identification</u>
2254	EST01751	OM	Phosphatidylinositol-4,5-bisphosphate phosphodiesterase
1654	EST01572	OM	Protochlorophyllide reductase
2073	EST01697	OM	Succinate dehydrogenase flavoprotein
2138	EST01715	OM	Succinate dehydrogenase flavoprotein
1771	EST01601	OM	Thiosulfate sulfurtransferase (rhodanese)
2173	EST01724	PI	Lon protease
2297	EST01775	PI	Prohormone cleavage enzyme
9	EST00376	PI	Prolyl endopeptidase
1726	EST01588	PI	XPR2 alkaline extracellular protease
1147	EST02169	PP	Tyrosine kinase
2282	EST01764	RT	Lamin B receptor
189	EST00282	RT	trkB
251	EST00370	SC	Actin, other
2146	EST01218	SC	Actin, other
248	EST00271	SC	Actinin, alpha
891	EST01891	SC	Actinin, alpha
1500	EST02538	SC	Actinin, alpha
132	EST00110	SC	Agrin
1852	EST01625	SC	Agrin
2004	EST01676	SC	Cofilin
650	EST00642	SC	Dilute (myosin heavy chain)
2217	EST01738	SC	Gelation factor ABP-280
77	EST00257	SC	Kinesin
78	EST00258	SC	Kinesin
2245	EST01748	SC	Kinesin
1468	EST02505	SC	Matrin 3
223	EST00368	SC	Microtubule-associated protein 1B
824	EST01865	SC	Microtubule-associated protein 1B
2032	EST01683	SC	Microtubule-associated protein 1B
506	EST01471	SC	Neuraxin
951	EST01960	SC	Spectrin, beta
1371	EST02402	SC	Talin
653	EST01512	SC	Tubulin, alpha
311	EST00270	SC	Tubulin, beta
594	EST01490	SC	Tubulin, beta
757	EST01542	SC	Tubulin, beta
1245	EST02274	SC	Tubulin, beta
1589	EST02634	SC	Tubulin, beta
1701	EST00853	SC	Unc-104
969	EST01982	ST	ADP-ribosylation factor 1
1126	EST02146	ST	Calbindin D28
1910	EST01645	ST	Calmodulin
161	EST00247	ST	MARCKS (myristoylated alanine-rich protein kinase)
769	EST00734	ST	MARCKS homolog
1386	EST02418	ST	MARCKS homolog
1931	EST01041	ST	cAMP-regulated phosphoprotein
1413	EST02447	ST	cAMP-specific phosphodiesterase
299	EST00249	ST	smg p25A GDP dissociation inhibitor

<u>SEQ ID</u>	<u>EST#</u>	<u>Group</u>	<u>Putative Identification</u>
2092	EST01700	TP	Anion exchanger homolog AE3
1956	EST01663	TP	Ca ²⁺ -transporting ATPase 2
1039	EST02055	TP	Calcium channel
1667	EST00825	TP	Gamma-aminobutyric acid transporter
1412	EST02446	TP	Glutamate-aspartate carrier protein
913	EST01913	TT	Clathrin coat assembly protein AP50 homolog
1035	EST02051	TT	J1 protein
93	EST00287	TT	Processing enhancing protein
38	EST00374	TT	RNA polymerase II 6th subunit (RPO26)
1715	EST01583	TT	Ribosomal protein L18a
1856	EST01627	TT	Ribosomal protein L1a
1974	EST01667	TT	Ribosomal protein L3
301	EST00300	TT	Ribosomal protein L30
22	EST00301	TT	Ribosomal protein S10
2402	EST01826	TT	Ribosomal protein S10
463	EST01459	TT	Ribosomal protein YL10
2121	EST01711	TT	Valine-tRNA ligase
1332	EST02362	TX	GA binding protein, beta subunit
1229	EST02258	TX	KUP protein
1395	EST02429	TX	Nuclear factor 1-like protein (NF1)
187	EST00152	TX	Wilm's tumor-related protein
249	EST00275	TX	Zinc Finger Proteins
413	EST01446	TX	Zinc Finger Proteins
469	EST01460	TX	Zinc Finger Proteins
833	EST01560	TX	Zinc Finger Proteins
1230	EST02259	TX	Zinc finger proteins
1496	EST02534	TX	Zinc finger proteins
2324	EST01352	TX	Zinc Finger Proteins

Group Key: CS: Cell Surface, DC: Developmental Control, EM: Energy Metabolism, KP: Kinases and Phosphatases, OG: Oncogenes, OM: Other Metabolism, PI, Peptidases and Peptidase Inhibitors, RT: Receptors, SC: Structural and Cytoskeletal, ST: Signal Transduction, TP: Transporters, TT: Transcription, Translation, and Subcellular Localization, TX: Transcription Factors.

-74-

EXAMPLE 11

cDNA Libraries Generated From Specific Genomic DNA
by Exon Expression & Amplification

5

Exon amplification was used to express potential exons from genomic DNA in a recombinant vector that contains some of the signals necessary for splicing. If an exon is present in the proper orientation in the vector, that exon will be spliced in a mammalian cell and will become part of the mRNA of that cell. The exon splice-product can be purified from other mRNA in the cell by conversion of the mRNA to cDNA and selective amplification of the recombinant splice-product cDNAs. Cosmid DNA from human chromosome 19q13.3 was digested with BamHI or BamHI/BglIII restriction enzymes. The fragments generated were collected and size specifically cloned into an expression vector (Buckler, et al. Proc. Nat'l. Acad. Sci. USA, 88:4005-4009 (1991)). After transfection by electroporation of these constructs into COS cells, RNA transcripts were generated using the SV40 early promoter and a polyadenylation signal derived from SV40 both present in the expression vector. When a fragment of genomic DNA contains an entire exon with flanking intron sequence in the sense orientation, the exon should be retained in the mature poly(A)+ cytoplasmic RNA. Therefore, the mRNA was used as template for cDNA synthesis using reverse transcriptase and vector-priming. Subsequently, the cDNAs were amplified by vector-priming using PCR. A fraction of this first PCR product was reamplified using internal vector-primers containing terminal cloning sites. These products were end-repaired with T4 DNA polymerase, digested with the appropriate restriction enzymes, gel purified and cloned into pBluescript vectors. The constructs were transfected into XL1-Blue competent cells and plated on LB/X-gal/IPTG/ampicillin plates. White colonies were selected and expanded to prepare DNA templates as described in Example 2.

10

15

20

25

30

35

-75-

When multiple cosmids or YAC clones were used as the source DNA, a pool of specific expressed exons was obtained as a cDNA library. The EST/cDNAs sequenced from this specific library are disclosed herein as SEQ ID NOS: 2412-2417.

5

EXAMPLE 12

PCR Amplification from Predicted Exons

10 Computational analyses can be applied to genomic DNA sequences to predict protein coding regions. The coding region prediction program CRM (E. Uberbacher and R. Mural, Proc. Natl. Acad. Sci. USA 88:11261-5 (1991)) finds open reading frames and classifies them according to their probability of being coding regions. These regions are subsequently examined using the GM program (C. Fields and C. Soderlund, Comp. Applic. Biosci. 6: 263, 1990), which predicts intron-exon structure. PCR primers are then designed to amplify the predicted exons and used to test human cDNA libraries (for example, fetal brain or placental libraries) for the presence of these putative exons using a PCR assay.

20 This strategy has been successfully applied in two large scale genomic sequencing projects, the Huntington's locus of human chromosome 4p16.3 (McCombie, et al., submitted) and human chromosome locus 19q13.3 (Martin-Gallardo, et al., submitted). Sequences from eleven predicted exons from chromosome 4 were present in tested cDNA libraries, indicating that this region has at least two and probably three expressed genes. In one case, the method resulted in an amplification product which spanned two predicted exons. (SEQ ID NO: 2411.) When sequenced, this PCR product indicated the presence of the two exons from which the primers were initially chosen, as well as an intervening exon which was also predicted by the CRM program, but not the intervening genomic sequences. In a similar fashion, the presence of the two predicted genes in the chromosome 19

35

-76-

sequence was confirmed by sequencing PCR products. SEQ ID NO 2410, includes a partial exon of one of these genes.

EXAMPLE 13

5 Complete Sequence of EST Clone Inserts

There are a number of methods known to those with skill in the art of molecular biology, to obtain sequence information from the cDNAs corresponding to the EST sequences. Procedures for these methods are provided in 10 Basic Methods in Molecular Biology (David et al. *supra*). One way to acquire more information about the cDNA from which an EST was derived is to sequence the remainder of the cDNA clone. The complete sequence of the inserts of four EST clones (representing SEQ ID NOs 188, 189, 223, and 227) was 15 determined using Exonuclease III deletions. Briefly, EST clones were digested with the restriction enzymes SalI and KpnI or PstI and BamHI (for deletions from the Forward primer and Reverse primer ends of the insert, respectively). The 20 KpnI and PstI enzymes leave 3' sticky ends following digestion, which Exonuclease III is unable to bind. This results in unidirectional deletions into the cDNA insert leaving the vector sequence undisturbed. After addition of Exonuclease III to the Forward and Reverse deletion 25 reactions, aliquots of the reaction were removed at defined time intervals and the reaction was stopped to prevent further deletion. S1 nuclease and Klenow DNA polymerase were added to create blunt ended fragments suitable for ligation.

Samples for each time point was purified by 30 electrophoresis through an agarose gel and religated. Two to four representative clones from each time point in each direction were sequenced to give between 200 and 400 base pairs of sequence data. Careful selection of deletion conditions and time points allow a deletion series of 35 approximately 100-200 base pairs difference in length at each consecutive time point. Sequence fragments were reassembled into a redundant contiguous sequence using the INHERIT

-77-

software from Applied Biosystems, Inc. (Foster City, CA). In this way, the complete insert from these four cDNA clones was sequenced on both strands to an average redundancy between three and four (each base was sequenced between three and four times, on average). Those complete insert sequences are disclosed herein as SEQ ID 2418, 2419, 2420, and 2421, corresponding to original ESTs with SEQ ID 223, 189, 227, and 188, respectively.

EXAMPLE 14

Determining Reading Frame, Orientation, Coding Regions: ESTs and Complete cDNA Sequences

Once the complete cDNA sequence has been determined in accordance with Example 13, the reading frame, orientation, and coding regions are determined by computer techniques. (The complete coding region is considered to be the largest open reading frame from a methionine to a stop codon.)

Specifically, the CRM program on the GRAIL server is used as explained in Example 9 to determine probable coding regions. This information is supplemented by location of start and stop codons. Where possible, the results of the CRM analysis are validated by comparison of the cDNA sequence to known sequences using database matching, in accordance with Examples 3 and 4. If a match of 50% (or even less) is found in any particular reading frame and orientation, this serves to verify corresponding CRM results. Alternatively, database matches can be used to determine reading frame and orientation without use of the CRM program. Of course, if the cDNA is derived from a directional library, the probable orientation is already known.

EXAMPLE 15

Preparation of PCR Primers and Amplification of DNA

The EST sequences and the corresponding cDNA sequences and genomic sequences may be used, in accordance with the

-78-

present invention, to prepare PCR primers for a variety of applications. The PCR primers are preferably at least 15 bases, and more preferably at least 18 bases in length. The procedure of Example 5 is repeated using the desired EST, or using the corresponding cDNA or genomic DNA sequence from Example 13. It is preferred that the primer pairs have approximately the same G/C ratio, so that melting temperatures are approximately the same. When screening cDNA, introns are of no concern; however, when screening genomic DNA, primers should be selected to avoid reading across introns, which usually are too large to amplify. The PCR primers and amplified DNA of this Example find use in the Examples that follow.

EXAMPLE 16

Forensic Matching by DNA Sequencing

In one exemplary method, DNA samples are isolated from forensic specimens of, for example, hair, semen, blood or skin cells by conventional methods. A panel of PCR primers derived from a number of the sequences of Example 1, 2, 11, 12 and/or 13 is then utilized in accordance with Example 12 to obtain DNA of approximately 100-200 bases in length from the forensic specimen. Corresponding sequences are obtained from a suspect. Each of these identification DNAs is then sequenced, and a simple database comparison determines the differences, if any, between the sequences from the suspect and those from the sample. Statistically significant differences between the suspect's DNA sequences and those from the sample conclusively prove a lack of identity. This lack of identity can be proven, for example, with only one sequence. Identity, on the other hand, should be demonstrated with a large number of sequences, all matching. Preferably, a minimum of 50 statistically identical sequences

-79-

of 100 bases in length are used to prove identity between the suspect and the sample.

EXAMPLE 17

5

Positive Identification by DNA Sequencing

The technique outlined in the previous example may also be used on a larger scale to provide a unique fingerprint-type identification of any individual. In this technique, primers are prepared from a large number of sequences from Examples 1, 2, 11, 12 and/or 13. Preferably, 20 to 50 different primers are used. These primers are used to obtain a corresponding number of PCR-generated DNA segments from the individual in question in accordance with Example 15. Each of these DNA segments is sequenced, using the methods set forth in Example 1. The database of sequences generated through this procedure uniquely identifies the individual from whom the sequences were obtained. The same panel of primers may then be used at any later time to absolutely correlate tissue or other biological specimen with that individual.

20

EXAMPLE 18

25

Southern Blot Forensic Identification

The procedure of Example 17 is repeated to obtain a panel of from 10 to 2000 amplified sequences from an individual and a specimen. This PCR-generated DNA is then digested with one or a combination of, preferably, four base specific restriction enzymes. Such enzymes are commercially available and known to those of skill in the art. After digestion, the resultant gene fragments are size separated in multiple duplicate wells on an agarose gel and transferred to nitrocellulose using Southern blotting techniques well known to those with skill in the art. For a review of Southern

30

35

-80-

blotting see Davis et al. (Basic Methods in Molecular Biology, 1986, Elsevier Press. pp 62-65).

A panel of ESTs or complete cDNA sequences from Examples 1, 2, and/or 13, or fragments thereof of at least 15 bases, are radioactively or colorimetrically labeled using end-labeled oligonucleotides derived from the ESTs, nick translated sequences or the like using methods known in the art and hybridized to the Southern blot using techniques known in the art (Davis et al., supra). Preferably, at least 5 to 10 of these labeled probes are used, and more preferably at least about 20 or 30 are used to provide a unique pattern. The resultant bands appearing from the hybridization of a large sample of ESTs will be a unique identifier. Since the restriction enzyme cleavage will be different for every individual, the band pattern on the Southern blot will also be unique. Increasing the number of EST probes will provide a statistically higher level of confidence in the identification since there will be an increased number of sets of bands used for identification.

EXAMPLE 19

Dot Blot Identification Procedure

Another technique for identifying individuals using the sequences disclosed herein utilizes a dot blot hybridization technique.

Genomic DNA is isolated from nuclei of subject to be identified. Oligonucleotide probes of approximately 30 bp in length were synthesized that correspond to sequences from the ESTs. The probes are used to hybridize to the genomic DNA through conditions known to those in the art. The oligonucleotides are end labelled with P^{32} using polynucleotide kinase (Pharmacia). Dot Blots are created by spotting about 50 ng cDNA of at least 10, preferably at least 50 sequences corresponding to a variety of the Sequence ID

-81-

5 NOs provided in Table 7 onto nitrocellulose or the like using a vacuum dot blot manifold (BioRad, Richmond California). The nitrocellulose filter containing the EST clone sequences is baked or UV linked to the filter, prehybridized and hybridized with labeled probe using techniques known in the art (Davis et al. supra). The ³²P labeled DNA fragments are sequentially hybridized with successively stringent conditions to detect minimal differences between the 30 bp sequence and the DNA. Tetramethylammonium chloride is useful for identifying clones containing small numbers of nucleotide mismatches (Wood et al., Proc. Natl. Acad. Sci. USA 82(6):1585-1588 (1985) which is hereby incorporated by reference. A unique pattern of dots distinguishes one individual from another individuals.

EXAMPLE 20

Alternative "Fingerprint" Identification Technique

20 EST sequences and the corresponding complete cDNA sequences can be used to create a unique fingerprint for an individual. Thus pools of EST sequences can be used in forensics, paternity suits or the like to differentiate one individual from another.

25 Entire EST sequences can be used; similarly oligonucleotides can be prepared from EST sequences. In this example, 20-mer oligonucleotides are prepared from 200 EST sequences using commercially available oligonucleotide services such as Oligos Etc., Wilsonville, OR. Patient cell samples are processed for DNA using techniques well known to those with skill in the art. The nucleic acid is digested with restriction enzymes EcoRI and XbaI. Following digestion, samples are applied to wells for electrophoresis. The procedure, as known in the art, may be modified to accommodate polyacrylamide electrophoresis, however in this example, samples containing 5 ug of DNA are loaded into wells

-82-

and separated on 0.8% agarose gels. The gels are transferred using Southern blotting techniques onto nitrocellulose.

10 ng of each of the oligos are pooled and end-labeled with P^{32} . The nitrocellulose is prehybridized with blocking solution and hybridized with the labeled probes. Following hybridization and washing, the nitrocellulose filter is exposed to X-Omat AR X-ray film. The resulting hybridization pattern will be unique for each individual.

It is additionally contemplated within this example that the representative number of EST sequences can be varied for additional accuracy or clarity.

EXAMPLE 21

Identification of genes associated with hereditary diseases

This example illustrates an approach useful for the association of EST sequences with particular phenotypic characteristics. In this example, a particular EST is used as a test probe to associate that EST with a particular phenotypic characteristic.

An EST clone corresponding to EST01643, (SEQ ID NO 1894) maps to a gene rich region of chromosome 6. EST clone HHCMH89, from which EST01643 was derived, was mapped to chromosome 6p21 by Dr. Julie Korenberg of UCLA/Cedar Sinai Hospital using FISH. A search of Mendelian Inheritance in Man (supra) revealed 6p21 to be a very gene rich region containing several known genes and several diseases for which genes have not been identified. The cDNA encoded by EST clone HHCMH89 thus becomes an immediate candidate for each of these genetic diseases.

Cells from patients with these diseases are isolated and expanded in culture. PCR primers from the EST sequences are used to screen genomic DNA and RNA or cDNA from the patients. ESTs that are not amplified in the patients can be positively associated with a particular disease by further analysis.

EXAMPLE 22

Identification of a gene associated with
Angelman's disease

5

Angelman's disease (AD) is characterized by deletions on the long arm of chromosome 15 (15q11q13) (Williams et al. Am. J. Med. Genet. 32:339-345 (1989) hereby incorporated by reference). The symptoms of the disease include developmental delay, seizures, inappropriate laughter and ataxic movements. These symptoms suggest that the disorder is a neurologic deficiency. This prophetic example illustrates how ESTs, preferably obtained from a cDNA library from human brain, may be used in identifying the defective gene or genes associated with Angelman's Disease. (The example is based on analogous work with genomic DNA, rather than cDNA and ESTs, in identifying the genetic defect associated with Angelman's Disease.) This example also illustrates how EST sequences may generally be used for identifying gene sequences associated with an inherited disease that is mapped to a chromosome location.

ESTs are screened using techniques described in Example 5 and Example 7 to identify those ESTs that localize to the long arm of chromosome 15 and preferably localize to chromosome 15 bands 15q11q13 from normal patients. ESTs that bind to the long arm of chromosome 15 are hybridized to chromosome 15 from AD patients. These studies are preferably performed using either fluorescence in situ hybridization or using somatic cell hybrids that contain fragments from the long arm of chromosome 15 from AD patients. Those chromosome 15-specific ESTs that do not map to chromosome 15 from AD patients are useful as markers for Angelman's Disease and can be incorporated into diagnostics for genetic screening. These ESTs are associated with chromosome deletions present in Angelman's disease. Identification of the gene associated with these AD negative ESTs and an analysis of the polypeptides encoded by the genes

-84-

from normal patients is essential for providing gene or other therapies for AD patients.

Genetic diseases are not always accompanied by gene deletions. Therefore, it is also important to use the ESTs that bind to bands 15q11q13 from AD patients as tools to identify the polymorphisms present within the disease population. Restriction fragment length polymorphism (RFLP) analysis can be performed on patient cells from AD disease or from somatic cell hybrids created using the long arm of chromosome 15. For a review of RFLP techniques see Donis-Keller et al. (Cell 51:319-337 (1987) hereby incorporated by reference). DNA is isolated from the somatic cell lines or from cells from AD patients. The DNA is digested with one or more restriction enzymes according to techniques of Donis-Keller et al. The resulting fragments are separated by gel electrophoresis, denatured, transferred to nitrocellulose and hybridized with the selected radio-labeled ESTs that localize to the region of interest. The autoradiographic pattern is compared both to a number of AD patients and to normal patients. Common patterns of EST hybridization in AD patients that are not present in normal patients indicates that the genes associated with these ESTs are candidate genes affected by AD.

cDNA libraries are prepared from the somatic cell hybrids from AD patients. Libraries are prepared using Lambda Zap II Library Kits (Stratagene, La Jolla, California) or other commercially available library kits. The ESTs of interest are used as probes to identify those bacterial colonies carrying genes corresponding to the EST probes. Positive clones are sequenced and the sequences are compared to homologous gene sequences derived from normal patients.

Alterations, including deletions and substitutions, within gene sequences, associated with bands 15q11q13, are thus positively identified and associated with AD disease. Wagstaff et al. were able to identify deletions and substitutions in sequences encoding the GABA_A receptor

-85-

protein subunit from patients with Angelman's disease (Am. J. Hum. Genet. 49:330-337, (1991)). It is likely that other genes will additionally be associated with the disease.

5

EXAMPLE 23**Preparation and Use of Antisense Oligonucleotides**

Antisense RNA molecules are known to be useful for
10 regulating translation within the cell. Antisense RNA
molecules can be produced from EST sequences or from the
corresponding gene sequences. These antisense molecules can
be used as diagnostic probes to determine whether or not a
particular gene is expressed in a cell. Similarly, the
15 antisense molecules can be used as a therapeutic to regulate
gene expression once the EST is associated with a particular
disease (see Example 22).

The antisense molecules are obtained from a nucleotide
sequence by reversing the orientation of the coding region
20 with regard to the promoter. Thus, the antisense RNA is
complementary to the corresponding mRNA. For a review of
antisense design see Green et al., Ann. Rev. Biochem. 55:569-
597 (1986), which is hereby incorporated by reference. The
antisense sequences can contain modified sugar phosphate
25 backbones to increase stability and make them less sensitive
to RNase activity. Examples of the modifications are
described by Rossi et al., Pharmacol. Ther. 50(2):245-254,
(1991).

Antisense molecules are introduced into cells that
30 express the gene corresponding to the EST of interest in
culture. In a preferred application of this invention, the
polypeptide encoded by the gene is first identified, so that
the effectiveness of antisense inhibition on translation can
be monitored using techniques that include but are not
35 limited to antibody-mediated tests such as RIAs and ELISA,
functional assays, or radiolabelling. The antisense molecule
is introduced into the cells by diffusion or by transfection

-86-

procedures known in the art. The molecules are introduced onto cell samples at a number of different concentrations preferably between $1 \times 10^{-10} \text{M}$ to $1 \times 10^{-4} \text{M}$. Once the minimum concentration that can adequately control translation is identified, the optimized dose is translated into a dosage suitable for use in vivo. For example, an inhibiting concentration in culture of 1×10^{-7} translates into a dose of approximately 0.6 mg/kg bodyweight. Levels of oligonucleotide approaching 100 mg/kg bodyweight or higher may be possible after testing the toxicity of the oligonucleotide in laboratory animals.

The antisense can be introduced into the body as a bare or naked oligonucleotide, oligonucleotide encapsulated in lipid, oligonucleotide sequence encapsidated by viral protein, or as oligonucleotide contained in an expression vector such as those described in Example 25. The antisense oligonucleotide is preferably introduced into the vertebrate by injection. It is additionally contemplated that cells from the vertebrate are removed, treated with the antisense oligonucleotide, and reintroduced into the vertebrate. It is further contemplated that the antisense oligonucleotide sequence is incorporated into a ribozyme sequence to enable the antisense to bind and cleave its target. For technical applications of ribozyme and antisense oligonucleotides see Rossi et al.

EXAMPLE 24

Preparation and use of Triple Helix Probes

Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity as it is associated with a particular gene. The EST sequences or complete sequences of the present invention or, more preferably, a portion of those sequences, can be used to inhibit gene

-87-

expression in individuals having diseases associated with a particular gene. Similarly, a portion of the EST or corresponding gene sequence can be used to study the effect of inhibiting transcription of a particular gene within a cell. Traditionally, homopurine sequences were considered the most useful. However, homopyrimidine sequences can also inhibit gene expression. Thus, both types of sequences from either the EST or from the gene corresponding to the EST are contemplated within the scope of this invention. Homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. As an example, 10-mer to 20-mer homopyrimidine sequences from the ESTs can be used to inhibit expression from homopurine sequences. SEQ ID NOS such as 282, 888, 719, 670, 994, 240, 873 and 761 contain homopyrimidine 15-mers. Moreover the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al. (*Science* 245:967-971 (1989), which is hereby incorporated by this reference).

The oligonucleotides may be prepared on an oligonucleotide synthesizer or they may be purchased commercially from a company specializing in custom oligonucleotide synthesis. The sequences are introduced into cells in culture using techniques known in the art that include but are not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake. Treated cells are monitored for altered cell function. These cell functions are predicted based upon the homologies of the gene, corresponding to the EST from which the oligonucleotide was derived, with known genes sequences that have been associated

-88-

with a particular function. The cell functions can also be predicted based on the presence of abnormal physiologies within cells derived from individuals with a particular inherited disease, particularly when the EST is associated with the disease using techniques described in Example 22.

EXAMPLE 25

Gene expression from DNA Sequences Corresponding to ESTs

10

A gene sequence of the present invention coding for all or part of a human gene product is introduced into an expression vector using conventional technology. (Techniques to transfer cloned sequences into expression vectors that direct protein translation in mammalian, yeast, insect or bacterial expression systems are well known in the art.) Commercially available vectors and expression systems are available from a variety of suppliers including Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence may be optimized for the particular expression organism, as explained by Hatfield, et al., U.S. Patent No. 5,082,767, incorporated herein by this reference.

25

The following is provided as one exemplary method to generate polypeptide from cloned cDNA sequences. The cDNA from the EST of interest is sequenced to identify the methionine initiation codon for the gene and the poly A sequence. If the cDNA lacks a poly A sequence, this sequence can be added to the construct by, for example, splicing out the Poly A sequence from pSG5 (Stratagene) using BglI and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector

30

35

-89-

includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene. The cDNA is obtained by PCR from the bacterial vector using oligonucleotide primers complementary to the cDNA and containing restriction endonuclease sequences for Pst I incorporated into the 5' primer and BglII at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the cDNA is positioned inframe with the poly A sequence. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1, now containing a poly A sequence and digested BglII.

The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification. Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri). The protein is preferrably released into the supernatant. However if the protein has membrane binding domains, the protein may additionally be retained within the cell or expression may be restricted to the cell surface.

Since it may be necessary to purify and locate the transfected product, synthetic 15-mer peptides synthesized from the predicted cDNA sequence are injected into mice to generate antibody to the polypeptide encoded by the cDNA.

If antibody production is not possible, the cDNA sequence is additionally incorporated into eukaryotic expression vectors and expressed as a chimeric with, for example, β -globin. Antibody to β -globin is used to purify the chimeric. Corresponding protease cleavage sites engineered between the β -globin gene and the cDNA are then used to separate the two polypeptide fragments from one another after translation. One useful expression vector for generating β -globin chimerics is pSG5 (Stratagene). This vector encodes rabbit β -globin. Intron II of the rabbit β -globin gene facilitates splicing of the expressed transcript,

-90-

and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques as described are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al. and many of the methods are available from the technical assistance representatives from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from either construct using in vitro translation systems such as In vitro Express™ Translation Kit (Stratagene).

Example 26

Production of an Antibody to a Human Protein

Substantially pure protein or polypeptide is isolated from the transfected or transformed cells as described in Example 25. Concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes of any of the peptides identified and isolated as described can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., Nature 256:495 (1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the selected protein over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a

-91-

microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as Elisa, as originally described by Engvall, E., *Meth. Enzymol.* 70:419 (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. *Basic Methods in Molecular Biology* Elsevier, New York. Section 21-2.

B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogenous epitopes of a single protein can be prepared by immunizing suitable animals with the expressed protein described above, which can be unmodified or modified to enhance immunogenicity. Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. For example, small molecules tend to be less immunogenic than other and may require the use of carriers and adjuvant. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. *J. Clin. Endocrinol. Metab.* 33:988-991 (1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., Chap. 19 in: *Handbook of Experimental Immunology* D. Wier (ed) Blackwell (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M). Affinity of the antisera for the antigen is

-92-

determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: **Manual of Clinical Immunology**, 2d Ed. (Rose and Friedman, eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

5 Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a
10 biological sample.

EXAMPLE 27

Identification of Tissue Types or Cell Species by Means of Labeled Tissue Specific Antibodies

15 Identification of specific tissues is accomplished by the visualization of tissue specific antigens by means of antibody preparations according to Example 26 which are conjugated, directly or indirectly to a detectable marker.
20 Selected labeled antibody species bind to their specific antigen binding partner in tissue sections, cell suspensions, or in extracts of soluble proteins from a tissue sample to provide a pattern for qualitative or semi-qualitative interpretation.

25 Antisera for these procedures must have a potency exceeding that of the native preparation, and for that reason, antibodies are concentrated to a mg/ml level by isolation of the gamma globulin fraction, for example, by ion-exchange chromatography or by ammonium sulfate
30 fractionation. Also, to provide the most specific antisera, unwanted antibodies, for example to common proteins, must be removed from the gamma globulin fraction, for example by means of insoluble immunoabsorbents, before the antibodies are labeled with the marker. Either monoclonal or
35 heterologous antisera is suitable for either procedure.

A. Immunohistochemical Techniques

Purified, high-titer antibodies, prepared as described above, are conjugated to a detectable marker, as described, for example, by Fudenberg, H., Chap. 26 in: **Basic & Clinical Immunology**, 3rd Ed. Lange, Los Altos, California (1980) or Rose, N. et al., Chap. 12 in: **Methods in Immunodiagnosis**, 2d Ed. John Wiley & Sons, New York (1980).

A fluorescent marker, either fluorescein or rhodamine, is preferred, but antibodies can also be labeled with an enzyme that supports a color producing reaction with a substrate, such as horseradish peroxidase. Markers can be added to tissue-bound antibody in a second step, as described below. Alternatively, the specific antitissue antibodies can be labeled with ferritin or other electron dense particles, and localization of the ferritin coupled antigen-antibody complexes achieved by means of an electron microscope. In yet another approach, the antibodies are radiolabeled, with, for example ^{125}I , and detected by overlaying the antibody treated preparation with photographic emulsion.

Preparations to carry out the procedures can comprise monoclonal or polyclonal antibodies to a single gene copy or protein, identified as specific to a tissue type, for example, brain tissue, or antibody preparations to several antigenically distinct tissue specific antigens can be used in panels, independently or in mixtures, as required.

Tissue sections and cell suspensions are prepared for immunohistochemical examination according to common histological techniques. Multiple cryostat sections (about 4 μm , unfixed) of the unknown tissue and known control, are mounted and each slide covered with different dilutions of the antibody preparation. Sections of known and unknown tissues should also be treated with preparations to provide a positive control, a negative control, for example, pre-immune sera, and a control for non-specific staining, for example, buffer.

-94-

Treated sections are incubated in a humid chamber for 30 min at room temperature, rinsed, then washed in buffer for 30-45 min. Excess fluid is blotted away, and the marker developed.

5 If the tissue specific antibody was not labeled in the first incubation, it can be labeled at this time in a second antibody-antibody reaction, for example, by adding fluorescein- or enzyme-conjugated antibody against the immunoglobulin class of the antiserum-producing species, for
10 example, fluorescein labeled antibody to mouse IgG. Such labeled sera are commercially available.

15 The antigen found in the tissues by the above procedure can be quantified by measuring the intensity of color or fluorescence on the tissue section, and calibrating that signal using appropriate standards.

B. Identification of Tissue Specific Soluble Proteins

20 The visualization of tissue specific proteins and identification of unknown tissues from that procedure is carried out using the labeled antibody reagents and detection strategy as described for immunohistochemistry; however the sample is prepared according to an electrophoretic technique to distribute the proteins extracted from the tissue in an orderly array on the basis of molecular weight for detection.

25 A tissue sample is homogenized using a Virtis apparatus; cell suspensions are disrupted by Dounce homogenization or osmotic lysis, using detergents in either case as required to disrupt cell membranes, as is the practice in the art. Insoluble cell components such as nuclei, microsomes, and membrane fragments are removed by ultracentrifugation, and
30 the soluble protein-containing fraction concentrated if necessary and reserved for analysis.

35 A sample of the soluble protein solution is resolved into individual protein species by conventional SDS polyacrylamide electrophoresis as described, for example, by Davis, L. et al., Section 19-2 in: *Basic Methods in Molecular Biology* (P. Leder, ed), Elsevier, New York (1986), using a

-95-

range of amounts of polyacrylamide in a set of gels to resolve the entire molecular weight range of proteins to be detected in the sample. A size marker is run in parallel for purposes of estimating molecular weights of the constituent proteins. Sample size for analysis is a convenient volume of from 5-50 μ l, and containing from about 1 to 100 μ g protein. An aliquot of each of the resolved proteins is transferred by blotting to a nitrocellulose filter paper, a process that maintains the pattern of resolution. Multiple copies are prepared. The procedure, known as Western Blot Analysis, is well described in Davis, L. et al., (above) Section 19-3. One set of nitrocellulose blots is stained with Coomassie Blue dye to visualize the entire set of proteins for comparison with the antibody bound proteins. The remaining nitrocellulose filters are then incubated with a solution of one or more specific antisera to tissue specific proteins prepared as described in Example 26. In this procedure, as in procedure A above, appropriate positive and negative sample and reagent controls are run.

In either procedure A or B, a detectable label can be attached to the primary tissue antigen-primary antibody complex according to various strategies and permutations thereof. In a straightforward approach, the primary specific antibody can be labeled; alternatively, the unlabeled complex can be bound by a labeled secondary anti-IgG antibody. In other approaches, either the primary or secondary antibody is conjugated to a biotin molecule, which can, in a subsequent step, bind an avidin conjugated marker. According to yet another strategy, enzyme labeled or radioactive protein A, which has the property of binding to any IgG, is bound in a final step to either the primary or secondary antibody.

The visualization of tissue specific antigen binding at levels above those seen in control tissues to one or more tissue specific antibodies, prepared from the gene sequences identified from EST sequences, can identify tissues of unknown origin, for example, forensic samples, or

-96-

differentiated tumor tissue that has metastasized to foreign bodily sites.

The entire contents of all references cited above are hereby incorporated by reference.

5 While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention.

10

VII. Correlation of EST and Clone Identifiers

15 The EST sequences of the present invention are identified herein by SEQ ID NO, and are identified in the GenBank database by a different number, are identified in the inventors' lab (and upcoming publications) by EST number, and clones have been submitted to the American Type Culture Collection (Rockville, Maryland USA) under clone names. Table 12 cross references those different numbers for the ESTs from cDNA, SEQ ID NOS 1-2409.

20 Certain Sequence ID NOS are excluded from some claims based on their homology to known non-human sequences (See Table 2).

Table 12. SEQ ID NO Cross References

SEQ ID	EST#	GB#	Clone	SEQ ID	EST#	GB#	Clone	SEQ ID	EST#	GB#	Clone	SEQ ID	EST#	GB#	Clone	SEQ ID	EST#	GB#	Clone
1	EST00007	M61959	HFAA01	64	EST000066	M62010	HHC13	128	EST000252	M62191	HHC57	129	EST000321	M62254	HHC60	130	EST000355	M62283	HHC61
2	EST00009	M61953	HFAA05	65	EST000067	M62011	HHC18	129	EST000322	M62284	HHC62	131	EST000356	M62285	HHC63	132	EST000357	M62286	HHC64
3	EST00010	M61961	HFAA07	66	EST000068	M62012	HHC21	130	EST000358	M62287	HHC65	133	EST000359	M62288	HHC66	134	EST000360	M62289	HHC67
4	EST00011	M61962	HFAA08	67	EST000069	M62013	HHC22	131	EST000361	M62290	HHC68	135	EST000362	M62291	HHC69	136	EST000363	M62292	HHC70
5	EST00012	M61963	HFAA10	68	EST000070	M62014	HHC27	132	EST000364	M62293	HHC71	137	EST000365	M62294	HHC72	138	EST000366	M62295	HHC73
6	EST00013	M61964	HFAA11	69	EST000071	M62015	HHC29	133	EST000367	M62296	HHC74	139	EST000368	M62297	HHC75	140	EST000369	M62298	HHC76
7	EST00014	M61965	HFAA12	70	EST000072	M62016	HHC31	134	EST000370	M62299	HHC77	141	EST000371	M62300	HHC78	142	EST000372	M62301	HHC79
8	EST00015	M61966	HFAA20	71	EST000073	M62017	HHC37	135	EST000373	M62302	HHC80	143	EST000374	M62303	HHC81	144	EST000375	M62304	HHC82
9	EST00016	M61967	HFAA23	72	EST000074	M62018	HHC40	136	EST000376	M62305	HHC83	145	EST000377	M62306	HHC84	146	EST000378	M62307	HHC85
10	EST00017	M61968	HFAA36	73	EST000075	M62019	HHC42	137	EST000379	M62308	HHC86	147	EST000380	M62309	HHC87	148	EST000381	M62310	HHC88
11	EST00018	M62212	HFAA51	74	EST000076	M62020	HHC44	138	EST000382	M62311	HHC89	149	EST000383	M62312	HHC90	149	EST000384	M62313	HHC91
12	EST00019	M62213	HFAA53	75	EST000077	M62021	HHC47	139	EST000385	M62314	HHC92	150	EST000386	M62315	HHC93	150	EST000387	M62316	HHC94
13	EST00020	M62214	HFAA59	76	EST000078	M62022	HHC70	140	EST000388	M62317	HHC95	151	EST000389	M62318	HHC96	151	EST000390	M62319	HHC97
14	EST00021	M62215	HFAA77	77	EST000079	M62023	HHC72	141	EST000391	M62320	HHC97	152	EST000392	M62321	HHC98	152	EST000393	M62322	HHC99
15	EST00022	M62216	HFAA77	78	EST000080	M62024	HHC74	142	EST000394	M62323	HHC99	153	EST000395	M62324	HHC100	153	EST000396	M62325	HHC101
16	EST00023	M62217	HFAA86	79	EST000081	M62025	HHC76	143	EST000397	M62326	HHC101	154	EST000398	M62327	HHC102	154	EST000399	M62328	HHC103
17	EST00024	M62218	HFAA86	80	EST000082	M62026	HHC77	144	EST000399	M62329	HHC102	155	EST000400	M62330	HHC103	155	EST000401	M62331	HHC104
18	EST00025	M62219	HFAA89	81	EST000083	M62027	HHC78	145	EST000402	M62332	HHC104	156	EST000403	M62333	HHC105	156	EST000404	M62334	HHC106
19	EST00026	M62220	HFAA90	82	EST000084	M62028	HHC80	146	EST000405	M62335	HHC106	157	EST000406	M62336	HHC107	157	EST000407	M62337	HHC108
20	EST00027	M62221	HFAA90	83	EST000085	M62029	HHC81	147	EST000408	M62337	HHC107	158	EST000409	M62338	HHC108	158	EST000410	M62339	HHC109
21	EST00028	M62222	HFAA90	84	EST000086	M62030	HHC82	148	EST000411	M62339	HHC109	159	EST000412	M62340	HHC109	159	EST000413	M62341	HHC110
22	EST00029	M62223	HFAA90	85	EST000087	M62031	HHC83	149	EST000414	M62341	HHC110	160	EST000415	M62342	HHC110	160	EST000416	M62343	HHC111
23	EST00030	M62224	HFAA90	86	EST000088	M62032	HHC84	150	EST000417	M62343	HHC111	161	EST000418	M62344	HHC111	161	EST000419	M62345	HHC112
24	EST00031	M62225	HFAA90	87	EST000089	M62033	HHC85	151	EST000420	M62345	HHC112	162	EST000421	M62346	HHC112	162	EST000422	M62347	HHC113
25	EST00032	M62226	HFAA90	88	EST000090	M62034	HHC86	152	EST000423	M62346	HHC113	163	EST000424	M62347	HHC113	163	EST000425	M62348	HHC114
26	EST00033	M62227	HFAA90	89	EST000091	M62035	HHC87	153	EST000426	M62347	HHC114	164	EST000427	M62348	HHC114	164	EST000428	M62349	HHC115
27	EST00034	M62228	HFAA90	90	EST000092	M62036	HHC88	154	EST000429	M62348	HHC115	165	EST000430	M62349	HHC115	165	EST000431	M62350	HHC116
28	EST00035	M62229	HFAA90	91	EST000093	M62037	HHC89	155	EST000432	M62349	HHC116	166	EST000433	M62350	HHC116	166	EST000434	M62351	HHC117
29	EST00036	M62230	HFAA90	92	EST000094	M62038	HHC90	156	EST000435	M62350	HHC117	167	EST000436	M62351	HHC117	167	EST000437	M62352	HHC118
30	EST00037	M62231	HFAA90	93	EST000095	M62039	HHC91	157	EST000438	M62351	HHC118	168	EST000439	M62352	HHC118	168	EST000440	M62353	HHC119
31	EST00038	M62232	HFAA90	94	EST000096	M62040	HHC92	158	EST000441	M62352	HHC119	169	EST000442	M62353	HHC119	169	EST000443	M62354	HHC120
32	EST00039	M62233	HFAA90	95	EST000097	M62041	HHC93	159	EST000444	M62353	HHC120	170	EST000445	M62354	HHC120	170	EST000446	M62355	HHC121
33	EST00040	M62234	HFAA90	96	EST000098	M62042	HHC94	160	EST000447	M62354	HHC121	171	EST000448	M62355	HHC121	171	EST000449	M62356	HHC122
34	EST00041	M62235	HFAA90	97	EST000099	M62043	HHC95	161	EST000450	M62355	HHC122	172	EST000451	M62356	HHC122	172	EST000452	M62357	HHC123
35	EST00042	M62236	HFAA90	98	EST000100	M62044	HHC96	162	EST000453	M62356	HHC123	173	EST000454	M62357	HHC123	173	EST000455	M62358	HHC124
36	EST00043	M62237	HFAA90	99	EST000101	M62045	HHC97	163	EST000456	M62357	HHC124	174	EST000457	M62358	HHC124	174	EST000458	M62359	HHC125
37	EST00044	M62238	HFAA90	100	EST000102	M62046	HHC98	164	EST000459	M62358	HHC125	175	EST000460	M62359	HHC125	175	EST000461	M62360	HHC126
38	EST00045	M62239	HFAA90	101	EST000103	M62047	HHC99	165	EST000462	M62359	HHC126	176	EST000463	M62360	HHC126	176	EST000464	M62361	HHC127
39	EST00046	M62240	HFAA90	102	EST000104	M62048	HHC100	166	EST000465	M62360	HHC127	177	EST000466	M62361	HHC127	177	EST000467	M62362	HHC128
40	EST00047	M62241	HFAA90	103	EST000105	M62049	HHC101	167	EST000468	M62361	HHC128	178	EST000469	M62362	HHC128	178	EST000470	M62363	HHC129
41	EST00048	M62242	HFAA90	104	EST000106	M62050	HHC102	168	EST000471	M62362	HHC129	179	EST000472	M62363	HHC129	179	EST000473	M62364	HHC130
42	EST00049	M62243	HFAA90	105	EST000107	M62051	HHC103	169	EST000474	M62363	HHC130	180	EST000475	M62364	HHC130	180	EST000476	M62365	HHC131
43	EST00050	M62244	HFAA90	106	EST000108	M62052	HHC104	170	EST000477	M62364	HHC131	181	EST000478	M62365	HHC131	181	EST000479	M62366	HHC132
44	EST00051	M62245	HFAA90	107	EST000109	M62053	HHC105	171	EST000480	M62365	HHC132								
45	EST00052	M62246	HFAA90	108	EST000110	M62054	HHC106												
46	EST00053	M62247	HFAA90	109	EST000111	M62055	HHC107												
47	EST00054	M62248	HFAA90	110	EST000112	M62056	HHC108												
48	EST00055	M62249	HFAA90	111	EST000113	M62057	HHC109												
49	EST00056	M62250	HFAA90	112	EST000114	M62058	HHC110												
50	EST00057	M62251	HFAA90	113	EST000115	M62059	HHC111												
51	EST00058	M62252	HFAA90	114	EST000116	M62060	HHC112												
52	EST00059	M62253	HFAA90	115	EST000117	M62061	HHC113												
53	EST00060	M62254	HFAA90	116	EST000118	M62062	HHC114												
54	EST00061	M62255	HFAA90	117	EST000119	M62063	HHC115												
55	EST00062	M62256	HFAA90	118	EST000120	M62064	HHC116												
56	EST00063	M62257	HFAA90	119	EST000121	M62065	HHC117												
57	EST00064	M62258	HFAA90	120	EST000122	M62066	HHC118												
58	EST00065	M62259	HFAA90	121	EST000123	M62067	HHC119												
59	EST00066	M62260	HFAA90	122	EST000124	M62068	HHC120												
60	EST00067	M62261	HFAA90	123	EST000125	M62069	HHC121												
61	EST00068	M62262	HFAA90	124	EST000126	M62070	HHC122												
62	EST00069	M62263	HFAA90	125	EST000127	M62071	HHC123												
63	EST00070	M62264	HFAA90	126	EST000128	M62072	HHC124												

SUBSTITUTE SHEET

SEQ	ID	EST#	GB#	Clone	SEQ	ID	EST#	GB#	Clone	SEQ	ID	EST#	GB#	Clone	SEQ	ID	EST#	GB#	Clone
374	374	EST00428	W78280	HFBA30	440	440	EST01454	W7870	HFBA22	507	507	EST00530	W78382	HFBC81	510	510	EST00531	W78383	HFBC82
375	375	EST01436	W78281	HFBA32	441	441	EST00481	W7871	HFBA24	508	508	EST00532	W78384	HFBC83	511	511	EST00533	W78385	HFBC84
376	376	EST01437	W78282	HFBA33	442	442	EST01456	W7872	HFBA26	509	509	EST00534	W78386	HFBC85	512	512	EST00535	W78387	HFBC86
377	377	EST00430	W78283	HFBA34	443	443	EST00482	W7873	HFBA27	510	510	EST00536	W78388	HFBC87	513	513	EST00537	W78389	HFBC88
378	378	EST00431	W78284	HFBA35	444	444	EST00483	W7874	HFBA28	511	511	EST00538	W78390	HFBC89	514	514	EST00539	W78391	HFBC90
379	379	EST01438	W78285	HFBA36	445	445	EST00484	W7875	HFBA29	512	512	EST00540	W78392	HFBC91	515	515	EST00541	W78393	HFBC92
380	380	EST01439	W78286	HFBA37	446	446	EST00485	W7876	HFBA30	513	513	EST00542	W78394	HFBC93	516	516	EST00543	W78395	HFBC94
381	381	EST00433	W78287	HFBA38	447	447	EST00486	W7877	HFBA31	514	514	EST00544	W78396	HFBC95	517	517	EST00545	W78397	HFBC96
382	382	EST00434	W78288	HFBA39	448	448	EST00487	W7878	HFBA32	515	515	EST00546	W78398	HFBC97	518	518	EST00547	W78399	HFBC98
383	383	EST00435	W78289	HFBA40	449	449	EST00488	W7879	HFBA33	516	516	EST00548	W78400	HFBC99	519	519	EST00549	W78401	HFBC00
384	384	EST00436	W78290	HFBA41	450	450	EST00489	W7880	HFBA34	517	517	EST00550	W78402	HFBC01	520	520	EST00551	W78403	HFBC02
385	385	EST00437	W78291	HFBA42	451	451	EST00490	W7881	HFBA35	518	518	EST00552	W78404	HFBC03	521	521	EST00553	W78405	HFBC04
386	386	EST00438	W78292	HFBA43	452	452	EST00491	W7882	HFBA36	519	519	EST00554	W78406	HFBC05	522	522	EST00555	W78407	HFBC06
387	387	EST00439	W78293	HFBA44	453	453	EST00492	W7883	HFBA37	520	520	EST00556	W78408	HFBC07	523	523	EST00557	W78409	HFBC08
388	388	EST00440	W78294	HFBA45	454	454	EST00493	W7884	HFBA38	521	521	EST00558	W78410	HFBC09	524	524	EST00559	W78411	HFBC10
389	389	EST01441	W78295	HFBA46	455	455	EST00494	W7885	HFBA39	522	522	EST00560	W78412	HFBC11	525	525	EST00561	W78413	HFBC12
390	390	EST01442	W78296	HFBA47	456	456	EST00495	W7886	HFBA40	523	523	EST00562	W78414	HFBC13	526	526	EST00563	W78415	HFBC14
391	391	EST00443	W78297	HFBA48	457	457	EST00496	W7887	HFBA41	524	524	EST00564	W78416	HFBC15	527	527	EST00565	W78417	HFBC16
392	392	EST00444	W78298	HFBA49	458	458	EST00497	W7888	HFBA42	525	525	EST00566	W78418	HFBC17	528	528	EST00567	W78419	HFBC18
393	393	EST00445	W78299	HFBA50	459	459	EST00498	W7889	HFBA43	526	526	EST00568	W78420	HFBC19	529	529	EST00569	W78421	HFBC20
394	394	EST00446	W78300	HFBA51	460	460	EST00499	W7890	HFBA44	527	527	EST00570	W78422	HFBC21	530	530	EST00571	W78423	HFBC22
395	395	EST00447	W78301	HFBA52	461	461	EST00500	W7891	HFBA45	528	528	EST00572	W78424	HFBC23	531	531	EST00573	W78425	HFBC24
396	396	EST00448	W78302	HFBA53	462	462	EST00501	W7892	HFBA46	529	529	EST00574	W78426	HFBC25	532	532	EST00575	W78427	HFBC26
397	397	EST00449	W78303	HFBA54	463	463	EST00502	W7893	HFBA47	530	530	EST00576	W78428	HFBC27	533	533	EST00577	W78429	HFBC28
398	398	EST00450	W78304	HFBA55	464	464	EST00503	W7894	HFBA48	531	531	EST00578	W78430	HFBC29	534	534	EST00579	W78431	HFBC30
399	399	EST00451	W78305	HFBA56	465	465	EST00504	W7895	HFBA49	532	532	EST00580	W78432	HFBC31	535	535	EST00581	W78433	HFBC32
400	400	EST00452	W78306	HFBA57	466	466	EST00505	W7896	HFBA50	533	533	EST00582	W78434	HFBC33	536	536	EST00583	W78435	HFBC34
401	401	EST00453	W78307	HFBA58	467	467	EST00506	W7897	HFBA51	534	534	EST00584	W78436	HFBC35	537	537	EST00585	W78437	HFBC36
402	402	EST00454	W78308	HFBA59	468	468	EST00507	W7898	HFBA52	535	535	EST00586	W78438	HFBC37	538	538	EST00587	W78439	HFBC38
403	403	EST00455	W78309	HFBA60	469	469	EST00508	W7899	HFBA53	536	536	EST00588	W78440	HFBC39	539	539	EST00589	W78441	HFBC40
404	404	EST00456	W78310	HFBA61	470	470	EST00509	W7900	HFBA54	537	537	EST00590	W78442	HFBC41	540	540	EST00591	W78443	HFBC42
405	405	EST00457	W78311	HFBA62	471	471	EST00510	W7901	HFBA55	538	538	EST00592	W78444	HFBC43	541	541	EST00593	W78445	HFBC44
406	406	EST00458	W78312	HFBA63	472	472	EST00511	W7902	HFBA56	539	539	EST00594	W78446	HFBC45	542	542	EST00595	W78447	HFBC46
407	407	EST00459	W78313	HFBA64	473	473	EST00512	W7903	HFBA57	540	540	EST00596	W78448	HFBC47	543	543	EST00597	W78449	HFBC48
408	408	EST00460	W78314	HFBA65	474	474	EST00513	W7904	HFBA58	541	541	EST00598	W78450	HFBC49	544	544	EST00599	W78451	HFBC50
409	409	EST00461	W78315	HFBA66	475	475	EST00514	W7905	HFBA59	542	542	EST00600	W78452	HFBC51	545	545	EST00601	W78453	HFBC52
410	410	EST00462	W78316	HFBA67	476	476	EST00515	W7906	HFBA60	543	543	EST00602	W78454	HFBC53	546	546	EST00603	W78455	HFBC54
411	411	EST00463	W78317	HFBA68	477	477	EST00516	W7907	HFBA61	544	544	EST00604	W78456	HFBC55	547	547	EST00605	W78457	HFBC56
412	412	EST00464	W78318	HFBA69	478	478	EST00517	W7908	HFBA62	545	545	EST00606	W78458	HFBC57	548	548	EST00607	W78459	HFBC58
413	413	EST00465	W78319	HFBA70	479	479	EST00518	W7909	HFBA63	546	546	EST00608	W78460	HFBC59	549	549	EST00609	W78461	HFBC60
414	414	EST00466	W78320	HFBA71	480	480	EST00519	W7910	HFBA64	547	547	EST00610	W78462	HFBC61	550	550	EST00611	W78463	HFBC62
415	415	EST00467	W78321	HFBA72	481	481	EST00520	W7911	HFBA65	548	548	EST00612	W78464	HFBC63	551	551	EST00613	W78465	HFBC64
416	416	EST00468	W78322	HFBA73	482	482	EST00521	W7912	HFBA66	549	549	EST00614	W78466	HFBC65	552	552	EST00615	W78467	HFBC66
417	417	EST00469	W78323	HFBA74	483	483	EST00522	W7913	HFBA67	550	550	EST00616	W78468	HFBC67	553	553	EST00617	W78469	HFBC68
418	418	EST00470	W78324	HFBA75	484	484	EST00523	W7914	HFBA68	551	551	EST00618	W78470	HFBC69	554	554	EST00619	W78471	HFBC70
419	419	EST00471	W78325	HFBA76	485	485	EST00524	W7915	HFBA69	552	552	EST00620	W78472	HFBC71	555	555	EST00621	W78473	HFBC72
420	420	EST00472	W78326	HFBA77	486	486	EST00525	W7916	HFBA70	553	553	EST00622	W78474	HFBC73	556	556	EST00623	W78475	HFBC74
421	421	EST00473	W78327	HFBA78	487	487	EST00526	W7917	HFBA71	554	554	EST00624	W78476	HFBC75	557	557	EST00625	W78477	HFBC76
422	422	EST00474	W78328	HFBA79	488	488	EST00527	W7918	HFBA72	555	555	EST00626	W78478	HFBC77	558	558	EST00627	W78479	HFBC78
423	423	EST00475	W78329	HFBA80	489	489	EST00528	W7919	HFBA73	556	556	EST00628	W78480	HFBC79	559	559	EST00629	W78481	HFBC80
424	424	EST00476	W78330	HFBA81	490	490	EST00529	W7920	HFBA74	557	557	EST00630	W78482	HFBC81	560	560	EST00631	W78483	HFBC82
425	425	EST00477	W78331	HFBA82	491	491	EST00530	W7921	HFBA75	558	558	EST00632	W78484	HFBC83	561	561	EST00633	W78485	HFBC84
426	426	EST00478	W78332	HFBA83	492	492	EST00531	W7922	HFBA76	559	559	EST00634	W78486	HFBC85	562	562	EST00635	W78487	HFBC86
427	427	EST00479	W78333	HFBA84	493	493	EST00532	W7923	HFBA77	560	560	EST00636	W78488	HFBC87	563	563	EST00637	W78489	HFBC88
428	428	EST00480	W78334	HFBA85	494	494	EST00533	W7924	HFBA78	561	561	EST00638	W78490	HFBC89	564	564	EST00639	W78491	HFBC90
429	429	EST00481	W78335	HFBA86	495	495	EST00534	W7925	HFBA79	562	562	EST00640	W78492	HFBC91	565	565	EST00641	W78493	HFBC92
430	430	EST00482	W78336	HFBA87	496	496	EST00535	W7926	HFBA80	563	563	EST00642	W78494	HFBC93	566	566	EST00643	W78495	HFBC94
431	431	EST00483	W78337	HFBA88	497	497	EST00536	W7927	HFBA81	564	564	EST00644	W78496	HFBC95	567	567	EST00645	W78497	HFBC96
432	432	EST00484	W78338	HFBA89	498	498	EST00537	W7928	HFBA82	565	565	EST00646	W78498	HFBC97	568	568	EST00647	W78499	HFBC98
433	433	EST00485	W78339	HFBA90	499	499	EST00538	W7929	HFBA83	566	566	EST00648	W78500	HFBC99	569	569	EST00649	W78501	HFBC00
434	434	EST00486	W78340	HFBA91	500	500	EST00539	W7930	HFBA84	567	567	EST00650	W78502	HFBC01	570	570	EST00651	W78503	HFBC02
435	435	EST00487	W78341	HFBA92	501	501	EST00540	W7931	HFBA85	568	568	EST00652	W78504	HFBC03	571	571	EST00653	W78505	HFBC04
436	436	EST00488	W78342	HFBA93	502	502	EST00541	W7932	HFBA86	569	569	EST00654	W78506	HFBC05	572	572	EST00655	W78507	HFBC06
437	437	EST00489	W78343	HFBA94	503	503	EST00542	W79											

564	EST00574	W78426	HFBCB92	CLONE	EST01521	W78337	HFBCD87	CLONE
565	EST00575	W78427	HFBCB93		EST00680	W78338	HFBCD88	
566	EST00576	W78428	HFBCB94		EST00681	W78339	HFBCD89	
567	EST00577	W78429	HFBCB95		EST00682	W78340	HFBCD90	
568	EST00578	W78430	HFBCB96		EST00683	W78341	HFBCD91	
569	EST00579	W78431	HFBCB97		EST00684	W78342	HFBCD92	
570	EST00580	W78432	HFBCB98		EST00685	W78343	HFBCD93	
571	EST00581	W78433	HFBCB99		EST00686	W78344	HFBCD94	
572	EST00582	W78434	HFBCB00		EST00687	W78345	HFBCD95	
573	EST00583	W78435	HFBCB01		EST00688	W78346	HFBCD96	
574	EST00584	W78436	HFBCB02		EST00689	W78347	HFBCD97	
575	EST00585	W78437	HFBCB03		EST00690	W78348	HFBCD98	
576	EST00586	W78438	HFBCB04		EST00691	W78349	HFBCD99	
577	EST00587	W78439	HFBCB05		EST00692	W78350	HFBCD00	
578	EST00588	W78440	HFBCB06		EST00693	W78351	HFBCD01	
579	EST00589	W78441	HFBCB07		EST00694	W78352	HFBCD02	
580	EST00590	W78442	HFBCB08		EST00695	W78353	HFBCD03	
581	EST00591	W78443	HFBCB09		EST00696	W78354	HFBCD04	
582	EST00592	W78444	HFBCB10		EST00697	W78355	HFBCD05	
583	EST00593	W78445	HFBCB11		EST00698	W78356	HFBCD06	
584	EST00594	W78446	HFBCB12		EST00699	W78357	HFBCD07	
585	EST00595	W78447	HFBCB13		EST00700	W78358	HFBCD08	
586	EST00596	W78448	HFBCB14		EST00701	W78359	HFBCD09	
587	EST00597	W78449	HFBCB15		EST00702	W78360	HFBCD10	
588	EST00598	W78450	HFBCB16		EST00703	W78361	HFBCD11	
589	EST00599	W78451	HFBCB17		EST00704	W78362	HFBCD12	
590	EST00600	W78452	HFBCB18		EST00705	W78363	HFBCD13	
591	EST00601	W78453	HFBCB19		EST00706	W78364	HFBCD14	
592	EST00602	W78454	HFBCB20		EST00707	W78365	HFBCD15	
593	EST00603	W78455	HFBCB21		EST00708	W78366	HFBCD16	
594	EST00604	W78456	HFBCB22		EST00709	W78367	HFBCD17	
595	EST00605	W78457	HFBCB23		EST00710	W78368	HFBCD18	
596	EST00606	W78458	HFBCB24		EST00711	W78369	HFBCD19	
597	EST00607	W78459	HFBCB25		EST00712	W78370	HFBCD20	
598	EST00608	W78460	HFBCB26		EST00713	W78371	HFBCD21	
599	EST00609	W78461	HFBCB27		EST00714	W78372	HFBCD22	
600	EST00610	W78462	HFBCB28		EST00715	W78373	HFBCD23	
601	EST00611	W78463	HFBCB29		EST00716	W78374	HFBCD24	
602	EST00612	W78464	HFBCB30		EST00717	W78375	HFBCD25	
603	EST00613	W78465	HFBCB31		EST00718	W78376	HFBCD26	
604	EST00614	W78466	HFBCB32		EST00719	W78377	HFBCD27	
605	EST00615	W78467	HFBCB33		EST00720	W78378	HFBCD28	
606	EST00616	W78468	HFBCB34		EST00721	W78379	HFBCD29	
607	EST00617	W78469	HFBCB35		EST00722	W78380	HFBCD30	
608	EST00618	W78470	HFBCB36		EST00723	W78381	HFBCD31	
609	EST00619	W78471	HFBCB37		EST00724	W78382	HFBCD32	
610	EST00620	W78472	HFBCB38		EST00725	W78383	HFBCD33	
611	EST00621	W78473	HFBCB39		EST00726	W78384	HFBCD34	
612	EST00622	W78474	HFBCB40		EST00727	W78385	HFBCD35	
613	EST00623	W78475	HFBCB41		EST00728	W78386	HFBCD36	
614	EST00624	W78476	HFBCB42		EST00729	W78387	HFBCD37	
615	EST00625	W78477	HFBCB43		EST00730	W78388	HFBCD38	
616	EST00626	W78478	HFBCB44		EST00731	W78389	HFBCD39	
617	EST00627	W78479	HFBCB45		EST00732	W78390	HFBCD40	
618	EST00628	W78480	HFBCB46		EST00733	W78391	HFBCD41	
619	EST00629	W78481	HFBCB47		EST00734	W78392	HFBCD42	
620	EST00630	W78482	HFBCB48		EST00735	W78393	HFBCD43	
621	EST00631	W78483	HFBCB49		EST00736	W78394	HFBCD44	
622	EST00632	W78484	HFBCB50		EST00737	W78395	HFBCD45	
623	EST00633	W78485	HFBCB51		EST00738	W78396	HFBCD46	
624	EST00634	W78486	HFBCB52		EST00739	W78397	HFBCD47	
625	EST00635	W78487	HFBCB53		EST00740	W78398	HFBCD48	
626	EST00636	W78488	HFBCB54		EST00741	W78399	HFBCD49	
627	EST00637	W78489	HFBCB55		EST00742	W78400	HFBCD50	
628	EST00638	W78490	HFBCB56		EST00743	W78401	HFBCD51	
629	EST00639	W78491	HFBCB57		EST00744	W78402	HFBCD52	

SUBSTITUTE SHEET

-101-

SEQ ID	EST#	CS#	Clone	SEQ ID	EST#	CS#	Clone	SEQ ID	EST#	CS#	Clone	SEQ ID	EST#	CS#	Clone
733	EST00721	W78573	HFBCE66	885	EST01885	M85371	HFBCE01	885	EST01885	M85371	HFBCE01	885	EST01885	M85371	HFBCE01
734	EST00722	W78574	HFBCE67	886	EST01886	M85372	HFBCE02	886	EST01886	M85372	HFBCE02	886	EST01886	M85372	HFBCE02
735	EST00723	W78575	HFBCE68	887	EST01887	M85373	HFBCE03	887	EST01887	M85373	HFBCE03	887	EST01887	M85373	HFBCE03
736	EST01541	W77957	HFBCE69	888	EST01888	M85374	HFBCE04	888	EST01888	M85374	HFBCE04	888	EST01888	M85374	HFBCE04
737	EST00724	W78576	HFBCE70	889	EST01889	M85375	HFBCE05	889	EST01889	M85375	HFBCE05	889	EST01889	M85375	HFBCE05
738	EST00725	W78577	HFBCE71	890	EST01890	M85376	HFBCE06	890	EST01890	M85376	HFBCE06	890	EST01890	M85376	HFBCE06
739	EST00726	W78578	HFBCE72	891	EST01891	M85377	HFBCE07	891	EST01891	M85377	HFBCE07	891	EST01891	M85377	HFBCE07
740	EST00727	W78579	HFBCE73	892	EST01892	M85378	HFBCE08	892	EST01892	M85378	HFBCE08	892	EST01892	M85378	HFBCE08
741	EST01544	W78580	HFBCE74	893	EST01893	M85379	HFBCE09	893	EST01893	M85379	HFBCE09	893	EST01893	M85379	HFBCE09
742	EST00728	W78581	HFBCE75	894	EST01894	M85380	HFBCE10	894	EST01894	M85380	HFBCE10	894	EST01894	M85380	HFBCE10
743	EST00729	W78582	HFBCE76	895	EST01895	M85381	HFBCE11	895	EST01895	M85381	HFBCE11	895	EST01895	M85381	HFBCE11
744	EST00730	W78583	HFBCE77	896	EST01896	M85382	HFBCE12	896	EST01896	M85382	HFBCE12	896	EST01896	M85382	HFBCE12
745	EST00731	W78584	HFBCE78	897	EST01897	M85383	HFBCE13	897	EST01897	M85383	HFBCE13	897	EST01897	M85383	HFBCE13
746	EST00732	W78585	HFBCE79	898	EST01898	M85384	HFBCE14	898	EST01898	M85384	HFBCE14	898	EST01898	M85384	HFBCE14
747	EST00733	W78586	HFBCE80	899	EST01899	M85385	HFBCE15	899	EST01899	M85385	HFBCE15	899	EST01899	M85385	HFBCE15
748	EST00734	W78587	HFBCE81	900	EST01900	M85386	HFBCE16	900	EST01900	M85386	HFBCE16	900	EST01900	M85386	HFBCE16
749	EST00735	W78588	HFBCE82	901	EST01901	M85387	HFBCE17	901	EST01901	M85387	HFBCE17	901	EST01901	M85387	HFBCE17
750	EST01546	W77962	HFBCE83	902	EST01902	M85388	HFBCE18	902	EST01902	M85388	HFBCE18	902	EST01902	M85388	HFBCE18
751	EST01547	W77963	HFBCE84	903	EST01903	M85389	HFBCE19	903	EST01903	M85389	HFBCE19	903	EST01903	M85389	HFBCE19
752	EST01548	W77964	HFBCE85	904	EST01904	M85390	HFBCE20	904	EST01904	M85390	HFBCE20	904	EST01904	M85390	HFBCE20
753	EST00737	W78589	HFBCE86	905	EST01905	M85391	HFBCE21	905	EST01905	M85391	HFBCE21	905	EST01905	M85391	HFBCE21
754	EST00738	W78590	HFBCE87	906	EST01906	M85392	HFBCE22	906	EST01906	M85392	HFBCE22	906	EST01906	M85392	HFBCE22
755	EST00739	W78591	HFBCE88	907	EST01907	M85393	HFBCE23	907	EST01907	M85393	HFBCE23	907	EST01907	M85393	HFBCE23
756	EST00740	W78592	HFBCE89	908	EST01908	M85394	HFBCE24	908	EST01908	M85394	HFBCE24	908	EST01908	M85394	HFBCE24
757	EST00741	W78593	HFBCE90	909	EST01909	M85395	HFBCE25	909	EST01909	M85395	HFBCE25	909	EST01909	M85395	HFBCE25
758	EST00742	W78594	HFBCE91	910	EST01910	M85396	HFBCE26	910	EST01910	M85396	HFBCE26	910	EST01910	M85396	HFBCE26
759	EST00743	W78595	HFBCE92	911	EST01911	M85397	HFBCE27	911	EST01911	M85397	HFBCE27	911	EST01911	M85397	HFBCE27
760	EST00744	W78596	HFBCE93	912	EST01912	M85398	HFBCE28	912	EST01912	M85398	HFBCE28	912	EST01912	M85398	HFBCE28
761	EST00745	W78597	HFBCE94	913	EST01913	M85399	HFBCE29	913	EST01913	M85399	HFBCE29	913	EST01913	M85399	HFBCE29
762	EST00746	W78598	HFBCE95	914	EST01914	M85400	HFBCE30	914	EST01914	M85400	HFBCE30	914	EST01914	M85400	HFBCE30
763	EST01551	W77969	HFBCE96	915	EST01915	M85401	HFBCE31	915	EST01915	M85401	HFBCE31	915	EST01915	M85401	HFBCE31
764	EST00747	W78599	HFBCE97	916	EST01916	M85402	HFBCE32	916	EST01916	M85402	HFBCE32	916	EST01916	M85402	HFBCE32
765	EST00748	W78600	HFBCE98	917	EST01917	M85403	HFBCE33	917	EST01917	M85403	HFBCE33	917	EST01917	M85403	HFBCE33
766	EST01555	W77971	HFBCE99	918	EST01918	M85404	HFBCE34	918	EST01918	M85404	HFBCE34	918	EST01918	M85404	HFBCE34
767	EST00749	W78601	HFBCE00	919	EST01919	M85405	HFBCE35	919	EST01919	M85405	HFBCE35	919	EST01919	M85405	HFBCE35
768	EST00750	W78602	HFBCE01	920	EST01920	M85406	HFBCE36	920	EST01920	M85406	HFBCE36	920	EST01920	M85406	HFBCE36
769	EST00751	W78603	HFBCE02	921	EST01921	M85407	HFBCE37	921	EST01921	M85407	HFBCE37	921	EST01921	M85407	HFBCE37
770	EST00752	W78604	HFBCE03	922	EST01922	M85408	HFBCE38	922	EST01922	M85408	HFBCE38	922	EST01922	M85408	HFBCE38
771	EST00753	W78605	HFBCE04	923	EST01923	M85409	HFBCE39	923	EST01923	M85409	HFBCE39	923	EST01923	M85409	HFBCE39
772	EST00754	W78606	HFBCE05	924	EST01924	M85410	HFBCE40	924	EST01924	M85410	HFBCE40	924	EST01924	M85410	HFBCE40
773	EST00755	W78607	HFBCE06	925	EST01925	M85411	HFBCE41	925	EST01925	M85411	HFBCE41	925	EST01925	M85411	HFBCE41
774	EST00756	W78608	HFBCE07	926	EST01926	M85412	HFBCE42	926	EST01926	M85412	HFBCE42	926	EST01926	M85412	HFBCE42
775	EST00757	W78609	HFBCE08	927	EST01927	M85413	HFBCE43	927	EST01927	M85413	HFBCE43	927	EST01927	M85413	HFBCE43
776	EST00758	W78610	HFBCE09	928	EST01928	M85414	HFBCE44	928	EST01928	M85414	HFBCE44	928	EST01928	M85414	HFBCE44
777	EST00759	W78611	HFBCE10	929	EST01929	M85415	HFBCE45	929	EST01929	M85415	HFBCE45	929	EST01929	M85415	HFBCE45
778	EST00760	W78612	HFBCE11	930	EST01930	M85416	HFBCE46	930	EST01930	M85416	HFBCE46	930	EST01930	M85416	HFBCE46
779	EST00761	W78613	HFBCE12	931	EST01931	M85417	HFBCE47	931	EST01931	M85417	HFBCE47	931	EST01931	M85417	HFBCE47
780	EST00762	W78614	HFBCE13	932	EST01932	M85418	HFBCE48	932	EST01932	M85418	HFBCE48	932	EST01932	M85418	HFBCE48
781	EST00763	W78615	HFBCE14	933	EST01933	M85419	HFBCE49	933	EST01933	M85419	HFBCE49	933	EST01933	M85419	HFBCE49
782	EST00764	W78616	HFBCE15	934	EST01934	M85420	HFBCE50	934	EST01934	M85420	HFBCE50	934	EST01934	M85420	HFBCE50
783	EST01854	W8617	HFBCE16	935	EST01935	M85421	HFBCE51	935	EST01935	M85421	HFBCE51	935	EST01935	M85421	HFBCE51
784	EST00765	W8618	HFBCE17	936	EST01936	M85422	HFBCE52	936	EST01936	M85422	HFBCE52	936	EST01936	M85422	HFBCE52
785	EST00766	W8619	HFBCE18	937	EST01937	M85423	HFBCE53	937	EST01937	M85423	HFBCE53	937	EST01937	M85423	HFBCE53
786	EST01855	W85341	HFBCE19	938	EST01938	M85424	HFBCE54	938	EST01938	M85424	HFBCE54	938	EST01938	M85424	HFBCE54
787	EST01856	W85342	HFBCE20	939	EST01939	M85425	HFBCE55	939	EST01939	M85425	HFBCE55	939	EST01939	M85425	HFBCE55
788	EST01857	W85343	HFBCE21	940	EST01940	M85426	HFBCE56	940	EST01940	M85426	HFBCE56	940	EST01940	M85426	HFBCE56
789	EST01858	W85344	HFBCE22	941	EST01941	M85427	HFBCE57	941	EST01941	M85427	HFBCE57	941	EST01941	M85427	HFBCE57
790	EST01859	W85345	HFBCE23												
791	EST01860	W85346	HFBCE24												
792	EST01861	W85347	HFBCE25												
793	EST01862	W85348	HFBCE26												
794	EST01863	W85349	HFBCE27												
795	EST01864	W85350	HFBCE28												
796	EST01865	W85351	HFBCE29												
797	EST01866	W85352	HFBCE30												
798	EST01867	W85353	HFBCE31												
799	EST01868	W85354	HFBCE32												
800	EST01869	W85355	HFBCE33												
801	EST01870	W85356	HFBCE34												
802	EST01871	W85357	HFBCE35												
803	EST01872	W85358	HFBCE36												
804	EST01873	W85359	HFBCE37												
805	EST01874	W85360	HFBCE38												
806	EST01875	W85361	HFBCE39												
807	EST01876	W85362	HFBCE40												
808	EST01877	W85363	HFBCE41												
809	EST01878	W85364	HFBCE42												
810	EST01879	W85365	HFBCE43												
811	EST01880	W85366	HFBCE44												
812	EST01881	W85367	HFBCE45												
813	EST01882	W85368	HFBCE46												
814	EST01883	W85369	HFBCE47												
815	EST01884	W85370	HFBCE48												
816	EST01885	W85371	HFBCE49												
817	EST01886	W85372	HFBCE50												
818	EST01887	W85373	HFBCE51												

SEQ ID	EST#	GB#	Clone	SEQ ID	EST#	GB#	Clone	SEQ ID	EST#	GB#	Clone
942	EST010947	M85431	HFBC11	1074	EST02092	M85576	HFBC129	1130	EST02150	M85632	HFBC113
943	EST010948	M85432	HFBC12	1075	EST02093	M85577	HFBC130	1131	EST02151	M85633	HFBC114
944	EST010949	M85433	HFBC13	1076	EST02094	M85578	HFBC131	1132	EST02152	M85634	HFBC115
945	EST010950	M85434	HFBC14	1077	EST02095	M85579	HFBC132	1133	EST02153	M85635	HFBC116
946	EST010951	M85435	HFBC15	1078	EST02096	M85580	HFBC133	1134	EST02154	M85636	HFBC117
947	EST010952	M85436	HFBC16	1079	EST02097	M85581	HFBC134	1135	EST02155	M85637	HFBC118
948	EST010953	M85437	HFBC17	1080	EST02098	M85582	HFBC135	1136	EST02156	M85638	HFBC119
949	EST010954	M85438	HFBC18	1081	EST02099	M85583	HFBC136	1137	EST02157	M85639	HFBC120
950	EST010955	M85439	HFBC19	1082	EST02100	M85584	HFBC137	1138	EST02158	M85640	HFBC121
951	EST010956	M85440	HFBC20	1083	EST02101	M85585	HFBC138	1139	EST02159	M85641	HFBC122
952	EST010957	M85441	HFBC21	1084	EST02102	M85586	HFBC139	1140	EST02160	M85642	HFBC123
953	EST010958	M85442	HFBC22	1085	EST02103	M85587	HFBC140	1141	EST02161	M85643	HFBC124
954	EST010959	M85443	HFBC23	1086	EST02104	M85588	HFBC141	1142	EST02162	M85644	HFBC125
955	EST010960	M85444	HFBC24	1087	EST02105	M85589	HFBC142	1143	EST02163	M85645	HFBC126
956	EST010961	M85445	HFBC25	1088	EST02106	M85590	HFBC143	1144	EST02164	M85646	HFBC127
957	EST010962	M85446	HFBC26	1089	EST02107	M85591	HFBC144	1145	EST02165	M85647	HFBC128
958	EST010963	M85447	HFBC27	1090	EST02108	M85592	HFBC145	1146	EST02166	M85648	HFBC129
959	EST010964	M85448	HFBC28	1091	EST02109	M85593	HFBC146	1147	EST02167	M85649	HFBC130
960	EST010965	M85449	HFBC29	1092	EST02110	M85594	HFBC147	1148	EST02168	M85650	HFBC131
961	EST010966	M85450	HFBC30	1093	EST02111	M85595	HFBC148	1149	EST02169	M85651	HFBC132
962	EST010967	M85451	HFBC31	1094	EST02112	M85596	HFBC149	1150	EST02170	M85652	HFBC133
963	EST010968	M85452	HFBC32	1095	EST02113	M85597	HFBC150				
964	EST010969	M85453	HFBC33	1096	EST02114	M85598	HFBC151				
965	EST010970	M85454	HFBC34	1097	EST02115	M85599	HFBC152				
966	EST010971	M85455	HFBC35	1098	EST02116	M85600	HFBC153				
967	EST010972	M85456	HFBC36	1099	EST02117	M85601	HFBC154				
968	EST010973	M85457	HFBC37	1100	EST02118	M85602	HFBC155				
969	EST010974	M85458	HFBC38	1101	EST02119	M85603	HFBC156				
970	EST010975	M85459	HFBC39	1102	EST02120	M85604	HFBC157				
971	EST010976	M85460	HFBC40	1103	EST02121	M85605	HFBC158				
972	EST010977	M85461	HFBC41	1104	EST02122	M85606	HFBC159				
973	EST010978	M85462	HFBC42	1105	EST02123	M85607	HFBC160				
974	EST010979	M85463	HFBC43	1106	EST02124	M85608	HFBC161				
975	EST010980	M85464	HFBC44	1107	EST02125	M85609	HFBC162				
976	EST010981	M85465	HFBC45	1108	EST02126	M85610	HFBC163				
977	EST010982	M85466	HFBC46	1109	EST02127	M85611	HFBC164				
978	EST010983	M85467	HFBC47	1110	EST02128	M85612	HFBC165				
979	EST010984	M85468	HFBC48	1111	EST02129	M85613	HFBC166				
980	EST010985	M85469	HFBC49	1112	EST02130	M85614	HFBC167				
981	EST010986	M85470	HFBC50	1113	EST02131	M85615	HFBC168				
982	EST010987	M85471	HFBC51	1114	EST02132	M85616	HFBC169				
983	EST010988	M85472	HFBC52	1115	EST02133	M85617	HFBC170				
984	EST010989	M85473	HFBC53	1116	EST02134	M85618	HFBC171				
985	EST010990	M85474	HFBC54	1117	EST02135	M85619	HFBC172				
986	EST010991	M85475	HFBC55	1118	EST02136	M85620	HFBC173				
987	EST010992	M85476	HFBC56	1119	EST02137	M85621	HFBC174				
988	EST010993	M85477	HFBC57	1120	EST02138	M85622	HFBC175				
989	EST010994	M85478	HFBC58	1121	EST02139	M85623	HFBC176				
990	EST010995	M85479	HFBC59	1122	EST02140	M85624	HFBC177				
991	EST010996	M85480	HFBC60	1123	EST02141	M85625	HFBC178				
992	EST010997	M85481	HFBC61	1124	EST02142	M85626	HFBC179				
993	EST010998	M85482	HFBC62	1125	EST02143	M85627	HFBC180				
994	EST010999	M85483	HFBC63	1126	EST02144	M85628	HFBC181				
995	EST010000	M85484	HFBC64	1127	EST02145	M85629	HFBC182				
996	EST010001	M85485	HFBC65	1128	EST02146	M85630	HFBC183				
997	EST010002	M85486	HFBC66	1129	EST02147	M85631	HFBC184				
998	EST010003	M85487	HFBC67	1130	EST02148	M85632	HFBC185				
999	EST010004	M85488	HFBC68				HFBC186				
1000	EST010005	M85489	HFBC69				HFBC187				
1001	EST010006	M85490	HFBC70				HFBC188				
1002	EST010007	M85491	HFBC71				HFBC189				
1003	EST010008	M85492	HFBC72				HFBC190				
1004	EST010009	M85493	HFBC73				HFBC191				
1005	EST010010	M85494	HFBC74				HFBC192				
1006	EST010011	M85495	HFBC75				HFBC193				
1007	EST010012	M85496	HFBC76				HFBC194				
1008	EST010013	M85497	HFBC77				HFBC195				
1009	EST010014	M85498	HFBC78				HFBC196				
1010	EST010015	M85499	HFBC79				HFBC197				
1011	EST010016	M85500	HFBC80				HFBC198				
1012	EST010017	M85501	HFBC81				HFBC199				
1013	EST010018	M85502	HFBC82				HFBC200				
1014	EST010019	M85503	HFBC83				HFBC201				
1015	EST010020	M85504	HFBC84				HFBC202				
1016	EST010021	M85505	HFBC85				HFBC203				

SUBSTITUTE SHEET

-103-

SEQ ID	EST#	CS#	Clone
262	EST02281	M85760	HFBC124
263	EST02282	M85761	HFBC125
264	EST02283	M85762	HFBC129
265	EST02284	M85763	HFBC131
266	EST02285	M85764	HFBC136
267	EST02286	M85765	HFBC137
268	EST02287	M85766	HFBC139
269	EST02288	M85767	HFBC140
270	EST02289	M85768	HFBC142
271	EST02290	M85769	HFBC146
272	EST02291	M85770	HFBC147
273	EST02292	M85771	HFBC148
274	EST02293	M85772	HFBC149
275	EST02294	M85773	HFBC150
276	EST02295	M85774	HFBC151
277	EST02296	M85775	HFBC152
278	EST02297	M85776	HFBC154
279	EST02298	M85777	HFBC155
280	EST02299	M85778	HFBC156
281	EST02300	M85779	HFBC157
282	EST02301	M85780	HFBC158
283	EST02302	M85781	HFBC159
284	EST02303	M85782	HFBC160
285	EST02304	M85783	HFBC161
286	EST02305	M85784	HFBC162
287	EST02306	M85785	HFBC164
288	EST02307	M85786	HFBC165
289	EST02308	M85787	HFBC166
290	EST02309	M85788	HFBC167
291	EST02310	M85789	HFBC168
292	EST02311	M85790	HFBC169
293	EST02312	M85791	HFBC171
294	EST02313	M85792	HFBC172
295	EST02314	M85793	HFBC177
296	EST02315	M85795	HFBC182
297	EST02316	M85796	HFBC183
298	EST02317	M85797	HFBC184
299	EST02318	M85798	HFBC185
300	EST02319	M85799	HFBC187
301	EST02320	M85800	HFBC188
302	EST02321	M85801	HFBC189
303	EST02322	M85802	HFBC190
304	EST02323	M85803	HFBC191
305	EST02324	M85804	HFBC192
306	EST02325	M85805	HFBC193
307	EST02326	M85806	HFBC194
308	EST02327	M85807	HFBC196
309	EST02328	M85808	HFBC199
310	EST02329	M85809	HFBC202
311	EST02330	M85810	HFBC205
312	EST02331	M85811	HFBC206
313	EST02332	M85812	HFBC207
314	EST02333	M85813	HFBC208
315	EST02334	M85814	HFBC209
316	EST02335	M85815	HFBC230
317	EST02336	M85816	HFBC231
318	EST02337	M85817	HFBC232
319	EST02338	M85818	HFBC233
320	EST02339	M85819	HFBC234
321	EST02340	M85820	HFBC235
322	EST02341	M85821	HFBC236
323	EST02342	M85822	HFBC237
324	EST02343	M85823	HFBC238

SEQ ID	EST#	CS#	Clone
197	EST02222	M85704	HFBC130
198	EST02223	M85705	HFBC131
199	EST02224	M85706	HFBC132
200	EST02225	M85707	HFBC134
201	EST02226	M85709	HFBC137
202	EST02227	M85710	HFBC138
203	EST02228	M85711	HFBC139
204	EST02229	M85712	HFBC141
205	EST02230	M85713	HFBC142
206	EST02231	M85714	HFBC143
207	EST02232	M85715	HFBC144
208	EST02233	M85716	HFBC145
209	EST02234	M85717	HFBC146
210	EST02235	M85718	HFBC148
211	EST02236	M85719	HFBC149
212	EST02237	M85720	HFBC150
213	EST02238	M85721	HFBC153
214	EST02239	M85722	HFBC154
215	EST02240	M85723	HFBC155
216	EST02241	M85724	HFBC156
217	EST02242	M85725	HFBC161
218	EST02243	M85726	HFBC164
219	EST02244	M85727	HFBC167
220	EST02245	M85728	HFBC170
221	EST02246	M85729	HFBC172
222	EST02247	M85730	HFBC173
223	EST02248	M85731	HFBC174
224	EST02249	M85732	HFBC175
225	EST02250	M85733	HFBC176
226	EST02251	M85734	HFBC177
227	EST02252	M85735	HFBC178
228	EST02253	M85736	HFBC179
229	EST02254	M85737	HFBC180
230	EST02255	M85738	HFBC181
231	EST02256	M85739	HFBC182
232	EST02257	M85740	HFBC183
233	EST02258	M85741	HFBC184
234	EST02259	M85742	HFBC185
235	EST02260	M85743	HFBC186
236	EST02261	M85744	HFBC187
237	EST02262	M85745	HFBC188
238	EST02263	M85746	HFBC189
239	EST02264	M85747	HFBC190
240	EST02265	M85748	HFBC191
241	EST02266	M85749	HFBC193
242	EST02267	M85750	HFBC194
243	EST02268	M85751	HFBC195
244	EST02269	M85752	HFBC196
245	EST02270	M85753	HFBC197
246	EST02271	M85754	HFBC198
247	EST02272	M85755	HFBC199
248	EST02273	M85756	HFBC200
249	EST02274	M85757	HFBC201
250	EST02275	M85758	HFBC202
251	EST02276	M85759	HFBC203
252	EST02277	M85760	HFBC204
253	EST02278	M85761	HFBC205
254	EST02279	M85762	HFBC206
255	EST02280	M85763	HFBC207

SEQ ID	EST#	CS#	Clone
131	EST02151	M85634	HFBC114
132	EST02152	M85635	HFBC118
133	EST02153	M85636	HFBC120
134	EST02154	M85637	HFBC122
135	EST02155	M85638	HFBC123
136	EST02156	M85639	HFBC124
137	EST02157	M85640	HFBC125
138	EST02158	M85641	HFBC126
139	EST02159	M85642	HFBC127
140	EST02160	M85643	HFBC128
141	EST02161	M85644	HFBC129
142	EST02162	M85645	HFBC130
143	EST02163	M85646	HFBC131
144	EST02164	M85647	HFBC132
145	EST02165	M85648	HFBC133
146	EST02166	M85649	HFBC134
147	EST02167	M85650	HFBC135
148	EST02168	M85651	HFBC136
149	EST02169	M85652	HFBC137
150	EST02170	M85653	HFBC138
151	EST02171	M85654	HFBC139
152	EST02172	M85655	HFBC140
153	EST02173	M85656	HFBC141
154	EST02174	M85657	HFBC142
155	EST02175	M85658	HFBC143
156	EST02176	M85659	HFBC144
157	EST02177	M85660	HFBC145
158	EST02178	M85661	HFBC146
159	EST02179	M85662	HFBC147
160	EST02180	M85663	HFBC148
161	EST02181	M85664	HFBC149
162	EST02182	M85665	HFBC150
163	EST02183	M85666	HFBC151
164	EST02184	M85667	HFBC152
165	EST02185	M85668	HFBC153
166	EST02186	M85669	HFBC154
167	EST02187	M85670	HFBC155
168	EST02188	M85671	HFBC156
169	EST02189	M85672	HFBC157
170	EST02190	M85673	HFBC158
171	EST02191	M85674	HFBC159
172	EST02192	M85675	HFBC160
173	EST02193	M85676	HFBC161
174	EST02194	M85677	HFBC162
175	EST02195	M85678	HFBC163
176	EST02196	M85679	HFBC164
177	EST02197	M85680	HFBC165
178	EST02198	M85681	HFBC166
179	EST02199	M85682	HFBC167
180	EST02200	M85683	HFBC168
181	EST02201	M85684	HFBC169
182	EST02202	M85685	HFBC170
183	EST02203	M85686	HFBC171
184	EST02204	M85687	HFBC172
185	EST02205	M85688	HFBC173
186	EST02206	M85689	HFBC174
187	EST02207	M85690	HFBC175
188	EST02208	M85691	HFBC176
189	EST02209	M85692	HFBC177
190	EST02210	M85693	HFBC178
191	EST02211	M85694	HFBC179
192	EST02212	M85695	HFBC180
193	EST02213	M85696	HFBC181
194	EST02214	M85697	HFBC182
195	EST02215	M85698	HFBC183
196	EST02216	M85699	HFBC184
197	EST02217	M85700	HFBC185
198	EST02218	M85701	HFBC186
199	EST02219	M85702	HFBC187
200	EST02220	M85703	HFBC188

SUBSTITUTE SHEET

SEQ ID	EST#	GB#	Clone	SEQ ID	EST#	GB#	Clone	SEQ ID	EST#	GB#	Clone
1314	EST02344	M85922	HFBC038	1446	EST02482	M85958	HFBC057	1446	EST02482	M85958	HFBC057
1315	EST02345	M85923	HFBC039	1447	EST02483	M85959	HFBC058	1447	EST02483	M85959	HFBC058
1316	EST02346	M85924	HFBC040	1448	EST02484	M85960	HFBC059	1448	EST02484	M85960	HFBC059
1317	EST02347	M85925	HFBC041	1449	EST02485	M85961	HFBC060	1449	EST02485	M85961	HFBC060
1318	EST02348	M85926	HFBC042	1450	EST02486	M85962	HFBC061	1450	EST02486	M85962	HFBC061
1319	EST02349	M85927	HFBC043	1451	EST02487	M85963	HFBC062	1451	EST02487	M85963	HFBC062
1320	EST02350	M85928	HFBC044	1452	EST02488	M85964	HFBC063	1452	EST02488	M85964	HFBC063
1321	EST02351	M85929	HFBC045	1453	EST02489	M85965	HFBC064	1453	EST02489	M85965	HFBC064
1322	EST02352	M85930	HFBC046	1454	EST02490	M85966	HFBC065	1454	EST02490	M85966	HFBC065
1323	EST02353	M85931	HFBC047	1455	EST02491	M85967	HFBC066	1455	EST02491	M85967	HFBC066
1324	EST02354	M85932	HFBC048	1456	EST02492	M85968	HFBC067	1456	EST02492	M85968	HFBC067
1325	EST02355	M85933	HFBC049	1457	EST02493	M85969	HFBC068	1457	EST02493	M85969	HFBC068
1326	EST02356	M85934	HFBC050	1458	EST02494	M85970	HFBC069	1458	EST02494	M85970	HFBC069
1327	EST02357	M85935	HFBC051	1459	EST02495	M85971	HFBC070	1459	EST02495	M85971	HFBC070
1328	EST02358	M85936	HFBC052	1460	EST02496	M85972	HFBC071	1460	EST02496	M85972	HFBC071
1329	EST02359	M85937	HFBC053	1461	EST02497	M85973	HFBC072	1461	EST02497	M85973	HFBC072
1330	EST02360	M85938	HFBC054	1462	EST02498	M85974	HFBC073	1462	EST02498	M85974	HFBC073
1331	EST02361	M85939	HFBC055	1463	EST02499	M85975	HFBC074	1463	EST02499	M85975	HFBC074
1332	EST02362	M85940	HFBC056	1464	EST02500	M85976	HFBC075	1464	EST02500	M85976	HFBC075
1333	EST02363	M85941	HFBC057	1465	EST02501	M85977	HFBC076	1465	EST02501	M85977	HFBC076
1334	EST02364	M85942	HFBC058	1466	EST02502	M85978	HFBC077	1466	EST02502	M85978	HFBC077
1335	EST02365	M85943	HFBC059	1467	EST02503	M85979	HFBC078	1467	EST02503	M85979	HFBC078
1336	EST02366	M85944	HFBC060	1468	EST02504	M85980	HFBC079	1468	EST02504	M85980	HFBC079
1337	EST02367	M85945	HFBC061	1469	EST02505	M85981	HFBC080	1469	EST02505	M85981	HFBC080
1338	EST02368	M85946	HFBC062	1470	EST02506	M85982	HFBC081	1470	EST02506	M85982	HFBC081
1339	EST02369	M85947	HFBC063	1471	EST02507	M85983	HFBC082	1471	EST02507	M85983	HFBC082
1340	EST02370	M85948	HFBC064	1472	EST02508	M85984	HFBC083	1472	EST02508	M85984	HFBC083
1341	EST02371	M85949	HFBC065	1473	EST02509	M85985	HFBC084	1473	EST02509	M85985	HFBC084
1342	EST02372	M85950	HFBC066	1474	EST02510	M85986	HFBC085	1474	EST02510	M85986	HFBC085
1343	EST02373	M85951	HFBC067	1475	EST02511	M85987	HFBC086	1475	EST02511	M85987	HFBC086
1344	EST02374	M85952	HFBC068	1476	EST02512	M85988	HFBC087	1476	EST02512	M85988	HFBC087
1345	EST02375	M85953	HFBC069	1477	EST02513	M85989	HFBC088	1477	EST02513	M85989	HFBC088
1346	EST02376	M85954	HFBC070	1478	EST02514	M85990	HFBC089	1478	EST02514	M85990	HFBC089
1347	EST02377	M85955	HFBC071	1479	EST02515	M85991	HFBC090	1479	EST02515	M85991	HFBC090
1348	EST02378	M85956	HFBC072	1480	EST02516	M85992	HFBC091	1480	EST02516	M85992	HFBC091
1349	EST02379	M85957	HFBC073	1481	EST02517	M85993	HFBC092	1481	EST02517	M85993	HFBC092
1350	EST02380	M85958	HFBC074	1482	EST02518	M85994	HFBC093	1482	EST02518	M85994	HFBC093
1351	EST02381	M85959	HFBC075	1483	EST02519	M85995	HFBC094	1483	EST02519	M85995	HFBC094
1352	EST02382	M85960	HFBC076	1484	EST02520	M85996	HFBC095	1484	EST02520	M85996	HFBC095
1353	EST02383	M85961	HFBC077	1485	EST02521	M85997	HFBC096	1485	EST02521	M85997	HFBC096
1354	EST02384	M85962	HFBC078	1486	EST02522	M85998	HFBC097	1486	EST02522	M85998	HFBC097
1355	EST02385	M85963	HFBC079	1487	EST02523	M85999	HFBC098	1487	EST02523	M85999	HFBC098
1356	EST02386	M85964	HFBC080	1488	EST02524	M86000	HFBC099	1488	EST02524	M86000	HFBC099
1357	EST02387	M85965	HFBC081	1489	EST02525	M86001	HFBC100	1489	EST02525	M86001	HFBC100
1358	EST02388	M85966	HFBC082	1490	EST02526	M86002	HFBC101	1490	EST02526	M86002	HFBC101
1359	EST02389	M85967	HFBC083	1491	EST02527	M86003	HFBC102	1491	EST02527	M86003	HFBC102
1360	EST02390	M85968	HFBC084	1492	EST02528	M86004	HFBC103	1492	EST02528	M86004	HFBC103
1361	EST02391	M85969	HFBC085	1493	EST02529	M86005	HFBC104	1493	EST02529	M86005	HFBC104
1362	EST02392	M85970	HFBC086	1494	EST02530	M86006	HFBC105	1494	EST02530	M86006	HFBC105
1363	EST02393	M85971	HFBC087	1495	EST02531	M86007	HFBC106	1495	EST02531	M86007	HFBC106
1364	EST02394	M85972	HFBC088	1496	EST02532	M86008	HFBC107	1496	EST02532	M86008	HFBC107
1365	EST02395	M85973	HFBC089	1497	EST02533	M86009	HFBC108	1497	EST02533	M86009	HFBC108
1366	EST02396	M85974	HFBC090	1498	EST02534	M86010	HFBC109	1498	EST02534	M86010	HFBC109
1367	EST02397	M85975	HFBC091	1499	EST02535	M86011	HFBC110	1499	EST02535	M86011	HFBC110
1368	EST02398	M85976	HFBC092	1500	EST02536	M86012	HFBC111	1500	EST02536	M86012	HFBC111
1369	EST02399	M85977	HFBC093	1501	EST02537	M86013	HFBC112	1501	EST02537	M86013	HFBC112
1370	EST02400	M85978	HFBC094	1502	EST02538	M86014	HFBC113	1502	EST02538	M86014	HFBC113
1371	EST02401	M85979	HFBC095								
1372	EST02402	M85980	HFBC096								
1373	EST02403	M85981	HFBC097								
1374	EST02404	M85982	HFBC098								
1375	EST02405	M85983	HFBC099								
1376	EST02406	M85984	HFBC100								
1377	EST02407	M85985	HFBC101								
1378	EST02408	M85986	HFBC102								
1379	EST02409	M85987	HFBC103								

SUBSTITUTE SHEET

Seq ID	EST#	Gene	Seq ID	EST#	Gene	Seq ID	EST#	Gene	Seq ID	EST#	Gene
1503	EST02641	MB6016	1691	EST01577	MB7992	1504	EST02642	MB6017	1692	EST01578	MB7993
1505	EST02643	MB6018	1693	EST01579	MB7994	1506	EST02644	MB6019	1694	EST01580	MB7995
1507	EST02645	MB6020	1695	EST01581	MB7996	1508	EST02646	MB6021	1696	EST01582	MB7997
1509	EST02647	MB6022	1697	EST01583	MB7998	1510	EST02648	MB6023	1698	EST01584	MB7999
1511	EST02649	MB6024	1699	EST01585	MB7999	1512	EST02650	MB6025	1700	EST01586	MB8000
1513	EST02651	MB6026	1701	EST01587	MB8001	1514	EST02652	MB6027	1702	EST01588	MB8002
1515	EST02653	MB6028	1703	EST01589	MB8003	1516	EST02654	MB6029	1704	EST01590	MB8004
1517	EST02655	MB6029	1705	EST01591	MB8005	1518	EST02656	MB6030	1706	EST01592	MB8006
1519	EST02657	MB6031	1707	EST01593	MB8007	1520	EST02658	MB6032	1708	EST01594	MB8008
1521	EST02659	MB6033	1709	EST01595	MB8009	1522	EST02660	MB6034	1710	EST01596	MB8010
1523	EST02661	MB6035	1711	EST01597	MB8011	1524	EST02662	MB6036	1712	EST01598	MB8012
1525	EST02663	MB6037	1713	EST01599	MB8013	1526	EST02664	MB6038	1714	EST01600	MB8014
1527	EST02665	MB6039	1715	EST01601	MB8015	1528	EST02666	MB6040	1716	EST01602	MB8016
1529	EST02667	MB6041	1717	EST01603	MB8017	1530	EST02668	MB6042	1718	EST01604	MB8018
1531	EST02669	MB6043	1719	EST01605	MB8019	1532	EST02670	MB6044	1720	EST01606	MB8020
1533	EST02671	MB6045	1721	EST01607	MB8021	1534	EST02672	MB6046	1722	EST01608	MB8022
1535	EST02673	MB6047	1723	EST01609	MB8023	1536	EST02674	MB6048	1724	EST01610	MB8024
1537	EST02675	MB6049	1725	EST01611	MB8025	1538	EST02676	MB6050	1726	EST01612	MB8026
1539	EST02677	MB6051	1727	EST01613	MB8027	1540	EST02678	MB6052	1728	EST01614	MB8028
1541	EST02679	MB6053	1729	EST01615	MB8029	1542	EST02680	MB6054	1730	EST01616	MB8030
1543	EST02681	MB6055	1731	EST01617	MB8031	1544	EST02682	MB6056	1732	EST01618	MB8032
1545	EST02683	MB6057	1733	EST01619	MB8033	1546	EST02684	MB6058	1734	EST01620	MB8034
1547	EST02685	MB6059	1735	EST01621	MB8035	1548	EST02686	MB6060	1736	EST01622	MB8036
1549	EST02687	MB6061	1737	EST01623	MB8037	1550	EST02688	MB6062	1738	EST01624	MB8038
1551	EST02689	MB6063	1739	EST01625	MB8039	1552	EST02690	MB6064	1740	EST01626	MB8040
1553	EST02691	MB6065	1741	EST01627	MB8041	1554	EST02692	MB6066	1742	EST01628	MB8042
1555	EST02693	MB6067	1743	EST01629	MB8043	1556	EST02694	MB6068	1744	EST01630	MB8044
1557	EST02695	MB6069	1745	EST01631	MB8045	1558	EST02696	MB6070	1746	EST01632	MB8046
1559	EST02697	MB6071	1747	EST01633	MB8047	1560	EST02698	MB6072	1748	EST01634	MB8048
1561	EST02699	MB6073	1749	EST01635	MB8049	1562	EST02700	MB6074	1750	EST01636	MB8050
1563	EST02701	MB6075	1751	EST01637	MB8051	1564	EST02702	MB6076	1752	EST01638	MB8052
1565	EST02703	MB6077	1753	EST01639	MB8053	1566	EST02704	MB6078	1754	EST01640	MB8054
1567	EST02705	MB6079	1755	EST01641	MB8055	1568	EST02706	MB6080	1756	EST01642	MB8056
1569	EST02707	MB6081	1757	EST01643	MB8057	1570	EST02708	MB6082	1758	EST01644	MB8058
1571	EST02709	MB6083	1759	EST01645	MB8059	1572	EST02710	MB6084	1760	EST01646	MB8060
1573	EST02711	MB6085	1761	EST01647	MB8061	1574	EST02712	MB6086	1762	EST01648	MB8062
1575	EST02713	MB6087	1763	EST01649	MB8063	1576	EST02714	MB6088	1764	EST01650	MB8064
1577	EST02715	MB6089	1765	EST01651	MB8065	1578	EST02716	MB6090	1766	EST01652	MB8066
1579	EST02717	MB6091	1767	EST01653	MB8067	1580	EST02718	MB6092	1768	EST01654	MB8068
1581	EST02719	MB6093	1769	EST01655	MB8069	1582	EST02720	MB6094	1770	EST01656	MB8070
1583	EST02721	MB6095	1771	EST01657	MB8071	1584	EST02722	MB6096	1772	EST01658	MB8072
1585	EST02723	MB6097	1773	EST01659	MB8073	1586	EST02724	MB6098	1774	EST01660	MB8074
1587	EST02725	MB6099	1775	EST01661	MB8075	1588	EST02726	MB6100	1776	EST01662	MB8076
1589	EST02727	MB6101	1777	EST01663	MB8077	1590	EST02728	MB6102	1778	EST01664	MB8078
1591	EST02729	MB6103	1779	EST01665	MB8079	1592	EST02730	MB6104	1780	EST01666	MB8080
1593	EST02731	MB6105	1781	EST01667	MB8081	1594	EST02732	MB6106	1782	EST01668	MB8082
1595	EST02733	MB6107	1783	EST01669	MB8083	1596	EST02734	MB6108	1784	EST01670	MB8084
1597	EST02735	MB6109	1785	EST01671	MB8085	1598	EST02736	MB6110	1786	EST01672	MB8086
1599	EST02737	MB6111	1787	EST01673	MB8087	1600	EST02738	MB6112	1788	EST01674	MB8088
1601	EST02739	MB6113	1789	EST01675	MB8089	1602	EST02740	MB6114	1790	EST01676	MB8090
1603	EST02741	MB6115	1791	EST01677	MB8091	1604	EST02742	MB6116	1792	EST01678	MB8092
1605	EST02743	MB6117	1793	EST01679	MB8093	1606	EST02744	MB6118	1794	EST01680	MB8094
1607	EST02745	MB6119	1795	EST01681	MB8095	1608	EST02746	MB6120	1796	EST01682	MB8096
1609	EST02747	MB6121	1797	EST01683	MB8097	1610	EST02748	MB6122	1798	EST01684	MB8098
1611	EST02749	MB6123	1799	EST01685	MB8099	1612	EST02750	MB6124	1800	EST01686	MB8100
1613	EST02751	MB6125	1801	EST01687	MB8101	1614	EST02752	MB6126	1802	EST01688	MB8102
1615	EST02753	MB6127	1803	EST01689	MB8103	1616	EST02754	MB6128	1804	EST01690	MB8104
1617	EST02755	MB6129	1805	EST01691	MB8105	1618	EST02756	MB6130	1806	EST01692	MB8106
1619	EST02757	MB6131	1807	EST01693	MB8107	1620	EST02758	MB6132	1808	EST01694	MB8108
1621	EST02759	MB6133	1809	EST01695	MB8109	1622	EST02760	MB6134	1810	EST01696	MB8110
1623	EST02761	MB6135	1811	EST01697	MB8111	1624	EST02762	MB6136	1812	EST01698	MB8112
1625	EST02763	MB6137	1813	EST01699	MB8113	1626	EST02764	MB6138	1814	EST01700	MB8114
1627	EST02765	MB6139	1815	EST01701	MB8115	1628	EST02766	MB6140	1816	EST01702	MB8116
1629	EST02767	MB6141	1817	EST01703	MB8117	1630	EST02768	MB6142	1818	EST01704	MB8118
1631	EST02769	MB6143	1819	EST01705	MB8119	1632	EST02770	MB6144	1820	EST01706	MB8120
1633	EST02771	MB6145	1821	EST01707	MB8121	1634	EST02772	MB6146	1822	EST01708	MB8122
1635	EST02773	MB6147	1823	EST01709	MB8123	1636	EST02774	MB6148	1824	EST01710	MB8124
1637	EST02775	MB6149	1825	EST01711	MB8125	1638	EST02776	MB6150	1826	EST01712	MB8126
1639	EST02777	MB6151	1827	EST01713	MB8127	1640	EST02778	MB6152	1828	EST01714	MB8128
1641	EST02779	MB6153	1829	EST01715	MB8129	1642	EST02780	MB6154	1830	EST01716	MB8130
1643	EST02781	MB6155	1831	EST01717	MB8131	1644	EST02782	MB6156	1832	EST01718	MB8132
1645	EST02783	MB6157	1833	EST01719	MB8133	1646	EST02784	MB6158	1834	EST01720	MB8134
1647	EST02785	MB6159	1835	EST01721	MB8135	1648	EST02786	MB6160	1836	EST01722	MB8136
1649	EST02787	MB6161	1837	EST01723	MB8137	1650	EST02788	MB6162	1838	EST01724	MB8138
1651	EST02789	MB6163	1839	EST01725	MB8139	1652	EST02790	MB6164	1840	EST01726	MB8140
1653	EST02791	MB6165	1841	EST01727	MB8141	1654	EST02792	MB6166	1842	EST01728	MB8142
1655	EST02793	MB6167	1843	EST01729	MB8143	1656	EST02794	MB6168	1844	EST01730	MB8144
1657	EST02795	MB6169	1845	EST01731	MB8145	1658	EST02796	MB6170	1846	EST01732	MB8146
1659	EST02797	MB6171	1847	EST01733	MB8147	1660	EST02798	MB6172	1848	EST01734	MB8148
1661	EST02799	MB6173	1849	EST01735	MB8149	1662	EST02799	MB6174	1850	EST01736	MB8150
1663	EST02800	MB6175	1851	EST01737	MB8151	1664	EST02801	MB6176	1852	EST01738	MB8152
1665	EST02802	MB6177	1853	EST01739	MB8153	1666	EST02802	MB6178	1854	EST01740	MB8154
1667	EST02803	MB6179	1855	EST01741	MB8155	1668	EST02803	MB6179	1856	EST01742	MB8156
1669	EST02804	MB6180	1857	EST01743	MB8157	1670	EST02804	MB6180	1858	EST01744	MB8158
1671	EST02805	MB6181	1859	EST01745	MB8159	1672	EST02805	MB6181	1860	EST01746	MB8160
1673	EST02806	MB6182	1861	EST01747	MB8161	1674	EST02806	MB6182	1862	EST01748	MB8162
1675	EST02807	MB6183	1863	EST01749	MB8163	1676	EST02807	MB6183	1864	EST01750	MB8164
1677	EST02808	MB6184	1865	EST01751	MB8165	1678	EST02808	MB6184	1866	EST01752	MB8166
1679	EST02809	MB6185	1867	EST01753	MB8167	1680	EST02809	MB6185	1868	EST01754	MB8168
1681	EST02810	MB6186	1869	EST01755	MB8169	1682	EST02810	MB6186	1870	EST01756	MB8170
1683	EST02811	MB6187	1871	EST01757	MB8171	1684	EST02811	MB6187	1872	EST01758	MB8172
1685	EST02812	MB6188	1873	EST01759	MB8173	1686	EST02812	MB6188	1874	EST01760	MB8174
1687	EST02813	MB6189	1875	EST01761	MB8175	1688	EST02813	MB6189	1876	EST01762	MB8176
1689	EST02814	MB6190	1877	EST01763	MB8177	1690	EST02814	MB6190	1878	EST01764	MB8178
1691	EST02815	MB6191	1879	EST01765	MB8179	1692	EST02815	MB6191	1880	EST01766	MB8180
1693	EST02816	MB6192	1881	EST01767	MB8181	1694	EST02816	MB6192	1882	EST01768	MB8182
1695	EST02817	MB6193	1883	EST01769	MB						

SEQ. ID	EST#	GS#	Clone	SEQ. ID	EST#	GS#	Clone	SEQ. ID	EST#	GS#	Clone
1692	EST00847	W78699	HHCHC42	1824	EST01617	W78030	HHCHG04	1824	EST01617	W78030	HHCHG04
1693	EST00848	W78700	HHCHC43	1825	EST00955	W78807	HHCHG07	1825	EST00955	W78807	HHCHG07
1694	EST00849	W78701	HHCHC44	1826	EST00956	W78808	HHCHG08	1826	EST00956	W78808	HHCHG08
1695	EST00850	W78702	HHCHC45	1827	EST01618	W78031	HHCHG10	1827	EST01618	W78031	HHCHG10
1696	EST00851	W78703	HHCHC46	1828	EST00957	W78809	HHCHG11	1828	EST00957	W78809	HHCHG11
1697	EST00852	W78704	HHCHC47	1829	EST00958	W78810	HHCHG12	1829	EST00958	W78810	HHCHG12
1698	EST02685	W86154	HHCHC48	1830	EST00959	W78811	HHCHG13	1830	EST00959	W78811	HHCHG13
1699	EST02686	W86155	HHCHC49	1831	EST01619	W78032	HHCHG15	1831	EST01619	W78032	HHCHG15
1700	EST01579	W77994	HHCHC50	1832	EST00960	W78812	HHCHG16	1832	EST00960	W78812	HHCHG16
1701	EST00853	W78705	HHCHC51	1833	EST00961	W78813	HHCHG17	1833	EST00961	W78813	HHCHG17
1702	EST00854	W78706	HHCHC52	1834	EST00962	W78814	HHCHG18	1834	EST00962	W78814	HHCHG18
1703	EST00855	W77995	HHCHC53	1835	EST01620	W78033	HHCHG21	1835	EST01620	W78033	HHCHG21
1704	EST01580	W78707	HHCHC54	1836	EST00963	W78815	HHCHG22	1836	EST00963	W78815	HHCHG22
1705	EST00856	W78708	HHCHC55	1837	EST01621	W78034	HHCHG25	1837	EST01621	W78034	HHCHG25
1706	EST00857	W78709	HHCHC56	1838	EST00964	W78816	HHCHG27	1838	EST00964	W78816	HHCHG27
1707	EST01581	W77996	HHCHC57	1839	EST00965	W78817	HHCHG28	1839	EST00965	W78817	HHCHG28
1708	EST00858	W78710	HHCHC58	1840	EST00966	W78818	HHCHG30	1840	EST00966	W78818	HHCHG30
1709	EST00859	W78711	HHCHC59	1841	EST00967	W78819	HHCHG31	1841	EST00967	W78819	HHCHG31
1710	EST00860	W78712	HHCHC60	1842	EST00968	W78820	HHCHG33	1842	EST00968	W78820	HHCHG33
1711	EST00861	W78713	HHCHC61	1843	EST00969	W78821	HHCHG36	1843	EST00969	W78821	HHCHG36
1712	EST00862	W78714	HHCHC62	1844	EST00970	W78822	HHCHG38	1844	EST00970	W78822	HHCHG38
1713	EST00863	W78715	HHCHC63	1845	EST00971	W78823	HHCHG40	1845	EST00971	W78823	HHCHG40
1714	EST00864	W78716	HHCHC64	1846	EST00972	W78824	HHCHG44	1846	EST00972	W78824	HHCHG44
1715	EST01583	W77998	HHCHC65	1847	EST00973	W78825	HHCHG45	1847	EST00973	W78825	HHCHG45
1716	EST00865	W78717	HHCHC66	1848	EST00974	W78826	HHCHG51	1848	EST00974	W78826	HHCHG51
1717	EST00866	W78718	HHCHC67	1849	EST00975	W78827	HHCHG53	1849	EST00975	W78827	HHCHG53
1718	EST00867	W78719	HHCHC68	1850	EST01624	W78037	HHCHG63	1850	EST01624	W78037	HHCHG63
1719	EST00868	W78720	HHCHC69	1851	EST00976	W78828	HHCHG71	1851	EST00976	W78828	HHCHG71
1720	EST00869	W78721	HHCHC70	1852	EST01625	W78038	HHCHG75	1852	EST01625	W78038	HHCHG75
1721	EST00870	W78722	HHCHC71	1853	EST00977	W78829	HHCHG75	1853	EST00977	W78829	HHCHG75
1722	EST00871	W78723	HHCHC72	1854	EST00978	W78830	HHCHG81	1854	EST00978	W78830	HHCHG81
1723	EST00872	W78724	HHCHC73	1855	EST01627	W78040	HHCHG83	1855	EST01627	W78040	HHCHG83
1724	EST00873	W78725	HHCHC74	1856	EST00980	W78832	HHCHG87	1856	EST00980	W78832	HHCHG87
1725	EST00874	W78726	HHCHC75	1857	EST00981	W78833	HHCHG88	1857	EST00981	W78833	HHCHG88
1726	EST01588	W78003	HHCHD29	1858	EST00982	W78834	HHCHG89	1858	EST00982	W78834	HHCHG89
1727	EST00875	W78727	HHCHD30	1859	EST00983	W78835	HHCHG91	1859	EST00983	W78835	HHCHG91
1728	EST00876	W78728	HHCHD31	1860	EST00984	W78836	HHCHG92	1860	EST00984	W78836	HHCHG92
1729	EST00877	W78729	HHCHD32	1861	EST00985	W78837	HHCHG94	1861	EST00985	W78837	HHCHG94
1730	EST00878	W78730	HHCHD33	1862	EST00986	W78838	HHCHG95	1862	EST00986	W78838	HHCHG95
1731	EST01590	W78005	HHCHD36	1863	EST00987	W78839	HHCHG96	1863	EST00987	W78839	HHCHG96
1732	EST01591	W78006	HHCHD37	1864	EST00988	W78840	HHCHG98	1864	EST00988	W78840	HHCHG98
1733	EST00880	W78731	HHCHD38	1865	EST00989	W78841	HHCHG98	1865	EST00989	W78841	HHCHG98
1734	EST00881	W78732	HHCHD39	1866	EST00990	W78842	HHCHG14	1866	EST00990	W78842	HHCHG14
1735	EST00882	W78733	HHCHD40	1867	EST00991	W78843	HHCHG17	1867	EST00991	W78843	HHCHG17
1736	EST01592	W78007	HHCHD43	1868	EST00992	W78844	HHCHG17	1868	EST00992	W78844	HHCHG17
1737	EST00883	W78734	HHCHD44	1869	EST00993	W78845	HHCHG18	1869	EST00993	W78845	HHCHG18
1738	EST00884	W78735	HHCHD45	1870	EST00994	W78846	HHCHG18	1870	EST00994	W78846	HHCHG18
1739	EST02687	W86156	HHCHD76	1871	EST00995	W78847	HHCHG22	1871	EST00995	W78847	HHCHG22
1740	EST00885	W78736	HHCHD77	1872	EST01630	W78043	HHCHG25	1872	EST01630	W78043	HHCHG25
1741	EST00886	W78737	HHCHD78	1873	EST00996	W78848	HHCHG27	1873	EST00996	W78848	HHCHG27
1742	EST00887	W78738	HHCHD79	1874	EST01631	W78044	HHCHG29	1874	EST01631	W78044	HHCHG29
1743	EST00888	W78739	HHCHD80	1875	EST00997	W78849	HHCHG31	1875	EST00997	W78849	HHCHG31
1744	EST00889	W78740	HHCHD81	1876	EST00998	W78850	HHCHG33	1876	EST00998	W78850	HHCHG33
1745	EST00890	W78741	HHCHD82	1877	EST00999	W78851	HHCHG34	1877	EST00999	W78851	HHCHG34
1746	EST00891	W78742	HHCHD83	1878	EST01633	W78046	HHCHG42	1878	EST01633	W78046	HHCHG42
1747	EST00892	W78743	HHCHD84	1879	EST01634	W78047	HHCHG42	1879	EST01634	W78047	HHCHG42
1748	EST00893	W78744	HHCHD85								
1749	EST01593	W78008	HHCHD87								
1750	EST00894	W78745	HHCHD88								
1751	EST00895	W78746	HHCHD90								
1752	EST00896	W78747	HHCHD93								
1753	EST00897	W78748	HHCHD94								
1754	EST00898	W78749	HHCHD96								
1755	EST00899	W78750	HHCHD97								
1756	EST00900	W78751	HHCHD98								
1757	EST01594	W78009	HHCHD99								

SUBSTITUTE SHEET

SEQ ID	EST#	Clone	Gene	EST#	Clone	Gene	SEQ ID
1881	EST010000	HICP148	M78882	EST01052	HICP005	M78904	2013
1882	EST010001	HICP149	M78883	EST01053	HICP006	M78905	2014
1883	EST010002	HICP150	M78884	EST01054	HICP007	M78906	2015
1884	EST010003	HICP151	M78885	EST01055	HICP008	M78907	2016
1885	EST010004	HICP152	M78886	EST01056	HICP009	M78908	2017
1886	EST010005	HICP153	M78887	EST01057	HICP010	M78909	2018
1887	EST010006	HICP154	M78888	EST01058	HICP011	M78910	2019
1888	EST010007	HICP155	M78889	EST01059	HICP012	M78911	2020
1889	EST010008	HICP156	M78890	EST01060	HICP013	M78912	2021
1890	EST010009	HICP157	M78891	EST01061	HICP014	M78913	2022
1891	EST010010	HICP158	M78892	EST01062	HICP015	M78914	2023
1892	EST010011	HICP159	M78893	EST01063	HICP016	M78915	2024
1893	EST010012	HICP160	M78894	EST01064	HICP017	M78916	2025
1894	EST010013	HICP161	M78895	EST01065	HICP018	M78917	2026
1895	EST010014	HICP162	M78896	EST01066	HICP019	M78918	2027
1896	EST010015	HICP163	M78897	EST01067	HICP020	M78919	2028
1897	EST010016	HICP164	M78898	EST01068	HICP021	M78920	2029
1898	EST010017	HICP165	M78899	EST01069	HICP022	M78921	2030
1899	EST010018	HICP166	M78900	EST01070	HICP023	M78922	2031
1900	EST010019	HICP167	M78901	EST01071	HICP024	M78923	2032
1901	EST010020	HICP168	M78902	EST01072	HICP025	M78924	2033
1902	EST010021	HICP169	M78903	EST01073	HICP026	M78925	2034
1903	EST010022	HICP170	M78904	EST01074	HICP027	M78926	2035
1904	EST010023	HICP171	M78905	EST01075	HICP028	M78927	2036
1905	EST010024	HICP172	M78906	EST01076	HICP029	M78928	2037
1906	EST010025	HICP173	M78907	EST01077	HICP030	M78929	2038
1907	EST010026	HICP174	M78908	EST01078	HICP031	M78930	2039
1908	EST010027	HICP175	M78909	EST01079	HICP032	M78931	2040
1909	EST010028	HICP176	M78910	EST01080	HICP033	M78932	2041
1910	EST010029	HICP177	M78911	EST01081	HICP034	M78933	2042
1911	EST010030	HICP178	M78912	EST01082	HICP035	M78934	2043
1912	EST010031	HICP179	M78913	EST01083	HICP036	M78935	2044
1913	EST010032	HICP180	M78914	EST01084	HICP037	M78936	2045
1914	EST010033	HICP181	M78915	EST01085	HICP038	M78937	2046
1915	EST010034	HICP182	M78916	EST01086	HICP039	M78938	2047
1916	EST010035	HICP183	M78917	EST01087	HICP040	M78939	2048
1917	EST010036	HICP184	M78918	EST01088	HICP041	M78940	2049
1918	EST010037	HICP185	M78919	EST01089	HICP042	M78941	2050
1919	EST010038	HICP186	M78920	EST01090	HICP043	M78942	2051
1920	EST010039	HICP187	M78921	EST01091	HICP044	M78943	2052
1921	EST010040	HICP188	M78922	EST01092	HICP045	M78944	2053
1922	EST010041	HICP189	M78923	EST01093	HICP046	M78945	2054
1923	EST010042	HICP190	M78924	EST01094	HICP047	M78946	2055
1924	EST010043	HICP191	M78925	EST01095	HICP048	M78947	2056
1925	EST010044	HICP192	M78926	EST01096	HICP049	M78948	2057
1926	EST010045	HICP193	M78927	EST01097	HICP050	M78949	2058
1927	EST010046	HICP194	M78928	EST01098	HICP051	M78950	2059
1928	EST010047	HICP195	M78929	EST01099	HICP052	M78951	2060
1929	EST010048	HICP196	M78930	EST01100	HICP053	M78952	2061
1930	EST010049	HICP197	M78931	EST01101	HICP054	M78953	2062
1931	EST010050	HICP198	M78932	EST01102	HICP055	M78954	2063
1932	EST010051	HICP199	M78933	EST01103	HICP056	M78955	2064
1933	EST010052	HICP200	M78934	EST01104	HICP057	M78956	2065
1934	EST010053	HICP201	M78935	EST01105	HICP058	M78957	2066
1935	EST010054	HICP202	M78936	EST01106	HICP059	M78958	2067
1936	EST010055	HICP203	M78937	EST01107	HICP060	M78959	2068
1937	EST010056	HICP204	M78938	EST01108	HICP061	M78960	2069
1938	EST010057	HICP205	M78939	EST01109	HICP062	M78961	2070
1939	EST010058	HICP206	M78940	EST01110	HICP063	M78962	2071
1940	EST010059	HICP207	M78941	EST01111	HICP064	M78963	2072
1941	EST010060	HICP208	M78942	EST01112	HICP065	M78964	2073
1942	EST010061	HICP209	M78943	EST01113	HICP066	M78965	2074
1943	EST010062	HICP210	M78944	EST01114	HICP067	M78966	2075
1944	EST010063	HICP211	M78945	EST01115	HICP068	M78967	2076
1945	EST010064	HICP212	M78946	EST01116	HICP069	M78968	2077
				EST01117	HICP070	M78969	2078
				EST01118	HICP071	M78970	2079
				EST01119	HICP072	M78971	2080
				EST01120	HICP073	M78972	2081
				EST01121	HICP074	M78973	2082
				EST01122	HICP075	M78974	2083
				EST01123	HICP076	M78975	2084
				EST01124	HICP077	M78976	2085
				EST01125	HICP078	M78977	2086
				EST01126	HICP079	M78978	2087
				EST01127	HICP080	M78979	2088
				EST01128	HICP081	M78980	2089
				EST01129	HICP082	M78981	2090
				EST01130	HICP083	M78982	2091
				EST01131	HICP084	M78983	2092
				EST01132	HICP085	M78984	2093
				EST01133	HICP086	M78985	2094
				EST01134	HICP087	M78986	2095
				EST01135	HICP088	M78987	2096
				EST01136	HICP089	M78988	2097
				EST01137	HICP090	M78989	2098
				EST01138	HICP091	M78990	2099
				EST01139	HICP092	M78991	2100
				EST01140	HICP093	M78992	2101
				EST01141	HICP094	M78993	2102
				EST01142	HICP095	M78994	2103
				EST01143	HICP096	M78995	2104
				EST01144	HICP097	M78996	2105
				EST01145	HICP098	M78997	2106
				EST01146	HICP099	M78998	2107
				EST01147	HICP100	M78999	2108
				EST01148	HICP101	M79000	2109
				EST01149	HICP102	M79001	2110
				EST01150	HICP103	M79002	2111
					HICP104	M79003	2112
					HICP105	M79004	2113
					HICP106	M79005	2114
					HICP107	M79006	2115
					HICP108	M79007	2116
					HICP109	M79008	2117
					HICP110	M79009	2118
					HICP111	M79010	2119
					HICP112	M79011	2120
					HICP113	M79012	2121
					HICP114	M79013	2122
					HICP115	M79014	2123
					HICP116	M79015	2124
					HICP117	M79016	2125
					HICP118	M79017	2126
					HICP119	M79018	2127
					HICP120	M79019	2128
					HICP121	M79020	2129
					HICP122	M79021	2130
					HICP123	M79022	2131
					HICP124	M79023	2132
					HICP125	M79024	2133
					HICP126	M79025	2134
					HICP127	M79026	2135
					HICP128	M79027	2136
					HICP129	M79028	2137
					HICP130	M79029	2138
					HICP131	M79030	2139
					HICP132	M79031	2140
					HICP133	M79032	2141
					HICP134	M79033	2142
					HICP135	M79034	2143
					HICP136	M79035	2144
					HICP137	M79036	2145
					HICP138	M79037	2146
					HICP139	M79038	2147
					HICP140	M79039	2148
					HICP141	M79040	2149
					HICP142	M79041	2150
					HICP143	M79042	2151
					HICP144	M79043	2152
					HICP145	M79044	2153
					HICP146	M79045	2154
					HICP147	M79046	2155
					HICP148	M79047	2156
					HICP149	M79048	2157
					HICP150	M79049	2158
					HICP151	M79050	2159
					HICP152	M79051	2160
					HICP153	M79052	2161
					HICP154	M79053	2162
					HICP155	M79054	2163
					HICP156	M79055	2164
					HICP157	M79056	2165
					HICP158	M79057	2166
					HICP159	M79058	2167
					HICP160	M79059	2168
					HICP161	M79060	2169
					HICP162	M79061	2170
					HICP163	M79062	2171
					HICP164	M79063	2172
					HICP165	M79064	2173
					HICP166	M79065	2174
					HICP167	M79066	2175
					HICP168	M79067	2176
					HICP169	M79068	2177
					HICP170	M79069	2178
					HICP171	M79070	2179
					HICP172	M79071	2180
					HICP173	M79072	2181
					HICP174	M79073	2182
					HICP175	M79074	2183
					HICP176	M79075	2184
					HICP177	M79076	2185
					HICP178	M79077	2186
					HICP179	M79078	2187
					HICP180	M79079	2188
					HICP181	M79080	2189
					HICP182	M79081	2190
					HICP183	M79082	2191
			</				

Seq. ID	EST#	GB#	Clone	Seq. ID	EST#	GB#	Clone	Seq. ID	EST#	GB#	Clone	Seq. ID	EST#	GB#	Clone
2070	EST011151	M79003	HHCPH24	2202	EST01732	M79119	HHCPH163	2203	EST01264	M79120	HHCPH163	2204	EST01265	M79121	HHCPH163
2071	EST011152	M79004	HHCPH33	2205	EST01266	M79122	HHCPH163	2206	EST01267	M79123	HHCPH163	2207	EST01268	M79124	HHCPH163
2072	EST011153	M79005	HHCPH33	2208	EST01269	M79125	HHCPH163	2209	EST01270	M79126	HHCPH163	2210	EST01271	M79127	HHCPH163
2073	EST011154	M79006	HHCPH33	2211	EST01272	M79128	HHCPH163	2212	EST01273	M79129	HHCPH163	2213	EST01274	M79130	HHCPH163
2074	EST011155	M79007	HHCPH33	2214	EST01275	M79131	HHCPH163	2215	EST01276	M79132	HHCPH163	2216	EST01277	M79133	HHCPH163
2075	EST011156	M79008	HHCPH33	2217	EST01278	M79134	HHCPH163	2218	EST01279	M79135	HHCPH163	2219	EST01280	M79136	HHCPH163
2076	EST011157	M79009	HHCPH33	2220	EST01281	M79137	HHCPH163	2221	EST01282	M79138	HHCPH163	2222	EST01283	M79139	HHCPH163
2077	EST011158	M79010	HHCPH33	2223	EST01284	M79140	HHCPH163	2224	EST01285	M79141	HHCPH163	2225	EST01286	M79142	HHCPH163
2078	EST011159	M79011	HHCPH33	2226	EST01287	M79143	HHCPH163	2227	EST01288	M79144	HHCPH163	2228	EST01289	M79145	HHCPH163
2079	EST011160	M79012	HHCPH33	2229	EST01290	M79146	HHCPH163	2230	EST01291	M79147	HHCPH163	2231	EST01292	M79148	HHCPH163
2080	EST011161	M79013	HHCPH33	2232	EST01293	M79149	HHCPH163	2233	EST01294	M79150	HHCPH163	2234	EST01295	M79151	HHCPH163
2081	EST011162	M79014	HHCPH33	2235	EST01296	M79152	HHCPH163	2236	EST01297	M79153	HHCPH163	2237	EST01298	M79154	HHCPH163
2082	EST011163	M79015	HHCPH33	2238	EST01299	M79155	HHCPH163	2239	EST01300	M79156	HHCPH163	2240	EST01301	M79157	HHCPH163
2083	EST011164	M79016	HHCPH33	2241	EST01302	M79158	HHCPH163	2242	EST01303	M79159	HHCPH163	2243	EST01304	M79160	HHCPH163
2084	EST011165	M79017	HHCPH33	2244	EST01305	M79161	HHCPH163	2245	EST01306	M79162	HHCPH163	2246	EST01307	M79163	HHCPH163
2085	EST011166	M79018	HHCPH33	2247	EST01308	M79164	HHCPH163	2248	EST01309	M79165	HHCPH163	2249	EST01310	M79166	HHCPH163
2086	EST011167	M79019	HHCPH33	2250	EST01311	M79167	HHCPH163	2251	EST01312	M79168	HHCPH163	2252	EST01313	M79169	HHCPH163
2087	EST011168	M79020	HHCPH33	2253	EST01314	M79170	HHCPH163	2254	EST01315	M79171	HHCPH163	2255	EST01316	M79172	HHCPH163
2088	EST011169	M79021	HHCPH33	2256	EST01317	M79173	HHCPH163	2257	EST01318	M79174	HHCPH163	2258	EST01319	M79175	HHCPH163
2089	EST011170	M79022	HHCPH33	2259	EST01320	M79176	HHCPH163	2260	EST01321	M79177	HHCPH163	2261	EST01322	M79178	HHCPH163
2090	EST011171	M79023	HHCPH33	2262	EST01323	M79179	HHCPH163	2263	EST01324	M79180	HHCPH163	2264	EST01325	M79181	HHCPH163
2091	EST011172	M79024	HHCPH33	2265	EST01326	M79182	HHCPH163	2266	EST01327	M79183	HHCPH163	2267	EST01328	M79184	HHCPH163
2092	EST011173	M79025	HHCPH33	2268	EST01329	M79185	HHCPH163	2269	EST01330	M79186	HHCPH163	2270	EST01331	M79187	HHCPH163
2093	EST011174	M79026	HHCPH33	2271	EST01332	M79188	HHCPH163	2272	EST01333	M79189	HHCPH163	2273	EST01334	M79190	HHCPH163
2094	EST011175	M79027	HHCPH33	2274	EST01335	M79191	HHCPH163	2275	EST01336	M79192	HHCPH163	2276	EST01337	M79193	HHCPH163
2095	EST011176	M79028	HHCPH33	2277	EST01338	M79194	HHCPH163	2278	EST01339	M79195	HHCPH163	2279	EST01340	M79196	HHCPH163
2096	EST011177	M79029	HHCPH33	2280	EST01341	M79197	HHCPH163	2281	EST01342	M79198	HHCPH163	2282	EST01343	M79199	HHCPH163
2097	EST011178	M79030	HHCPH33	2283	EST01344	M79200	HHCPH163	2284	EST01345	M79201	HHCPH163	2285	EST01346	M79202	HHCPH163
2098	EST011179	M79031	HHCPH33	2286	EST01347	M79203	HHCPH163	2287	EST01348	M79204	HHCPH163	2288	EST01349	M79205	HHCPH163
2099	EST011180	M79032	HHCPH33	2289	EST01350	M79206	HHCPH163	2290	EST01351	M79207	HHCPH163	2291	EST01352	M79208	HHCPH163
2100	EST011181	M79033	HHCPH33	2292	EST01353	M79209	HHCPH163	2293	EST01354	M79210	HHCPH163	2294	EST01355	M79211	HHCPH163
2101	EST011182	M79034	HHCPH33	2295	EST01356	M79212	HHCPH163	2296	EST01357	M79213	HHCPH163	2297	EST01358	M79214	HHCPH163
2102	EST011183	M79035	HHCPH33	2298	EST01359	M79215	HHCPH163	2299	EST01360	M79216	HHCPH163	2300	EST01361	M79217	HHCPH163
2103	EST011184	M79036	HHCPH33	2301	EST01362	M79218	HHCPH163	2302	EST01363	M79219	HHCPH163	2303	EST01364	M79220	HHCPH163
2104	EST011185	M79037	HHCPH33	2304	EST01365	M79221	HHCPH163	2305	EST01366	M79222	HHCPH163	2306	EST01367	M79223	HHCPH163
2105	EST011186	M79038	HHCPH33	2307	EST01368	M79224	HHCPH163	2308	EST01369	M79225	HHCPH163	2309	EST01370	M79226	HHCPH163
2106	EST011187	M79039	HHCPH33	2310	EST01371	M79227	HHCPH163	2311	EST01372	M79228	HHCPH163	2312	EST01373	M79229	HHCPH163
2107	EST011188	M79040	HHCPH33	2313	EST01374	M79230	HHCPH163	2314	EST01375	M79231	HHCPH163	2315	EST01376	M79232	HHCPH163
2108	EST011189	M79041	HHCPH33	2316	EST01377	M79233	HHCPH163	2317	EST01378	M79234	HHCPH163	2318	EST01379	M79235	HHCPH163
2109	EST011190	M79042	HHCPH33	2319	EST01380	M79236	HHCPH163	2320	EST01381	M79237	HHCPH163	2321	EST01382	M79238	HHCPH163
2110	EST011191	M79043	HHCPH33	2322	EST01383	M79239	HHCPH163	2323	EST01384	M79240	HHCPH163	2324	EST01385	M79241	HHCPH163
2111	EST011192	M79044	HHCPH33	2325	EST01386	M79242	HHCPH163	2326	EST01387	M79243	HHCPH163	2327	EST01388	M79244	HHCPH163
2112	EST011193	M79045	HHCPH33	2328	EST01389	M79245	HHCPH163	2329	EST01390	M79246	HHCPH163	2330	EST01391	M79247	HHCPH163
2113	EST011194	M79046	HHCPH33	2331	EST01392	M79248	HHCPH163	2332	EST01393	M79249	HHCPH163	2333	EST01394	M79250	HHCPH163
2114	EST011195	M79047	HHCPH33	2334	EST01395	M79251	HHCPH163	2335	EST01396	M79252	HHCPH163	2336	EST01397	M79253	HHCPH163
2115	EST011196	M79048	HHCPH33	2337	EST01398	M79254	HHCPH163	2338	EST01399	M79255	HHCPH163	2339	EST01400	M79256	HHCPH163
2116	EST011197	M79049	HHCPH33	2340	EST01401	M79257	HHCPH163	2341	EST01402	M79258	HHCPH163	2342	EST01403	M79259	HHCPH163
2117	EST011198	M79050	HHCPH33	2343	EST01404	M79260	HHCPH163	2344	EST01405	M79261	HHCPH163	2345	EST01406	M79262	HHCPH163
2118	EST011199	M79051	HHCPH33	2346	EST01407	M79263	HHCPH163	2347	EST01408	M79264	HHCPH163	2348	EST01409	M79265	HHCPH163
2119	EST011200	M79052	HHCPH33	2349	EST01410	M79266	HHCPH163	2350	EST01411	M79267	HHCPH163	2351	EST01412	M79268	HHCPH163
2120	EST011201	M79053	HHCPH33	2352	EST01413	M79269	HHCPH163	2353	EST01414	M79270	HHCPH163	2354	EST01415	M79271	HHCPH163
2121	EST011202	M79054	HHCPH33	2355	EST01416	M79272	HHCPH163	2356	EST01417	M79273	HHCPH163	2357	EST01418	M79274	HHCPH163
2122	EST011203	M79055	HHCPH33	2358	EST01419	M79275	HHCPH163	2359	EST01420	M79276	HHCPH163	2360	EST01421	M79277	HHCPH163
2123	EST011204	M79056	HHCPH33	2361	EST01422	M79278	HHCPH163	2362	EST01423	M79279	HHCPH163	2363	EST01424	M79280	HHCPH163
2124	EST011205	M79057	HHCPH33	2364	EST01425	M79281	HHCPH163	2365	EST01426	M79282	HHCPH163	2366	EST01427	M79283	HHCPH163
2125	EST011206	M79058	HHCPH33	2367	EST01428	M79284	HHCPH163	2368	EST01429	M79285	HHCPH163	2369	EST01430	M79286	HHCPH163
2126	EST011207	M79059	HHCPH33	2370	EST01431	M79287	HHCPH163	2371	EST01432	M79288	HHCPH163	2372	EST01433	M79289	HHCPH163
2127	EST011208	M79060	HHCPH33	2373	EST01434	M79290	HHCPH163	2374	EST01435	M79291	HHCPH163	2375	EST01436	M79292	HHCPH163
2128	EST011209	M79061	HHCPH33	2376	EST01437	M79293	HHCPH163	2377	EST01438	M79294	HHCPH163	2378	EST01439	M79295	HHCPH163
2129	EST011210	M79062	HHCPH33	2379	EST01440	M79296	HHCPH163	2380	EST01441	M79297	HHCPH163	2381	EST01442	M79298	HHCPH163
2130	EST011211	M79063	HHCPH33	2382	EST01443	M79299	HHCPH163	2383	EST01444	M79300	HHCPH163	2384	EST01445	M79301	HHCPH163
2131	EST011212	M79064	HHCPH33	2385	EST01446	M79302	HHCPH163	2386	EST01447	M79303	HHCPH163	2387	EST01448	M79304	HHCPH163
2132	EST011213	M79065	HHCPH33	2388	EST01449	M79305	HHCPH163	2389	EST01450	M79306	HHCPH163	2390	EST01451	M79307	HHCPH163
2133	EST011214	M79066	HHCPH33	2391	EST01452	M79308	HHCPH163	2392	EST01453	M79309	HHCPH163	2393	EST01454	M79310	HHCPH163
2134	EST011215	M79067	HHCPH33	2394	EST01455	M79311	HHCPH163	2395	EST01456	M79312	HHCPH163	2396	EST01457	M79313	HHCPH163
2135	EST011216	M79068	HHCPH33	2397	EST01458	M79314	HHCPH163	2398	EST01459	M79315	HHCPH163	2399	EST01460	M79316	HHCPH163

SUBSTITUTE SHEET

SEQ ID	EST#	Gene	Clone
2393	EST01116	M79261	HRBAA06
2394	EST01117	M79262	HRBAA07
2395	EST01118	M79263	HRBAA20
2396	EST01119	M79264	HRBAA26
2397	EST01120	M79265	HRBAA27
2398	EST01121	M79266	HRBBA06
2399	EST01122	M79267	HRBBA08
2400	EST01123	M79268	HRBBA11
2401	EST01124	M79269	HRBBA12
2402	EST01125	M79270	HRBBA21
2403	EST01126	M79271	HRBBA22
2404	EST01127	M79272	HRBBA23
2405	EST01128	M86176	HRBAA27
2406	EST02113	M86176	HRBAA27
2407	EST02114	M86176	HRBAA27
2408	EST00273	M86176	HRBAA27
2409	EST00273	M86176	HRBAA27

SEQ ID	EST#	Gene	Clone
2393	EST01116	M79261	HRBAA06
2394	EST01117	M79262	HRBAA07
2395	EST01118	M79263	HRBAA20
2396	EST01119	M79264	HRBAA26
2397	EST01120	M79265	HRBAA27
2398	EST01121	M79266	HRBBA06
2399	EST01122	M79267	HRBBA08
2400	EST01123	M79268	HRBBA11
2401	EST01124	M79269	HRBBA12
2402	EST01125	M79270	HRBBA21
2403	EST01126	M79271	HRBBA22
2404	EST01127	M79272	HRBBA23
2405	EST01128	M86176	HRBAA27
2406	EST02113	M86176	HRBAA27
2407	EST02114	M86176	HRBAA27
2408	EST00273	M86176	HRBAA27
2409	EST00273	M86176	HRBAA27

SEQ ID	EST#	Gene	Clone
2393	EST01116	M79261	HRBAA06
2394	EST01117	M79262	HRBAA07
2395	EST01118	M79263	HRBAA20
2396	EST01119	M79264	HRBAA26
2397	EST01120	M79265	HRBAA27
2398	EST01121	M79266	HRBBA06
2399	EST01122	M79267	HRBBA08
2400	EST01123	M79268	HRBBA11
2401	EST01124	M79269	HRBBA12
2402	EST01125	M79270	HRBBA21
2403	EST01126	M79271	HRBBA22
2404	EST01127	M79272	HRBBA23
2405	EST01128	M86176	HRBAA27
2406	EST02113	M86176	HRBAA27
2407	EST02114	M86176	HRBAA27
2408	EST00273	M86176	HRBAA27
2409	EST00273	M86176	HRBAA27

SUBSTITUTE SHEET

-110-

NOTE REGARDING SEQUENCE LISTINGS: The listings of SEQ ID NOS: 1-2421 are in numerical order. However, an occasional number (for example, SEQ ID NO: 44) is not found in this list. In all, 9 SEQ ID NOS are not used. Nevertheless, the convention "1-2421" is used, for example, to refer to all the SEQ ID NOS in the following list, while "1-315" is used, for example, to refer to all the listed sequences falling between SEQ ID NO 1 and SEQ ID NO 315.

-111-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Venter, J. Craig
Adams, Mark D.
Moreno, Ruben F.
- (ii) TITLE OF INVENTION: Sequences Characteristic of Human Gene
Transcription Product
- (iii) NUMBER OF SEQUENCES: 2412 (1-2421, with 9 SEQ ID NOS unused.)
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Knobbe, Martens, Olson, and Bear
 - (B) STREET: 620 Newport Center Dr. Sixteenth Floor
 - (C) CITY: Newport Beach
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 92660
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: 07/837,195
 - (B) FILING DATE: 12-FEB-1992
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 07/716,831
 - (B) FILING DATE: 20-JUN-1991
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Israelsen, Ned A.
 - (B) REGISTRATION NUMBER: 29,655
 - (C) REFERENCE/DOCKET NUMBER: NIH004.004CP1
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 619-235-8550
 - (B) TELEFAX: 619-235-0176

SEQ ID NO:1: (Length of Sequence = 362 Nucleotides)

CTTCCCTTT GTTCCCTCA GTTCCTTT TAATGCTTC CCTCATTTC CCTAGCAGC ATCCTAGTTG ATGGTCTGGG
TTATCAGAGG AGCAAAACA TTAAAGTGC AAATAATGCT CATGTCTCC CTGGGATTTC TAAACAGAAA AAATGAAGAA

418

CACTACGGCG GGTGGTCAG CCTCATCCCC CTCATCCTAG ACTTAATGAA AGAATGGWTC GCCACTTCG AGAAGTTGCC
GCGCAGGTG CTGCAGGGCA CGGGGCTGC CTGCACT

SEQ ID NO:1931: (Length of Sequence = 343 Nucleotides)

ATCACTTCCC CACCCACAG GATCTGCCCC AGAGAAAGTC CTGCTGCTC ACCAGCAAGC TTGGGGTGG CCAAGTTGAA
TGATGCTGCC CGGGCTCTG CCAGATCCTG AGACGCTTC CCTCCCTGOC CCACCCGGGT CCTGTGCTGG NTCCTGCCCC
TTCTGCTTT TGACGCCAGG GGTGAGGAG TGGCTCGGT GTGGGCTGGA GAGGCAGAAG CCTTTCTCTG TTGGTGTCCC
AGCATATGGA GCCCCTTGG CTGAGCACCA AGACCTTGAA CCTTTTTTGT TTTACCTTTT TTCCAAATAA CAGTTTGGAG
AAATATCAAT GAAATCTGGG GGT

SEQ ID NO:1932: (Length of Sequence = 314 Nucleotides)

TTTCATGGGT TTTTGTTTTG TTTATTTGGA ATACTGAAAA AGTCCTTTGG GCTCTGTGGG GTTCCCCACG CTCAGGCTC
CTTTCTCCA CACTCACTGC CCTTCTTCCC ACAGCAAATC TATTTCAAGG ACAGTACTTT TTAATATGAT TAATGTTGAG
TTCTCAACTA GCTCTGAGA ACTAGAGGAG CTGTTTGCAT CTGCTGTGTC GGATGGAGTT TCTTTTATCT GACCCAGGT
CTCCAACCAC ACTGATGCAA GGCATTTTAT CTACAGAGCT CAACTAGAAC CCTTTTTC A TTAGGCTACT CCAA

SEQ ID NO:1933: (Length of Sequence = 378 Nucleotides)

AGCTTCTGC GGGACCACAG CTATGTGACT GAAGCTGACA TCATCTCTAC CGTTGAGTTC AACCACAQGG GAGAGCTGCT
GGCCACAGGT GACAAGGGCG GCGGGTGT CATCTTCCAG CGGGAACCAG AGAGTAAAAA TGCGCCCCAC AGCCAGGGCG
AATACGAGT GTACAGCACT TTCCAGAGCC ACGAGCGGA GTTTGACTAT CTCAGAGCC TGGAGATAGA GGAGAAGATC
AACAAGATCA AGTGGCTCCC ACAGCAGAAC GCGCCCACT CACTCTGT TTCCACCAAGA TAAACTATC AAATTATGGA
AGATTACGA ACGAGATAAA AGGCCCGAAG GATACAACT GAAGGATGAA GAGGGGAA

SEQ ID NO:1934: (Length of Sequence = 239 Nucleotides)

ATTTAATTTG ACAGCCTTC ATTTTTOGAG AAAGTACAAA CAGAACTGCT TTAGCACCCA TOGAGCCCCA AACGGGTAG
GTAAGCCAAG GTTTTAATGA CCAGCCAGT ATCTAAGCTT CCAAACGGAT GCCAGCCCAT CACATACTYA CCTGGGAGG
CTGCTGCAG GGCATTCTCC YGATGCTCAC GGCCTTGGK GTAGGTTTCA RGATGGCTC TTTGAGGAAG GACTTCAGG

SEQ ID NO:1935: (Length of Sequence = 319 Nucleotides)

TTAATTTTTT TINTCCATAG AGGAATAGCA TTACAGTCTA ACAATCAGAA TTCTGTTACA CACATACACA GGCATGCCAC
ATGACCCAGT TGAGGTGGTT GINTCCTTGA GTCTGTGAC ACGTCACATG GTCAAAGTCT CCTCATTTCA GCCAGTCTCA
ACACAAAACA CCCAACAGG ATGCACTCAA CTGTGTGGTT CCATGTGGAA CTAGGTGGCA GGGCGAGAGG GAAAGTAGTA
GAAGGGGGCT ATGGTGTGTC TGCACTCAGT CCCCTCATAT AAAGCCCAT GGATCTAGGG GGGGTATCCA AGAGCTCTG

SEQ ID NO:1936: (Length of Sequence = 415 Nucleotides)

CTATTTTAC AAATTATAAC TAATGAGTAA AATTAGTGA AAGTGATAAC ATGCTTCTAC CTGTATTCT AGTGACCTT
TAGGGCAGG TATTTATACC TGGTATTAT GATGCAGTAT ATAAGTGGTG AACAATAACT GACAGTATG TGCTTGCTGT
ACATGCTGG TCTTTTGAAA CAGATTTAG TAAGCATTTT CCAGAGGTAA AACTGTGTCC TTATTCTAAT TTTATCTCA
GGGCAAAGTA GACAGGGATT ATTCCTTGA ATCTATTTCC AAATTAATAT TTTTTCTTT GGTATTTCTA CACTTTAAGG
CCATTGGTG CAATTTAGAA AGTGTGGCC TCCTTCCGC TAGCCACATT CAAATTAAC TTCCAAAACC TCAGGAACAG
TACAAGGAAT TTGAA